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 These investigations are focused on the design and formulation of novel non-
viral lipopolyamine vectors capable of efficiently and safely delivering DNA to the 
nucleus, and siRNA to the cytoplasm, in two tissue cultured (primary and cancer) 
cell lines. The thesis starts with a focussed literature review on the non-viral gene 
therapy (NVGT) vectors currently used in the formulation of DNA and siRNA. 
 The first experimental part tests the ability of our novel lipospermines in 
NVGT, this includes structure-activity relationship (SAR) studies changing the:  













-dialkyl spermines. The ability of these lipospermines in DNA 
condensation is investigated using ethidium bromide fluorescence-quenching, and 
gel electrophoresis (including gel shift and DNase protection) assays followed by 
nanoparticle characterization techniques (particle size and zeta potential). 
Transfection efficiency of pEGFP (using FACS) and cytotoxicity (using MTT) were 







dioleoyl spermine). Some of these novel lipospermines are shown to be as good as, 









-Dioleoyl spermine is the best transfecting agent from the all tested novel 
lipospermines displaying the lowest N/P ratio, highest transfection efficiency and the 
lowest cytotoxicity on both tested cell lines. 
We extended this SAR study to examine the same lipospermines in siRNA 
delivery. The ability of these compounds to bind siRNA was studied using the 
RiboGreen intercalation assay followed by similar nanoparticle characterization 
techniques. Transfection efficiency for delivery of Label IT
®
 RNAi Delivery Control 
(using FACS) and cytotoxicity (MTT) were also studied in both cancer and primary 
cell lines, and compared with a market leader siRNA transfecting agent Trans-IT

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1.1. INTRODUCTION 
 Polynucleic acid delivery has many potential applications in medicine. One of 
the main applications is DNA delivery for gene therapy or siRNA delivery. Gene 
therapy, an approach to the treatment or prevention of diseases associated with 
defective gene expression, involves the insertion of a therapeutic gene into cells, 
followed by expression and production of the required protein(s). This approach 
enables the introduction of new genes, replacement of damaged genes, or inhibition of 
the expression of undesired genes. Gene delivery for therapeutic applications currently 
involves two strategies:  corrective and cytotoxic gene therapy. The former includes 
correction of genetic defects in target cells. This strategy is exploited for the treatment 
of diseases with single gene disorders (e.g., severe combined immuno-deficiency 
syndromes SCID, cystic fibrosis, hemophilia, sickle cell anemia, β-thalassemia, 
muscular dystrophy) and malignant tumours including ovarian carcinoma. The latter 
strategy includes the destruction of target cells using a cytotoxic pathway. This 
strategy is used for treatment of uterine leiomyomata and of malignant tumours, 
including ovarian, breast, and endometrial carcinoma (1), it is also used for DNA 
vaccination. RNA interference (RNAi) has become a powerful tool for the knockdown 
of target gene expression and subsequent phenotypic analysis of gene function in 
mammalian cells in culture. Critical to the success of any small interfering RNA 
(siRNA) (synthetic double-stranded RNA sequences of 19-23 nucleotides) knockdown 
in cells is the efficient delivery of the siRNA to those cells. As a result, there has 
recently been a significant surge of interest in the application of siRNA in functional 
genomics programmes as a means of deciphering specific gene function.  
For a gene or an siRNA to be a medicine giving the desired therapeutic effect 
it should be formulated and delivered to its site of action. For DNA this is the nucleus, 
and for siRNA the cytoplasm of the cells. There are two major methods for delivery of 
genes. One method utilizes viral vectors and is generally an efficient tool of 
transfection. Attempts, however, to resolve drawbacks with viral vectors (e.g., high 
risk of mutagenicity, immunogenicity, low production yield, limited gene payload 
size, oncogene activation, etc.), led to the development of an alternative method which 
makes use of non-viral vectors. Non-viral delivery systems include the use of DNA 
alone, so called “naked DNA”, or complexed with synthetic cationic lipids 
(lipoplexes) or cationic polymers (polyplexes). These vectors not only circumvent the 
drawbacks of viral vectors, but also have the advantages of simplicity of use and the 
 - 3 - 
ease of large-scale production. They can be classified as liposomal and non-liposomal 
non-viral delivery vectors. Liposomal delivery vectors usually contain two types of 
lipids, a cationic lipid (a positively charged amphiphile) for DNA condensation and 
cellular membrane interaction, and a neutral helper lipid (phospholipid), to increase 
transfection efficiency as it has a membrane fusion promoting ability (2-4). Non-
liposomal cationic-lipid delivery vectors (lipopolyamines) combine both the 
characteristics of cationic and helper lipids. Although lipopolyamines are less efficient 
in comparison with viral vectors, their promising lower toxicity than viral vectors 
means that it is important to design novel lipopolyamines with improved transfection 
efficiency based on unmet medical need. 
Our considerations are of structure-activity relationships (SAR) within 
naturally occurring and synthetic polyamines. The covalent addition of a lipid moiety, 
typically one or two alkyl or alkenyl chains, or a steroid, allows much greater 
efficiency in DNA condensation and in the cellular transfection achieved. Thus, 
efficient DNA or siRNA condensation and subsequently drug delivery (i.e., with DNA 
or siRNA as the drug) can be brought about using novel polyamine conjugates.  
Cationic lipid-mediated gene transfer is an attractive technique. It is of general 
use with respect to cell type and DNA size, as it is entirely driven by non-specific 
ionic interactions. It may be of low toxicity if the carrier is designed to be 
biodegradable. It can be prepared in significant quantities with relative ease 
(compared to viral vectors) and extensively characterised. Furthermore, each of the 
constituent parts can be modified, thereby facilitating the elucidation of the much 
needed SAR. 
It may be foreseen that in order to be successful, incorporating the various 
functions is required in order to perform the different steps involved in gene 
transfection. Such self-assembly nanosystems are a current challenge in molecular 
pharmaceutics (5-10). Thus, the aims of our research are to understand, design, 
prepare and evaluate small-molecule lipopolyamines for non-viral gene therapy 
(NVGT). These novel lipopolyamine conjugates mimic the positive charge 
distribution found in the tri-amine spermidine and the tetra-amine spermine alkaloids. 
After optimizing their SAR, these probes will be useful in monitoring gene delivery 
by NVGT, and in early experiments to validate siRNA delivery, in vitro. Then, in the 
future, in vivo studies can be considered (7-12). 
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1.2. GENE THERAPY CLINICAL TRIALS UPDATE IN MARCH 2008 
 The J. Gene Medicine Clinical Trials site, the most comprehensive source of 
information on worldwide gene therapy clinical trials available on the internet 
(www.wiley.co.uk/genmed/clinical/) gives a clear idea about recent updates in gene 
therapy clinical trials from different aspects e.g., therapeutic strategies based on the 
addition of genes to compensate for faulty genes, addition of genes with new 
functions, or disruption of gene expression. From the point of view of possible target 
disease states, we find most of the clinical trials are for the treatment of cancer 
diseases (66.5%, Table 1.1) which include the strategy of introducing genetic 
materials into cells for the production of therapeutic proteins or blocking the synthesis 
of harmful proteins (e.g., melanoma, leukaemia, breast cancer, cervical carcinoma, 
ovarian cancer, lung cancer, prostate cancer, lymphoma, pancreatic carcinoma, 
gliogblastoma and squamous cell carcinoma), followed by cardiovascular (e.g., 
myocardial angiogenesis, severe peripheral artery occlusive disease, critical limb 
ischaemia, chronic granulomatosis coronary heart disease and peripheral arterial 
occlusive disease PAOD) and monogenic diseases (e.g., severe combined immuno-
deficiency syndromes SCID, cystic fibrosis, haemophilia, sickle cell anaemia, β-
thalassemia, muscular dystrophy). 
 
Table 1.1. Gene Therapy Clinical Trials (Indications, 1989-2007) from J. Gene 
Medicine. 
Gene Therapy Clinical Trials  
Indications 
Number % 
Cancer diseases 896 66.5 
Cardiovascular diseases 121 9 
Gene marking 50 3.7 
Healthy volunteers 26 1.9 
Infectious diseases 89 6.6 
Monogenic diseases 110 8.2 
Neurological diseases 17 1.3 
Ocular diseases 12 0.9 
Others 26 1.9 
Total 1347 100 
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The number of approved clinical trials increased significantly in the last ten years 
(Table 1.2). Even though these trials started 20 years ago, in 1989, there was only a 
2.7% in Phase III (Table 1.3). Viral vectors are the majority of these trials (66.9%) 
followed by naked DNA (17.8%), lipofection (7.4%), and siRNA (1.4%) trials. 
 
Table 1.2. Gene Therapy Clinical Trials (Year of clinical trial, 1989-2007) from J. 
Gene Medicine. 
Gene Therapy Clinical Trials  
Years 
Number % 
1989-1993 62 4.6 
1994-1998 306 22.7 
1999-2003 489 36.3 
2004-2007 358 26.6 
unknown 132 9.8 
Total 1347 100 
 
Table 1.3. Gene Therapy Clinical Trials (Phase of clinical trial, 1989-2007) from J. 
Gene Medicine. 
Gene Therapy Clinical Trials  
Phase 
Number % 
Phase I 820 60.9 
Phase I/II 262 19.5 
Phase II 216 16 
Phase II/III 13 1 
Phase III 36 2.7 
Total 1347 100 
 
Therefore, the development of safe and efficient vectors for gene (plasmid DNA) and 
siRNA formulation and delivery is still a major challenge in order for them to become 
real medicines. We urgently need to meet this challenge to enable gene therapy, DNA 
vaccination, or RNA silencing to become a clinical reality. An understanding of the 
background to these problems is provided by two literature reviews on gene and 
siRNA polynucleic acid delivery. 
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1.3. GENE DELIVERY – AN INTRODUCTION 
 Treatment with traditional drugs is based on molecular substitution, which 
involves the chemical modification of various compounds that are then subjected to 
screening programmes. An increasing array of inherited and acquired diseases is now 
understood by an “inside out” approach involving the identification and targeting of 
the underlying genetic cause. As a result, therapeutic strategies based on the addition 
of genes to compensate for faulty genes, addition of genes with new functions, or 
disruption of gene expression have been developed and they are rapidly growing in 
diversity and scope to treats diseases caused by the malfunction of a gene. Gene 
therapy is a method to introduce genetic materials into cells for the production of 
therapeutic proteins or blocking the synthesis of harmful proteins. The former 
includes correction of genetic defects in target cells. This strategy is exploited for the 
treatment of diseases with single gene disorders (e.g., severe combined immuno-
deficiency syndromes, cystic fibrosis, haemophilia, sickle cell anaemia, β-thalassemia, 
muscular dystrophy) and malignant tumours, including ovarian carcinoma. The latter 
strategy includes destruction of target cells using a cytotoxic pathway. This strategy is 
used for treatment of uterine leiomyomata and of malignant tumours, including 
ovarian, breast, and endometrial carcinoma (1,13). During the past decade, gene 
therapy technologies have progressed remarkably, and many clinical trials have been 
reported. Intracellular delivery of genetic material is the key step in gene therapy. 
 Gene therapy research is divided into two major research fields. One is to 
develop a therapeutic gene. This research includes development of an effective 
therapeutic gene for a specific disease and a tissue specific or regulated gene 
expression system. The other is to develop an efficient and safe delivery system. 
Optimization of delivery vectors is of major importance for turning gene therapy into 
a successful therapeutic method, so the development of safe and effective gene 
delivery methods is a major challenge to enable gene therapy or DNA vaccines to 
become a reality (14). Gene delivery systems are divided into viral vectors including 
retroviruses, lentivirus and adenoviruses and non-viral vectors including physical 
methods (naked DNA) and chemical methods including complexed with synthetic 
cationic lipids (lipoplexes) or cationic polymers (polyplexes) (5,15). They can be 
classified as liposomal and non-liposomal non-viral delivery vectors. Liposomal 
delivery vectors usually contain two types of lipids, a cationic lipid (a positively 
charged amphiphile based upon a polyamine or at least a cationic skeleton) for DNA 
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condensation and cellular membrane interaction, and a neutral helper lipid 
(phospholipid), to increase transfection efficiency as it has a membrane fusion 
promoting ability (2-4). Non-liposomal cationic-lipid delivery vectors combine both 
the characteristics of cationic and helper lipids (lipopolyamines). Although 
lipopolyamines are less efficient in comparison with viral vectors, their promising 
significantly lower toxicity than viral vectors ensures a continuous effort to design 
novel lipopolyamines with improved transfection efficiency. 
 The choice of the delivery system is determined by the nature of the disease to 
be treated and the need for long-term vs. transient and low vs. high expression of the 
gene of interest. Although at present viral systems dominate in clinical trials for gene 
therapy, cationic lipids have been studied in several clinical trials for treatment of 
cystic fibrosis, cancer, and, more recently, cardiovascular diseases at this point, some 
positive results have been attained, but the overall outcome indicates that a crucial 
requirement for successful gene therapy is the use of more efficient vectors (9,16). 
 Non-viral vectors have many advantages over viral gene vectors, although 
viral vectors are currently the most efficient way to deliver genes to cells. Unlike viral 
vectors, non-viral vectors have low cytotoxicity, low immunogenicity, no size limit, 
low cost, and reproducibility added to the practical issues of large scale production 
and quality control. 
 The ideal vector for gene delivery would have at least the following 
characteristics:  1) safety with low cytotoxicity and low immunogenicity, 2) high gene 
delivery efficiency with the ability to express, in an appropriately regulated fashion, 
the therapeutic gene for as long as required, 3) specificity for delivery of genes to 
target organs and 4) resistance to metabolic degradation and/or attack by the immune 
system. Until now, many gene carriers have been developed to meet the requirements 
of gene delivery to humans. These carriers were able to condense and protect plasmid 
DNA from DNase enzyme, resulting in the enhancement of gene delivery efficiency. 
However, there still remain drawbacks such as low biocompatibility and transfection 
efficiency (14,17). Most gene carriers have positive charges at their amine groups. 
The positive charges of the carriers interact with negative charges of phosphate groups 
in plasmid DNA, resulting in condensation of plasmid DNA. The lipoplex/plasmid 
DNA complexes are usually prepared in the presence of an excess amount of lipoplex, 
and the complex has a net positive charge. The positively charged complexes interact 
with negatively charged cell membranes, facilitating cellular uptake of the 
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lipoplex/plasmid DNA complexes via endocytosis. The lipoplex/plasmid DNA 
complexes have small particle size of around 100-200 nm. Although there is no size 
limit for the transfection, it was suggested that lipoplex/ plasmid DNA complex with 
diameters of around 100-200 nm corresponds to the diameter of the coated pits in 
endocytosis. Degradation of DNA by nucleases is a problem for gene therapy. 
Degradation of plasmid DNA by nucleases results in loss of gene expression. 
Therefore, carriers must protect plasmid DNA from nucleases. Condensation of 
plasmid DNA by carriers prevents the access of nucleases to plasmid DNA, improving 
resistance of plasmid DNA against enzymatic degradation (18). 
 For drug formulators, it is difficult to deliver a drug molecule of 3.3 kDa 
molecular weight carrying 10 negative charges, but in the case of the (pro-drug) DNA, 
a 5 kbp plasmid has a molecular weight of about 3.3 megaDaltons and carries 10,000 
negative charges. So the first key step in gene formulation is DNA condensation into a 
nanoparticle form, through masking the negative charges of the phosphate backbone 
which causes alleviation of charge repulsion between remote phosphates on the DNA 
helix leading to collapse into a more compact structure (11,19). The importance of 
DNA condensation is attributed to the correlation of the transfection efficiency with 
the formation of DNA nanoparticles that are essential for the delivery of DNA through 
the cell membrane. Cationic lipids are considered to be the major gene carriers among 
the non-viral delivery systems. They have the ability to condense DNA into particles 
that can be readily endocytosed by (cultured) cells, and facilitate endosomal escape 
leading to efficient delivery to the nucleus. 
 We are studying how these polyamine conjugates interact with circular 
plasmids in order to produce nanometre-sized particles suitable for transfecting cells. 
Our main considerations are of structure-activity relationships (SAR) within naturally 
occurring and synthetic polyamines. The covalent addition of a lipid moiety, typically 
one or two alkyl or alkenyl chains, or a steroid, allows much greater efficiency in 
DNA condensation and in the cellular transfection achieved. Thus, efficient DNA or 
RNA condensation and subsequently drug delivery (e.g., with DNA or RNA as the 
drug) can be brought about using novel polyamine conjugates. The current aims of our 
research are to understand, design, prepare and evaluate small-molecule 
lipopolyamines for non-viral gene therapy (NVGT). These novel lipopolyamine 
conjugates mimic the positive charge distribution found in the tri-amine spermidine 
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and the tetra-amine spermine alkaloids. After optimizing their SAR, these probes will 
be useful in monitoring NVGT in vitro and then in vivo (7-10,12,14). 
 
1.3.1. Mechanisms in NVGT 
 
Fig. 1.1. Steps in the process of non-viral gene therapy by endocytosis showing the 
barriers for DNA nanoparticles, from the formation of the DNA complex (lipoplex) to 
gene delivery. 
 
 There is a need for a better understanding of the mechanism of gene delivery 
to targeted cells and more detailed understanding of the barriers for non-viral gene 
delivery to achieve efficient formulation (Fig. 1.1) (20,21). The barriers that hinder 
the delivery of DNA to its physical site of action (the nucleus) have been summarized 
as follows: 
 
1. DNA condensation 
Cationic lipids and polymers have the ability to condense DNA into particles that can 
be readily endocytosed. The formed nanoparticles and their size are essential for the 
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development of gene delivery vehicles (22-24). In addition, the cationic polymers or 
lipids increase the stability of DNA in serum (25). DNA is condensed by naturally 
occurring positively charged polyamines spermine and spermidine working together 
with the basic proteins, histones (11,19). 
 
2. Cell membrane entry 
The mammalian cell membrane is selectively and/or passively permeable, even to 
charged molecules. It is a phospholipid bilayer which contains many proteins 
including enzymes and selective ion channels. It allows the transport of 
macromolecules by endocytosis. Neutralization of the many negative charges on DNA 
by lipopolyamines will enable the delivery of DNA through the cell membrane as 
there are negative charges on both DNA and cell membrane. Also, the positively 
charged lipid complex (the nanobioparticle) will mediate transfection by fusion with 
cell membranes. Several trials have linked a DNA lipoplex to a targeting ligand in 
order to improve the efficiency of transfection, where the lipoplex is internalized by 
efficient receptor-mediated endocytosis in cells that present receptors for the target 
ligand (26-31). 
 
3. Endosomal escape 
Major barriers to the efficient delivery of DNA into the nucleus are located in the 
cytoplasm. Although the DNA complex is efficiently internalized in the cell, only a 
small fraction is transferred to the nucleus and expressed. As the DNA complex is 
internalized, it is retained inside the early endosomes, then in the late endosomes that 
are characterized by increased acidity (low pH values, about 5.5). At this stage, the 
efficient escape of DNA from the endosome is an important factor for successful gene 
delivery, before any further trafficking of the trapped DNA to the lysosomal 
compartment where the DNA is subjected to degradation by the nucleases found in the 
lysosomes (32-35). The possible mechanisms for endosomal escape are:   
1.  Disruption of endosomal membrane through mixing with the cationic lipid vector (36). 
2.  Cationic lipid interaction with the negatively charged endosomal membrane (37). 
3.  Proton sponge hypothesis, where a cationic lipid, has the ability of endosomal pH 
buffering that leads to chloride ion influx together with water molecules (H3O
+
) that 
leads to membrane swelling and disruption (38). 
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4.  Membrane destabilising peptides, which includes fusogenic or lytic peptides, such 
as the basic peptide KALA (39), acidic peptide EGLA (40), or the uncharged peptides 
at neutral pH such as H5WYG (41). These peptides have the ability to disrupt the 
endosomal membrane and increase the release of DNA to the cytosol. 
 
4. Through the cytoplasm 
While ribozymes and antisense oligonucleotides may already be active in the cytosol, 
plasmid DNA has (typically) to be transported into the nucleus, in order to exhibit the 
desired gene expression. The cytoplasm is a critical place with respect to the stability 
of DNA and RNA, due to the presence of nucleases that reduce their half-life 
dramatically. Naked plasmid DNA, for example, exhibits a half-life as short as 50–90 
mins. As the majority of plasmid DNA enters the nucleus during cell division, it must 
remain stable until the next disassembly of the nuclear envelope. Another factor that 
plays an important role in nucleic acid transit through the cytoplasm is the rate of 
mobility which depends on both the size and spherical structure of the molecule. The 
mobility of large molecules, e.g., plasmid DNA, is extremely low in the cytoplasm 
(42). Low mobility means a longer trafficking time to the nucleus and thus prolonged 
exposure to (aggressive) nucleases (34,35,43). 
 Increased cytosolic mobility result from complexation of DNA with cationic 
carriers (DNA condensation into a compacted state) (44,45), compared to naked DNA 
(46). Another reason for the higher level of gene expression of complexes (compared 
to naked DNA) could be the protection of DNA from cytoplasmic nuclease 
degradation. Several studies have demonstrated excellent stabilization using cationic 
complexes (47), when comparing the stability of naked and complexed DNA/RNA in 
the presence of DNases or RNases. It was demonstrated that cationic carriers could 
interact with F-actin fibres altering the structure of the cytoskeleton and thus 
enhancing the permeability for large molecules (48). 
 
5. Nuclear entry 
One of the crucial steps for successful delivery of DNA into its site of action is 
crossing the nuclear membrane. The entry of macromolecules to the nucleus occurs 
through the nuclear pore complex (NPC) which allows a passive diffusion of 
molecules of up to 50 kDa molecular weight or about 10 nm in diameter, but in the 
case of larger molecules NPC is capable of actively transporting particles of about 25-
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50 MDa or about 25 nm diameter (49). Nuclear localization signals (NLS), due to 
their characteristics to target macromolecules to the nucleus and increase transfection 
efficiency, are being actively investigated (50). The other way for DNA to enter to the 
nucleus is during mitosis where the nuclear membrane is broken down so that DNA 
and macromolecules can easily gain access. 
 
6. Decomplexation 
The dissociation of DNA from the condensing agent is an important step for the host 
transcription factors to initiate the transcription reaction. The decomplexation process 
may occur after endosomal escape in the cytoplasm (36) or after nuclear entry (44) 
(see:  Fig. 1.1). 
 
7. Transcription and translation 
Inside the nucleus, the next step for gene therapy is the transcription process which 
depends on the promoter strength and presence of an enhancer in the vector which 
effects on transfection efficiency (51). The successful transcription process leads to 
the translation and formation of the desired protein (the active form of the required 
drug, achieved by delivering of the prodrug DNA). 
 
1.3.2. Naked Plasmid DNA Transfection 
1. Mechanical methods 
 
1. Microinjection:  The most direct method to introduce DNA into cells is 
microinjection, either into the cytoplasm or into the nucleus. 
2. Particle bombardment - the “gene gun”:  The idea behind gene-mediated particle 
bombardment (or use of the so-called “gene gun”) is to move naked DNA plasmid 
into target cells on an accelerated particle carrier. Biolistic (a contraction of biological 
and ballistic) delivery utilises heavy metal particles propelled at a sufficient velocity 
into the target cell. Acceleration is achieved by a high-voltage electric spark, or a 
helium discharge. 
 
3. Naked DNA transfer by transient occlusion of blood flow:  The strategy for this 
approach is to increase the retention time of plasmid DNA by transiently blocks the 
blood flow through the target organ. Due to the technical difficulty in blocking blood 
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flow through the lung, trials started with the liver. In this approach, satisfactory gene 
transfer can be achieved by a simple occlusion of blood flow through the liver 
following intravenous administration of naked plasmid DNA (4). 
 
2. Physical methods 
 
1. Electroporation:  This technique, termed electroporation or 
electropermeabilization, exposes the cell membrane to high-intensity electrical pulses 
that can cause transient and localized destabilization of the barrier. During this 
perturbation, the cell membrane becomes highly permeable to exogenous molecules, 
e.g., DNA, present in the surrounding medium. 
2. Sonoporation:  Sonoporation enhances cell permeability via the application of 
ultrasound, using sinusoidal probes at MHz frequencies. 
3. Laser irradiation:  The laser beam is commonly focused onto the target cell via a 
lens. Predictably, the permeability of the cell membrane is modified at the site of the 
beam impact (probably) by a local thermal effect. 
4. Magnetic field-enhanced transfection-magnetofection:  The idea is to associate 
magnetic nanoparticles with DNA and either its transfection reagent or its viral vector. 
The magnetic nanoparticles are made of iron oxide, which is biodegradable, with a 
polymer coating. The magnetic particles are then concentrated preferentially into the 
target cells by the influence of an external magnetic field. This technology allows 
delivery of genetic material to the target cell surface (52,53). 
 
1.3.3. Complexed Plasmid DNA Transfection 
1. Cationic polymers (Polyplexes) for gene delivery 
Since the cellular membrane is negatively charged, cationic polymers have received 
most of the attention as potential carriers for genes. The Coulombic forces governing 
the interaction between plasma membrane and polycations are so strong that the 
influence of other properties of the polymers (e.g., hydrophilicity) is drastically 
diminished. However, the cationic polymers do not constitute the ideal solution. 
Cationic carriers must contain enough charge to neutralise the DNA and also to 
provide sufficient residual charge for interaction with the membrane of cells. On the 
other hand, in conditions of contact with serum, the positive charge of the carrier 
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might be never enough to counterbalance the negatively charged serum components. 
The internalisation of conjugates can be prohibited (2). 
 
1. Cationic polypeptides 
The interaction of nucleic acids with basic polyelectrolytes is a process that has been 
known for a long time. An early application of polycations was the development of a 
standard procedure for assaying infectious viral nucleic acids, based on the 
observation that cationic polyelectrolytes such as PL, polyornithine, or 
diethylaminoethyl dextran, application of cationic polypeptides (PL, polyornithine, 
polyarginine) included their use as model compounds in the investigation of 
interaction between nucleic acids and histone species, which plays an important role 
in the regulation of genetic process. These studies suggested that the binding reaction 
is more than a simple electrostatic neutralisation, involving steric selectivity and 
inducing stabilisation of DNA. these polymers have been used so far in the gene 
delivery (54). 
2. Dendritic polyamidoamines 
The dendrimers are highly branched polymers with a globular architecture. 
Polyamidoamine (PAMAM) dendrimers can be synthesised with a well-defined 
diameter and a precise number of terminal amino groups at each branching level 
(“generation”). Haensler and Szoka (55) were the first to investigate their use as 
carriers for DNA in gene therapy. Subsequent studies demonstrated that PAMAM–
DNA complexes were able to mediate an efficient transfer of plasmid DNA into 
various cell types in vitro. So far, PAMAM dendrimers have been applied as carriers 
for gene delivery (55,56). 
3. Polyethylenimine 
Polyethylenimine (PEI) is produced by the acid-catalysed polymerisation of aziridine, 
involving propagation through cyclic ammonium cations. Due to end-group reactions 
and to the high reactivity of the intermediate ammonium species, the resulting polymer 
is usually branched. PEI is very soluble in water and has a high capacity to carry 
positive charges, as every third atom is ionisable nitrogen (1,13). PEI has been 
proposed as a carrier for plasmid DNA, but the larger molecular weight PEIs are often 
found to be too toxic to target cells (38). This together with its inherent inhomogeneity 
makes it an unsuitable vector. 
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4. Cationic block copolymers 
Cationic block (or graft) copolymers have been developed as carriers for DNA or 
antisense phosphorothioate oligonucleotides (PS-ODN), from polyspermine and 
polyethylene glycol (PEG, polyethylene oxide), by Kabanov and co-workers (57-59). 
Such a block copolymer cationic carrier architecture contains both the water soluble 
polycations of spermine and the water-soluble non-ionic PEG moieties. They 
delivered antisense ODNs to achieve increased antiviral activity in vitro (57-59). 
5. Polyethylene glycol 
PEG is the term used for the polyoxyethylene polymers with low molecular weight, 
while the term polyethylene oxide is preferred to designate polyoxyethylenes with 
high molecular weight. This convention is rather obscure and generally overlooked. 
PEGs constitute a class of water-soluble polymers with many applications (60). When 
crosslinked, PEGs behave like typical hydrogels, a form in which they were employed 
as carriers in various drug delivery formulations. However, their use in the delivery of 
genes is not based on hydrogels. PEG chains were incorporated covalently as 
chemical modifiers in order to (a) mask the identity of genes, protecting them from 
recognition by nucleases, and (b) enhance cellular penetration, due probably to the 
chain structure of PEG (1,18). 
6. Cyclodextrins 
Cyclodextrins (CDs) comprise a group of water-soluble cyclic polysaccharides 
containing glucose units with (1,4)-linkages. α-CD, β-CD, and γ-CD have 
respectively 6, 7, and 8 glucose units and they are all available commercially. Their 
cyclic structure provides an internal hydrophobic cone-shaped cavity that is 
surrounded by a hydrophilic shell containing a large number of hydroxyl groups. Due 
to this conformation, CDs and their derivatives readily form complexes with a large 
variety of compounds, and consequently they have been investigated as carriers for 
drugs (61). 
7. Electrically conductive polymers 
Polymers possessing conjugated p-electron backbone chains have unusual electronic 
properties. The application of these materials in oligonucleotide chemistry originated 
in the development of an electrochemically controlled synthesis of conductive 
polymer films containing genes. Copolymerisation of pyrrole and pyrrole-ODN 
covalent conjugates was performed electrochemically and resulted in deposition on an 
electrode of solid films. 
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2. Cationic lipids (Lipoplexes) 
Cationic lipids are especially attractive as they can be easily prepared and extensively 
characterised. Further, each of their constituent parts can be modified, thereby 
facilitating the elucidation of structure-activity relationships. A great number and an 
impressive variety of synthetic vectors have been prepared and their transfection 
efficiency evaluated not only in experimental studies, but also in clinical trials for 
treatment of diseases such as cancer (62,63) and cystic fibrosis (64,65). At this point, 
some positive results have been attained, but the overall outcome indicates that a 
crucial requirement for successful gene therapy is the use of more efficient vectors 
(66). Their three fundamental constituent parts are:  the cationic headgroup, 
hydrophobic domain and connecting linker. There are possible correlations between 
the length, saturation, and type of hydrophobic moiety and transfection efficiency. 
Intracellular DNA-release strategies that can be triggered as a function of the 
incorporation of cellular environmentally-sensitive groups (pH-, redox- and enzyme-
sensitive) within the linker moiety are also under investigation. 
 The length and type of the aliphatic chains incorporated into cationic lipids 
significantly affect their transfection efficiency. Thus, vectors are often prepared in a 
series differing in their hydrophobic domain. The hydrophobic domain has also been 
functionally modified by the inclusion of highly fluorinated alkyl chains which are 
both hydrophobic and lipophobic, a characteristic which may better protect the 
lipoplex from unwanted interactions. At first, a series of close fluorinated analogues 
of DOGS (with either both chains fluorinated to varying degrees or just a single chain 
fluorinated with the other remaining a regular alkyl chain) were prepared in order to 
chart the effect of the hydrophobic/lipophobic balance on the transfection efficiency 
(67). 
 
1.3.4. Basic Principles of Cationic Lipid-Mediated Gene Transfection 
 The first step in the preparation of vector/DNA aggregates suitable for gene 
transfer is the condensation of the DNA, which is driven by an electrostatic interaction 
between the cationic lipid and the polyanionic DNA. Spontaneous self-assembly into 
nanometre-scale particles (lipoplexes, nanobioparticles) results, leading to shielding of 
the DNA from the nucleases of the extracellular medium. Use of an excess of cationic 
amphiphile (quantified by the lipid/DNA ratio resulting in a mean theoretical charge 
ratio of the lipoplex (+/-)) gives the lipoplex surface a positive charge, which is 
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presumed to mediate subsequent cellular uptake by interaction with negative cell 
surface structures such as heparin sulfates. 
 As a result of non-specific endocytosis, the lipoplex is encapsulated in 
intracellular vesicles, though fusion-based cellular uptake is not totally excluded. The 
DNA must then avoid degradation in the late endosome/lysosome compartment by 
escaping from the (early) endosome into the cytoplasm. Trafficking of the DNA 
through the cytoplasm precedes uptake by the nucleus of the target cell, and then 
transgene expression occurs. In the nucleus, the DNA appears to be separated from its 
vector. Microinjection experiments have suggested that gene expression does not 
occur if the DNA remains condensed in intact lipoplexes (68). The efficiency of 
cationic lipids for gene transfection can be evaluated in terms of gene delivery 
(percentage of transfected cells) or gene expression (amount of transgene protein 
produced). The efficiency of any transfection reagent also strongly depends on the cell 
system chosen for its evaluation (transformed cell lines or primary cells in vitro, in 
vivo administration), efficiency gains in vitro do not therefore automatically lead to 
higher efficiencies in vivo. How the relative efficiency of cationic lipids is compared 
is crucial, so quantifying the efficiency of cationic lipid systems needs to take into 
account their intended use, i.e., on the experimental or clinical setting. 
 Cationic lipids were first introduced by Felgner et al. (2,69), following early 
attempts to transfer DNA via encapsulation in liposomes (70,71). Thus, the first 
reported lipid was DOTMA (N-(1-(2,3-dioleyloxy)propyl)-N,N,N-
trimethylammonium chloride), which consists of a quaternary amine connected to two 
unsaturated aliphatic hydrocarbon chains via ether groups (2). Synthesis of the 
multivalent lipopolyamine DOGS (dioctadecylamido-glycylspermine) was reported 
soon afterwards (72) and the efficiency of the vector DC-Chol (3β-(N-(N’,N’-
dimethylaminoethyl)carbamoyl) cholesterol) with cholesterol as the hydrophobic 
portion closely followed (73). The transfection activity of cationic lipids (especially 
those which cannot form bilayers alone) can be increased by their formulation as 
stable liposomes with the neutral colipid DOPE (dioleoyl phosphatidylethanolamine) 
(3). Inclusion of DOPE is presumed to enhance endosomal escape of the lipoplexes 
into the cytoplasm as DOPE is thought to have fusogenic properties important for 
endosomal membrane disruption (74). The use of these initial lipids demonstrated the 
transfection ability of cationic lipids. However, this “proof of principle” stage has 
been followed by a highly challenging period. Indeed, progress in improving the level 
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of transfection efficiency up to that required for therapeutic use has been slow. This is 
possibly linked to an unclear structure-activity relationship in vector design, and to the 
related incomplete understanding of the highly complex series of steps involved in 
transfection. Thus, the development of novel lipids is justified, a novel cationic lipid 
being not just a “me too” addition, but rather opening new possibilities for differently 
influencing those steps (9). Accordingly, numerous novel vectors were developed, 
representing a wide variety in structures and thus numerous potential mechanisms by 
which better transfection levels might be obtained (9,75-79). 
 
1.3.5. Basic Structural Features of Cationic Lipids 
 A cationic lipid is a positively charged amphiphile, which generally contains 
the three following structural domains (Fig. 1.2):  i) a hydrophilic headgroup which is 
positively charged, usually via the protonation of one (monovalent lipid) or several 
(multivalent lipid) amino groups; ii) a hydrophobic portion composed of a steroid or 
of alkyl chains (saturated or unsaturated); and iii) a linker (connecting the cationic 
headgroup with the hydrophobic anchor) whose nature and length may impact on the 
stability and the biodegradability of the vector. Modifications of the hydrophobic 
domain have shown that optimal vector structure is often dependant on this moiety, 
which can fall into various structural classes and variants. Finally, labile linkers have 
been introduced which are sensitive to various biological stimuli, inducing DNA 
release at defined time-points during the intracellular trafficking of the lipoplex. The 
following sections will therefore successively cover the important advances made to 
these three fundamental functional domains of any cationic lipid. 
 
Cationic Headgroup Design 
 
Monovalent lipids and the hydration/packing issue 
 DNA binding by the vector requires a headgroup which is capable of 
sustaining a positive charge at physiological pH (Fig. 1.2). The charge is most often 
located on amino groups, as was the case for the ‘early’ vectors. However, other 
charged groups have been employed. The vast majority of cationic lipids for gene 
delivery rely on the charge accommodated on a nitrogen atom, and there appears to be 
a relationship between the hydration of such mono-ammonium headgroups and the 
transfection activity. Figuratively, the greater the imbalance between the cross-
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sectional area of the headgroup (small end) and the hydrophobic moiety (large end) 
i.e., the more cone-shaped the cationic lipid - the more unstable the resulting lipid 
assembly and so the greater the likeliness to undergo fusion with anionic vesicles. 
Lipoplex instability is presumed to result in improved transfection as fusion between 
the cationic lipoplex and the endosomal membrane leads to DNA release into the 
cytoplasm (36,80-82).  
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Multivalent headgroups 
 As multivalent cationic lipids may form liposomes with a greater surface 
charge density than their monovalent counterparts, they are generally expected to be 
better at DNA binding and delivery. A rational approach was the incorporation of 
natural polyamines e.g., spermidine and spermine with their ability to interact with the 
minor groove of B-DNA (83). Triamine spermidine in cholesteryl-spermidine (84), 
and tetraamine spermine in the lipid DOGS (72) are early representative examples. 
The presence of protonation sites with different pKa values in DOGS may actually 
result in buffering of the endosomal acidification, thereby protecting the DNA from 
degradation and facilitating its escape from the endosome. The results suggested that 
the tetramethylene portion of spermine might be able to bridge between the 
complementary strands of DNA, whereas a polyamine with a trimethylene central 
spacer would only interact with adjacent phosphate groups on the same DNA strand. 
As these branched structures have the advantage of avoiding the folding problems of 
linear polyamine chains, they can include additional protonation sites without 
affecting DNA binding. Importantly, with more protonation sites per molecule, the 
resulting lipoplexes can thus achieve the same charge density with lesser amounts of 
the cationic lipid in the formulation. This may lessen the drawback of cationic lipid-
associated cytotoxicity. Indeed, as cationic lipids exhibit some degree of cytotoxicity, 
an optimal set of conditions resulting in high transgene expression and acceptable 
toxicity need to be found (15,85,86). 
 The hydrophobic and hydrophilic moieties of cationic lipids are commonly 
linked using carbamate, amide, ester or ether bonds. The linking bond mediates the 
stability of the cationic amphiphile, there is a balance between a vector’s persistence 
and its toxicity which is likely to be related to its half-life in the cell. Although no 
particular bond emerges as consistently optimal in structure-activity studies across 
different vector types, ether linked vectors are stable (87); consequently, they are 
expected to be more toxic than ester linked lipids which may be more easily cleaved 
within the cell (80,81). Carbamates are thought to achieve a reasonable balance 
between stability and toxicity and are therefore often used (73). 
 The multivalent polycationic headgroups can be used for pDNA delivery. 
What of siRNA delivery (siFection)? There are initial similarities between pDNA and 
siRNA with regard to double stranded (ds) nucleic acid chains, rich in phosphate 
anions. Can we utilise existing non-viral gene delivery vectors for siRNA delivery? 
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1.4. siRNA DELIVERY – AN INTRODUCTION 
The development of efficient vectors for siRNA formulation and delivery, in 
order for them to become real medicines is a challenge for formulation which needs 
an understanding of the background provided by a literature review. Many vectors 
used for gene delivery can be selected for the delivery of siRNA. The initial selection 
was based on established gene delivery and pDNA formulation (88). The emphasis 
hereinafter is given to the delivery of siRNA as there exist many differences between 
pDNA formulation and obtaining results for an optimized siRNA formulation (88). 
RNA interference (RNAi) is a recently discovered gene-silencing tool that has 
generated remarkable excitement in biomedical research. The phenomenon of specific 
RNA inactivation was first discovered in fungi and plants as a defence mechanism 
against virus infection. Over a decade ago, this gene-silencing phenomenon was first 
described in plants and fungi (89). In 1998, Fire and colleagues demonstrated that 
RNAi could also be invoked in animals (90). Its physiologic function appears to lie in 
viral defence, transposon silencing, and regulation of developmental pathways. In 
experimental settings, RNAi was readily appreciated as a powerful tool in gene 
function validation (91). In addition to its use in functional genomics, RNAi holds a 
promise as a novel therapeutic strategy. Its attractive properties include a strong 
knockdown of the targeted gene for a relatively prolonged period of time and 
presumed high sequence specificity. Single nucleotide difference between targets can 
result in dramatic differences in the RNAi-mediated gene silencing, which is an 
interesting quality for treatment of several dominant-negative disorders by targeting 
specific alleles with single nucleotide mutations compared to the wild type (92). 
Challenging diseases failing conventional therapeutics could become treatable by 
specific silencing of key pathogenic genes. More specifically, therapeutic targets 
previously deemed “undruggable” by small molecules, are now coming within reach 
of RNAi based therapy. For RNAi to be effective and elicit a gene silencing response, 
the ds RNA molecules must be delivered to the target cell. Unfortunately, delivery of 
these RNA duplexes has been challenging, halting rapid development of RNAi-based 
therapies. The advantages of RNAi over other therapeutic modalities include its high 
specificity (in some cases, a single point mutation can abolish silencing effect), 
versatility (interfering RNA can be designed against virtually any gene), and 
efficiency (in many cases, genes can be silenced by over 90%) (93,94). 
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1.4.1. Mechanisms in RNAi 
 mRNA is produced by cells when the cellular metabolism is in need of a 
specific protein, and subject to degradation thereafter. RNAi is triggered by the 
presence of double-stranded RNA (dsRNA) in the cell and results in the rapid 
destruction of the mRNA containing identical or nearly identical sequence. Use of 
RNAi by means of long dsRNAs (greater than 50 bp) has been limited in mammalian 
systems (95). The mechanism of siRNA is not completely understood. However, the 
generally proposed model is that a double stranded (ds) RNA, which is targeted 
against a homologous mRNA, binds to the mRNA and mediates its degradation, 
causing the silencing of the corresponding gene (92). Between intracellular 
introduction of the dsRNA and the silencing of the gene, several steps occur inside the 
cell. The dsRNA is cleaved into smaller duplexes by an RNase III-like activity 
involving an endogenous ribonuclease enzyme, dicer. These shorter fragments consist 
of 19–21 nucleotide duplexes with two nucleotide overhangs on the 3'-position and 
are known as small interfering RNAs (siRNAs). Subsequently, siRNAs associate with 
several proteins that together form a nuclease complex known as the RNA-induced 
silencing complex (RISC). As the siRNA unwinds, probably through the action of a 
helicase, the RISC becomes activated, and the antisense siRNA strand “guides” the 
RISC to the complementary target mRNA through Watson-Crick base pairing 
interactions between the siRNA antisense strand and the mRNA. Finally, the mRNA 
is cleaved approximately 12 nucleotides from the 3'-terminus of the complementary 
siRNA strand, thereby silencing the corresponding gene (96-98). 
 Gene downregulation by siRNA was initially studied in Caenorhabditis 
elegans, Drosophila melanogaster, and other non-vertebrates, but RNAi-mediated 
gene knockdown in mammalian cells has been demonstrated (99,100). The difficulty 
in showing a sequence-specific siRNA mediated gene silencing in most mammalian 
cell types lies in a nonspecific protein production shutdown, partly mediated by the 
RNA-dependent protein kinase pathway, by introduction of long (>30 nucleotides) 
dsRNA molecules. Only by introducing the smaller siRNA can a sequence specific 
gene silencing effect be observed (100). siRNA, in mammalian cells, is both transient 
and confined to the cells in which it was introduced (100).  
 siRNA can be introduced in two forms into mammalian cells:  1) via transfection 
from the extracellular compartment as a chemically or enzymatically synthesized 
product or 2) as a product of intracellularly transcribed DNA upon transfection, 
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transduction, or infection with the transcript-encoding genetic material. Tuschl and 
colleagues have identified many of the requirements and preferred characteristics of 
siRNA with regard to silencing efficacy (100,101). siRNAs preferably consist of 19 
nucleotide duplexes with 2 nucleotide overhangs on each 3'-position. The overhang 
sequence does not appear to be critical and can even include 2'-deoxynucleotides (like 
TT) which are thought to be more resistant to the action of nucleases (100,101). 
However, replacement of either strand with a strand composed of 2'-deoxynucleotides 
obliterates siRNA activity. In general, modifications to the 3'-position are better 
tolerated than modifications to the 5'-positions with regard to preserving silencing 
efficacy (101,102). The phosphorylation of the 5'-end of the siRNA, needed for activity, 
may explain this difference. Although base modifications may offer the prospect of 
increased siRNA stability, modified bases may distort normal cell metabolism, with 
possible toxic sequelae. Due to its high target sequence specificity, mismatches between 
mRNA and the siRNA duplex have been shown strongly to reduce activity (100-104). 
Tuschl and colleagues have identified many of the requirements and preferred 
characteristics of siRNA with regard to silencing efficacy (100,101). The 
complementary regions are connected in shRNA, produced by plasmids containing the 
RNA polymerase III dependent promoter (H1-RNA) region, consist of 19-nucleotide 
inverted repeats (forming the hairpin-stem) and a, not strictly regulated, number of 
spacer nucleotides forming the loop (105,106). The 3'-overhang is generally composed 
of 4 uridine nucleotides. By cotransfecting such a vector with a gene conferring 
puromycin-resistance, stable expression can be achieved (107). 
 
1.4.2. Methods of Delivery 
 The therapeutic application of siRNA is largely dependent on the development 
of a delivery vehicle that can efficiently deliver the siRNA to target cells (108). In 
addition, such delivery vehicles must be administered efficiently, safely and 
repeatedly (109). Employed in the field of gene therapy research for over a decade, 
and now in some clinical trials, viral vectors have been applied to RNAi. The five 
types of viral vectors that are currently in use for RNAi include:  retrovirus, lentivirus, 
adenovirus, adeno-associated-virus (AAV), and baculovirus. 
 Retroviruses have serious safety concerns and limitations in efficiency. 
Lentiviruses, a subclass of retroviruses, may find in vivo applications and are widely 
used for proof of concept experiments. While safety concerns still exist, lentiviruses 
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are free of some of the major disadvantages of retroviruses. Adenoviral vectors are 
found in ~25% of current clinical gene therapy trials. These are vectors of choice for 
tumour-targeting gene therapy, where a relatively short duration of action is sufficient, 
unlike the need for long-term gene replacement therapy in treatment of genetic 
disorders (e.g., cystic fibrosis). A major disadvantage of adenoviral vectors, however, 
is the lack of clear tissue tropism and dependence on defined surface receptors of the 
target cell, which are often absent in the tissues of interest (especially tumour cells), 
but adenovirus hepatotoxicity is significant and can be dose-limiting, so reducing 
possible therapeutic effects in the target tissue (110). 
 Delivery of RNAi without viral vectors has been tried with a wide variety of 
agents:  injection of pure, unmodified (“naked”) siRNA, chemically stabilized or 
modified RNA, encapsulating the siRNA in microparticles or liposomes, and binding 
siRNA to cationic or other particulate (nanoparticle) carriers (111). 
 
1.4.3. Chemically Modified siRNA Molecules 
 Duration of siRNA activity in vivo and any possible therapeutic effect will 
depend on its stability in the serum. Double stranded RNA is more stable than single 
strand RNA in serum, but it is still degraded within a few hours by RNase. Chemical 
modifications may increase siRNA stability in serum without affecting the RNAi 
effect. Ideally, these chemical modifications could also contribute to increase thermal 
stability, cellular tropism, silencing activity and the pharmacokinetic properties of the 
siRNA (112). Other chemical alterations include modifications of residues added at 
the 2' position of the ribose:  2'-O-Me, 2'-O-allyl, and 2’-deoxyfluorouridine 
modifications. These modifications were based on early reports showing that the 2’-
OH group is not required for silencing in siRNA (113,114). 
 
1.4.4. Liposomes and Nanoparticles 
 Research into delivery of siRNA is at quite a preliminary level. One reason for 
this may be the apparent misconception that all poly-nucleic acids are much alike and 
should be delivered to cells in comparable ways using comparable delivery systems. 
Superficially this is true. Both pDNA and siRNA have anionic phosphodiester 
backbones with identical negative charge:nucleotide ratios and should therefore 
interact electrostatically with cationic lipids to form lipoplex nanoparticles that are 
able to transfer the nucleic acids into cells. However, pDNA and siRNA are otherwise 
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very different from each other in molecular weight and molecular topography with 
potentially important consequences (115). 
 Unmodified siRNA has a half-life of less than an hour in human plasma, and 
circulating siRNAs are rapidly excreted by kidneys thanks to their small size. To 
address the concerns of low stability in serum and rapid renal excretion, several 
different approaches have been developed to deliver envelope packaged siRNA. The 
most popular envelopes included liposomes and other nanoparticles, both as simple 
packages, but also in combination with specific homing signals designed to direct the 
preferential uptake by a specific target tissue or a group of target cells. Some research 
groups have used liposomes for in vivo delivery with good results. Sorensen et al. 
(116) used cationic DOTAP liposomes to inject RNAi against TNF-α, and were able 
to suppress lethal reaction to LPS injection in a mouse model of sepsis. In the same 
publication, they report successful silencing of a marker gene (GFP) in liver after 
intravenous injection of liposomes (116). 
 
1.4.5. Cationic Lipids 
 Cationic lipids, the most used non-viral vectors, are composed of positively 
charged lipid bilayers and can be complexed to negatively charged siRNA duplexes 
(116,117). Cationic lipids are routinely used for delivery of poly-nucleic acids into 
mammalian cells in vitro, and systemic i.v. administration of lipoplexes (composed of 
cationic lipid, neutral helper lipid and nucleic acid) has been applied for gene and 
siRNA delivery in vivo. The development of novel siRNA formulations for the systemic 
in vivo application of siRNAs is a current challenging area of research. In contrast to 
“naked” or non-formulated siRNA molecules, the siRNA-lipoplexes are strongly taken 
up by the vascular endothelium in the liver, heart, and lung (118). Vectors are being 
developed based on cationic polymers or lipids that contain functional groups to 
mediate appropriate interactions with the extracellular environment or to bind to 
specific cellular macromolecules. siRNA delivery decreases target protein production 
(119). However, the efficacy of RNAi depends upon efficient delivery of the 
intermediates of RNAi, short interfering RNA (siRNA) and short hairpin RNA (shRNA) 
oligonucleotides. The delivery challenge is even greater when the aim is to inhibit the 
expression of target genes in animal models (120).  
 While there is a great deal of structural variation in lipid molecules that are 
able to mediate transfection, all have a number of common features. First, there is a 
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positively charged head group that usually contains one or more positively charged 
nitrogen atoms to allow interaction between the transfection reagent and the 
negatively charged sugar–phosphate backbone of a nucleic acid molecule. A spacer 
usually links the charged head group to one, two or three hydrocarbon chains. In some 
instances, this spacer may play a role in promoting contact between the cationic lipid 
and the nucleic acid. The hydrocarbon chains are often 14 or more carbon atoms in 
length. The degree of saturation and the presence of cis- or trans-isomers introduce 
more potential for structural variation (109). 
 RNAi is being exploited for a variety of laboratory applications in biology and 
as a promising therapeutic product. The clinical use of siRNA is hindered by three 
major problems:  1) rapid enzymatic degradation resulting in a short half-life in the 
blood; 2) poor cellular uptake; 3) insufficient tissue bioavailability. In general, these 
problems can be partly overcome by mixing siRNAs with cationic lipids or cationic 
polymers to form complexes, which could be additionally surface-modified with 
specific ligands allowing for targeting of required tissues (97). 
 
1.4.6. siRNA Delivery Steps 
 
Fig. 1.3. Steps in the process of non-viral siFection by endocytosis showing the 
barriers for RNA nanoparticles, from the RNA-lipoplex formation to gene silencing. 
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 There is a need for a better understanding of the mechanism of gene silencing 
to targeted cells and detailed understanding of the barriers for siRNA delivery to 
achieve efficient formulation (Fig. 1.3). These barriers that hinder the delivery of 
siRNA to its physical site of action (the cytoplasm) are summarized, and they follow 
after RNA condensation, cell membrane entry, and endosomal escape as outlined 
above for DNA delivery. The dissociation of RNA from the condensing agent, 
decomplexation, is an important step for the host transcription factors to initiate the 
transcription reaction. This decomplexation process occurs after endosomal escape in 
the cytoplasm. It can be compared with the dissociation of DNA from its condensing 
agent, a step that must occur for the host transcription factors to initiate transcription. 
DNA decomplexation may occur after endosomal escape in the cytoplasm (36) or 
after nuclear entry (44). A sufficient amount of synthetic siRNA must be delivered to 
cells to show an RNAi effect, gene silencing 
 
1.4.7. In Vitro Use of siRNA 
 In vitro use simplify many of the problems associated with targeted cell 
delivery, target selectivity, homeostasis mechanisms, and possible non-target cell 
toxicity encountered in vivo. Yet, the cellular membrane is still an important physical 
barrier to the efficient intracellular introduction of nucleic acids. Similarly as in gene 
and antisense studies, passage through the cell membrane of nucleic acids is difficult 
to achieve as a result of their hydrophilic and polyanionic nature. Experience with 
DNA and antisense oligonucleotides has provided a variety of chemical and physical 
techniques that would allow the transfection or infection of cells with extracellularly 
synthesized siRNA, as reviewed recently (16,33,121). The chemical techniques are 
generally based on the use of (poly)cations. The cationic compounds condense the 
siRNA, resulting in the formation of particles. These particles generally have a net 
positive charge, as an excess of the cation provides efficient condensation and 
prevents particle aggregation. The net positive charge of the particle additionally 
promotes electrostatic interaction with the overall negative charge of the cell 
membrane. Both by condensing the siRNA and promoting cell membrane interaction, 
relatively efficient cell transfection can be achieved. A whole range of cations exists 
that have been shown to promote the intracellular delivery of nucleic acids 
(16,33,121). Of these, the cationic lipids, cationic polyamines and combinations of 
both are the most prominent. 
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 The ultimate in vitro transfection-efficiency of a cationic compound appears to 
be dependent on the characteristics of the cell e.g., cell type, confluency, and passage 
number, as well as the properties of the cationic particle, e.g., cell medium 
compatibility, cell toxicity, cation structure, strength of electrostatic interaction, and 
particle size. It appears that the most popular cationic agents possess an ability to 
influence the intracellular processing of the particle in addition to their nucleic acid 
condensing ability. Although interaction between the cell surface and the delivery 
system promotes siRNA uptake, appropriate intracellular trafficking should still 
follow the interaction. The cationic lipoplexes are likely to be taken into cells by 
endocytosis. Therefore, the lipoplex and/or its siRNA should be able to escape the 
endosomal vesicle to evade lysosomal degradation and allow RNAi effects to occur. 
 Although, systematic studies evaluating the efficiency of siRNA introduction into 
cells by various transfection reagents are lacking thus far, it is conceivable that some 
polycations will have a more suitable structure for the introduction of small siRNA than 
others. Physical techniques to overcome the cellular membrane barrier either force the 
nucleic acid into the cell (like gene gun, magnetofection) or lower the cell membrane 
barrier (electroporation, or ultrasound) (121). For transfection of genetic material 
encoding for transcript siRNAs or shRNAs the same considerations are valid. Recent 
research suggests that nuclear localization of siRNA produced by transcription may be 
required for efficient gene silencing (66), although another study reports cytoplasmic 
degradation of mRNA by externally applied siRNA (122). It has been suggested that the 
intracellular processing of externally applied siRNA or intracellularly transcribed siRNA 
may be different (66). For transcript-encoding DNA, additionally, viruses can be used to 
deliver the genetic material. The viral techniques make use of the evolutionary 
adaptations of virions for efficient cell attachment and correct intracellular processing for 
high-level transcription of delivered genetic material. From gene therapy studies, useful 
viruses have been identified:  the retrovirus, adenovirus, herpes virus, lentivirus, and 
baculovirus, each having its own advantages and disadvantages. These viral systems can 
also be attractive for the delivery of transcript-encoding DNA in vitro. Taken together, 
these systems could provide means for studying loss-of-function phenotypes, target 
identification and validation, and identifying possible therapeutic strategies for siRNA in 
vitro. Still, to assess a protein’s importance and potential in disease-control, which is in 
the ultimate interest of pharmaceutical applications, in vivo studies are needed. 
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 The production of gene-specific synthetic siRNA sequences useful in 
functional genomics programs and, more intriguingly, potentially as drugs to treat 
disease is now feasible. siFection with siRNA requires a delivery system displaying 
the capability to mediate the RNA sequence to the intracellular environment. Cationic 
lipids carriers have long been used to mediate the transfer of DNA into cells; since the 
nature of their interactions with DNA and RNA is identical (charge/charge), it seems 
obvious to adapt formulations that were developed for pDNA to the delivery of 
siRNA. However, a closer look at this process reveals problems. One particularity of 
DNA formulation with a cationic entity such as peptides, proteins, polymers, or 
cationic lipids is the occurrence of the so-called bDNA condensation process. This 
phenomenon is triggered when 70–90% of the DNA phosphodiester charge is 
neutralized, and is manifested by the collapse of DNA into nanostructures of 
differential morphology due to the predominant hydrophobic nature of the DNA 
nanoparticle. A minimal length of the DNA of about 800 bp is required for a DNA 
condensation process to occur. This finding has important consequences:  short 
double-stranded siRNAs are devoid of such a condensation process. While the volume 
occupied by a condensed DNA nanoparticle is about 10,000-times smaller than of its 
uncondensed counterpart, short double-stranded siRNA stretches retain their initial 
volume when complexed to a cationic entity. As a result, several copies of siRNA are 
complexed/incorporated per liposome rather than one single entity of condensed DNA 
(11). 
Interestingly, pDNAs delivered to cultured cells by a transfection reagent 
naturally localize to the nucleus within short time after transfection, whereas their 
carrier molecules remain in perinuclear area. In sharp contrast, synthetic siRNAs 
localize to perinuclear regions and not to the nucleus after siFection, even after 
extended periods of time (108). These differences in uptake, intracellular trafficking, 
and storage have important consequences:  firstly, the formulation parameters of 
synthetic siRNA need to be carefully established prior to use. In other words, a 
delivery reagent developed for DNA is most likely not suitable for siRNA. Secondly, 
siRNA delivery must be devoid of any toxic effects which come with the siFection 
reagent. We have shown that certain widely used transfection reagents induce a degree 
of cellular toxicity that severely interferes with the outcome of the gene down-
regulation study.  
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1.4.8. Delivering siRNA In Vivo Using Non-viral Carriers 
 Many non-viral carriers used in the delivery of DNA for gene therapy have been 
adopted for siRNA delivery. As RNAi is active in the cytoplasm, delivery of siRNA is 
relatively easier than delivery of plasmid or viral DNA, which has to be in the nucleus 
for expression. Non-viral siRNA delivery to the disease tissue does not elicit an immune 
response, which has a great advantage for its application in drug target validation and 
also allows multiple administrations of siRNA, which are crucial for siRNA therapeutic 
applications. Cationic lipids and polymers are two major classes of non-viral siRNA 
delivery carriers and both are positively charged and can form complexes with 
negatively charged siRNA. The siRNA–carrier complex can be condensed into 
nanoparticles of ~100 nm, allowing very efficient cellular uptake of the siRNA agent 
through endocytosis. Several studies, reviewed in (120), have shown that cationic lipids 
and polymers can enhance siRNA delivery in vivo through systemic routes either 
intravenously (i.v.) or i.p. Carrier-administered siRNA agents were efficiently knocking 
down the target genes and achieved antitumor efficacies. Some ligand-targeted siRNA 
delivery systems have been developed using the cationic liposome complex and 
polymer complex systems. Recent successes using ligand-targeted complexes (123-125) 
to deliver therapeutic siRNA into tumour tissues and liver tissues suggest that targeted 
systemic delivery for siRNA therapeutics is promising (126,127). Systemic siRNA 
delivery requires stability in the blood and in the local environment to enter the target 
cells. Recent studies showed that tumour-targeting siRNA delivery was achieved by 
using a cyclic RGD-tripeptide ligand-directed nanoparticle and that its application in 
antiangiogenic treatment for cancer was obtained by systemic siRNA delivery (128). 
Antibody-mediated delivery of siRNA was reported for tumour targeting via cell-
surface receptors (124). This antibody-mediated binding to artificial tumour cells is 
interesting for a proof of concept, but it might well have limitations for clinical-viable 
delivery (120). 
 
1.4.9. Delivering siRNA In Vivo Using Local Administration 
 The choice between local and systemic delivery depends on what tissues and 
cell types are targeted. Skin and muscle are better accessed using local siRNA 
delivery, but lung and tumours are reached efficiently by local or systemic siRNA 
deliveries. Different approaches show that siRNA can be efficiently delivered to 
various tissue types (103). 
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Intranasal 
Airway delivery of siRNA is a very useful method for target validation and 
therapeutic development because of the relevance of the respiratory system in various 
diseases (129,130). 
Intraocular 
An increasing number of clinical protocols have been approved for treating eye diseases 
with nucleic acid drugs, such as antisense oligonucleotides or RNA aptamers (131). 
Intracerebral 
The brain tissue is the foundation of the central nervous system (CNS), obviously a 
very important biological system that draws interest for functional genomics research 
and therapeutic development. A recent study showed that infusion of an aqueous 
solution of chemically protected siRNA oligonucleotides directly into the brain was 
able to selectively inhibit gene expression (132).  
Intramuscular 
The skeletal-muscle tissue is accessible for local siRNA administration. Direct 
injection of siRNA formulated with cationic lipids or polymers can be considered for 
local delivery, although inflammation caused by the injection is a common problem. 
A recent study with non-formulated siRNA delivered by direct injection into mouse 
muscle followed by electroporation demonstrated a significant gene silencing that 
lasted for 11 days (133).  
Intratumoural 
Intratumoural delivery of siRNA is a very attractive approach for functional validation 
of tumourigenic genes. Inhibition of tumour growth in two human breast cancer 
xenografts using intratumoural delivery of VEGF specific siRNA was observed (134).  
 
1.4.10. siRNA Delivery In Vivo Using Systemic Administration 
 Usually, the purpose of systemic administration is not to deliver siRNA 
throughout the entire body, but to reach specific diseased tissues. Two tissue types 
have been of particular interest for many siRNA delivery efforts:  liver and tumour.  
 Malignant tumours grow fast and spread throughout the body via the blood or 
the lymphatic system. Metastatic tumours established at distant locations are usually 
not encapsulated and thus, more amenable for systemic delivery. The local siRNA 
administration methods discussed above can meet the requirements for most 
functional genomics studies by acting on primary tumours or xenograft models, which 
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form the basis of most cancer biology research. However, systemic delivery of siRNA 
is needed not only for studies related to gene functions, but also for siRNA-based 
cancer therapeutics, targeting the tumour and the neovasculature. Systemic siRNA 
delivery imposes several requirements and greater hurdles than local siRNA delivery, 
the stablety of oligonucleotides in the blood and in the local environment are needed 
to enter the target cells, and the siRNA needs to pass through multiple tissue barriers 
to reach the target cell (107). 
 
1.5. AIMS 
The aims of this thesis are to design and develop non-toxic, non-viral vectors for 
in vitro and then possible in vivo applications. These vectors are based upon our novel 
spermine conjugates, and we have made systematic changes to the length, type, and 
position of the hydrophobic anchor. These lipospermine verctors (cationic lipids) 
probably assist in the self-assembling of polycationic scaffolds as well as facilitating 
absorptive endocytosis and/or fusion with cell membranes. These lipospermines form 
spontaneous complexes with negatively charged poly-nucleic acids leading to the 
formation of nanoparticles after removal of small counterions from both the cationic 
carriers and the nucleic acids in a thermodynamically favoured step which drives and 
stabilizes complex formation. Thus, these formed nanoparticles are suitable for gene or 
siRNA delivery. We have chosen pEGFP as the reporter gene and a commercially 
available fluorescein-labelled model siRNA. The formed complexes will be monitored 
using:  ethidium bromide (EthBr) fluorescence quenching assay for DNA, RiboGreen 
intercalation assay for siRNA, a light scattering assay, gel-shift (gel electrophoresis) 
assays (including DNase protection), particle size measurement by laser-light scattering, 
zeta-potential measurement, and confocal microscopy visualization. 
The transfection efficiency of these novel lipopolyamine vectors will then be 
investigated in an immortalized cancer cell line (HtTA) and in a primary (hard-to-
transfect) skin cell line (FEK4). Furthermore, we will achieve a key aim if we are able 
to deliver efficiently in the presence of serum, i.e., in the presence of DNase and 
RNase. Also, the cytotoxicity of these compounds will be investigated using the MTT 
cytotoxicity assay for the comparison between structure and function versus 
cytotoxicity for both DNA and siRNA delivery. 
 
 
































































































-dioleoyl spermine, and N4-lithocholoyl,N9-oleoyl 
spermine were kindly provided by Shi Li, Department of Pharmacy and Pharmacology, 

























































diacyl spermines were kindly provided by Mostafa Khamis, Department of Pharmacy 
and Pharmacology, University of Bath, UK. 
Ethidium bromide (EthBr), (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid) (HEPES), ethylenediaminetetraacetic (EDTA) sodium salt, tris-acetate-EDTA 
(TAE 1x), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
dimethyl sulfoxide (DMSO) were routinely purchased from Sigma-Aldrich unless 
otherwise stated and used without purification. Luria Bertani (LB) broth, LB agar and 
ampicillin were purchased from Sigma-Aldrich. Escherichia coli competent cells 
JM109, high efficiency (>10
8
 cfu/µg) were purchased from Promega. 
LB broth and LB agar were prepared by dissolving the specified amount of 
powder in 1 L milliQ water according to the formula shown below. Both LB agar and 
LB broth were autoclaved (121 °C, 15 lb/inch2) for 30 mins, then both media were 
allowed to cool to 40 °C. 
 
LB broth is composed of: 
Tryptone (pancreatic digest of casein) 2 parts  (10 g/L)* 
Yeast extract 1 part   (5 g/L) 
NaCl 1 part   (5 g/L) 
*(g/L) is the concentration of each ingredient after preparation of 20 g/L milliQ water 
as recommended by the manufacturer. 
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LB agar is composed of : 
Agar 3 parts  (15 g/L)* 
Tryptone (pancreatic digest of casein) 2 parts  (10 g/L) 
Yeast extract 1 part   (5 g/L) 
NaCl 1 part   (5 g/L) 
*(g/L) is the concentration of each ingredient after preparation of 35 g/L milliQ water 
as recommended by the manufacturer. 
 
Cell culture chemicals used for media preparation were purchased from Gibco 
used without further purification. Cell culture plates, flasks and Pipettes from fisher. 
Sterile Falcon polypropylene tubes (15 and 50 ml) and FACS polystyrene test tubes 
from Falcon. Ultracentrifuge tubes obtained from Eppendorf Ltd. Lipofectin and 
Lipofectamine were purchased from Invitrogen, Transfectam
®
 was from Promega and 
Foetal Calf Serum FCS was from PAA laboratories. Autoclaved (sterile) phosphate-
buffered saline (PBS) pH 7.3 contains 10 mM phosphate buffer, 2.7 mM KCl and 137 
mM NaCl in MilliQ water. Trypsin was diluted to a working concentration of 0.25 % 
w/v with PBS. 
pEGFP vector (4.7 kbp) was purchased from Clontech, and deoxyribonucleic 
acid (DNA) from calf thymus, activated and lyophilized powder was purchased from 
Sigma-Aldrich. Plasmids were isolated and purified using HiSpeed™ plasmid Maxi 
kit, obtained from Qiagen. MilliQ water was obtained from a MilliQ PF plus system 
with ultra-filtration cartridge, Millipore Ltd., free of DNase and RNase. Label IT
®
 
RNAi Delivery Controls (Fluorescently labelled RNAi duplexes) and TransIT-TKO
®
 
Transfection Reagent were purchased from Mirus. 
 
2.2. BUFFERS AND MEDIA 
EMEM       Earle’s Minimal Essential Medium 
FCS            Foetal Calf Serum 
HEPES buffer (20 mM NaCl, 2 mM HEPES,10 µM EDTA, pH 7.4) 
PBS             Phosphate-buffered saline 
TE buffer   (50 µl, 200mM Tris-HCl, 20 mM EDTA, pH 7.5, in DEPC-treated water) 
TAE buffer (Tris-Acetate-EDTA, 40 mM Tris-Acetate and 1 mM EDTA) 
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2.3. SUPPLIERS 
Chemicals, reagents, kits, solvents, plasmids, disposables, instruments were 
obtained from UK suppliers (unless otherwise stated): 
 
1. Beckman Coulter, Oakley Court, Kingsmead Business Park, London Road, 
High Wycombe, Buckinghamshire. 
2. Becton Dickinson Biosciences, 21 Towns Road, Cowley, Oxford. 
3. Biochrom Ltd, Cambridge Science Park, Milton Road, Cambridge. 
4. Bio-Rad Laboratories Ltd., Bio-Rad House, Maxted Road, Hemel 
Hempstead, Hertfordshire. 
5. BMG LABTECH GmbH, Hanns-Martin-Schleyer-Str. Offenburg/Germany. 
6. Calbiochem, Merck Chemicals Limited, Padge Road, Nottingham, 
7. Carl Zeiss Ltd. Woodfield Road, Welwyn Garden City, Hertfordshire 
8. Clontech, Clontech BD Biosciences, Between Towns Road, Cowley Oxford. 
9. Corning Ltd., Fisher Scientific UK Ltd., Bishop Meadow Road, 
Loughborough, Leicestershire. 
10. Dharmacon RNAi Technologies, Perbio Science UK Ltd, Unit 9 Atley Way, 
North Nelson Industrial Estate, Cramlington, Northumberland. 
11. Eppendorf, Fisher Scientific UK Ltd., Bishop Meadow Road, Loughborough, 
Leicestershire. 
12. Falcon, Fisher Scientific UK Ltd., Bishop Meadow Road, Loughborough, 
Leicestershire. 
13. Fisher, Fisher Scientific UK Ltd., Bishop Meadow Road, Loughborough, 
Leicestershire. 
14. Gibco, Gibco-Invitrogen Ltd, 3 Fountain Drive, Inchinnan Business Park, 
Paisley. 
15. Grant, Keison Products, Chelmsford, Essex.  
16. Heraeus, Kendro Laboratory Products Plc, Stortford Hall Park, Bishop's 
Stortford, Hertfordshire. 
17. Intermed MDH Ltd., Kenn Road, Clevedon, Somerset.  
18. Invitrogen Ltd, 3 Fountain Drive, Inchinnan Business Park, Paisley. 
19. Kodak, Hemel Hempstead, Hertfordshire. 
20. Malvern Instruments Ltd, Enigma Business Park, Grovewood Road, 
Malvern, Worcestershire. 
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21. Merck, VWR International Ltd., Merck House, Poole, Dorset. 
22. Millipore UK Ltd., Units 3&5 the Courtyards, Hatters Lane, Watford. 
23. Mirus, Cambridge BioScience 24-25 Signet Court Newmarket Road 
Cambridge  
24. NanoSight Ltd., 2 Centre One, Lysander Way, Old Sarum Park, Salisbury, 
Wiltshire. 
25. New Brunswick Scientific, 17 Alban Park, Hatfield Road, St. Albans, 
Hertfordshire. 
26. NUNC, Fisher Scientific UK Ltd Bishop Meadow Road, Loughborough, 
Leicestershire. 
27. PAA laboratories Ltd, 1 Technine, Guard Avenue, Houndstone Business 
Park, Yeovil, Somerset. 
28. Promega, Delta House, Southampton Science Park, Southampton. 
29. Qiagen Ltd., Qiagen House, Fleming Way, Crawley, West Sussex. 
30. Rank Brothers Ltd., 56 High Street, Bottisham, Cambridge  
31. Sanyo, Integrated Services TCP Inc., Palisades Park, New Jersey, USA. 
32. Sigma-Aldrich Company Ltd. The Old Brickyard, New Road, Gillingham, 
Dorset.  
33. Syngene, Beacon House, Nuffield Rd., Cambridge. 
34. Wilovert Hund, the Helmut Hund Ltd. Company, Helmut Hund GmbH, 




2.4.1. Amplification and Purification of Plasmid DNA 
pEGFP plasmids 
pDNA (EGFP) under CMV promoter, obtained from Clontech, was used as 
reporter gene in this study and DNA condensation studies. DNA can amplify in a 
large scale (up to 750 µg) using Qiagen HiSpeed™ plasmid Maxi kit (Qiagen Ltd.). 
Large-scale preparation of plasmids DNA protocol, described below, is based on a 
modified method described by Sambrook et al. (135) and using Qiagen anion-
exchange resin. A positively charged diethylaminoethanol (DEAE) resin was used to 
separate negatively charged phosphate groups of DNA, by properly adjusting the 
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NaCl concentration of the elution solution. Aqueous NaCl solution (1.2-1.6 M) was 
used to elute DNA and separate the plasmid.  
 
2.4.1.1. Plasmid amplification 
The plasmid, pEGFP was transformed into E. coli JM 109 bacterial host strain. 
The transformed cells were grown in larger quantities (0.2–0.3 l) of LB broth 
supplemented with 100 mg/L ampicillin as follows: 
LB broth was prepared by dissolving LB broth base powder (10 g) in 500 ml 
milliQ water. LB agar, for the preparation of agar plates, was prepared by dissolving 
LB agar powder (17.5 g) in 500 ml milliQ water. Both LB agar and LB broth were 
autoclaved (121 °C, 15 lb/inch2) for 30 mins. Then, both media were left to cool to 40 
°C. Ampicillin solution (0.1 g/ml in milliQ water, 500 µl) was added to both (500 ml) 
media and mixed well. 
Sterile LB broth can be kept at 20 °C in a tightly closed bottle for one month. 
To prepare LB agar plates, about 10 ml of warm LB agar was poured in a 9 cm plate, 
using aseptic techniques. LB agar was then left for 30 mins to cool. LB agar plates 
were then incubated for 20 mins in a hot room (37 °C) upside down until dry. The 
solidified agar plates were kept in a cold room (4 °C) for use within 3 months. 
 
2.4.1.2. Transformation of competent cells and plasmid propagation 
Heat shock technique was used for E. coli JM 109 transformation. Sterile 
Falcon polypropylene tubes (50 ml) were chilled on ice one per transformation. 
Competent cells (E. coli JM 109) were thawed from -80 °C on ice. The thawed 
competent cells were gently mixed by flicking, and then 100 µl were transferred to 
each chilled tube. For each 100 µl competent cells, 50-100 ng of DNA was added and 
mixed by flicking. Tubes were placed on ice for 10 mins. Cells were heat-shocked for 
45-50 s in a temperature controlled water bath (Grant) at 42 °C without shaking. 
Tubes were then immediately put on ice for 2 mins. Cold (4 °C) LB broth (900 µl) 
was added and the tubes were incubated for 60 mins at 37 °C with shaking (200 rpm) 
using a temperature-controlled flask shaker (New Brunswick Scientific). 
For each transformation, 100 µl transformed cells were plated on LB agar 
medium containing 100 µg/ml ampicillin. Plates were then incubated upside down for 
18 h in an incubator (Heraeus Instruments) at 37 °C. A single colony was isolated 
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from LB plate and incubated in 2 ml of LB broth containing ampicillin (100 µg/ml) in 
a 50 ml Falcon tube. The culture was grown for 8 h at 37 °C with shaking (200 rpm). 
The culture was then scaled-up by the addition of the starter culture (2 ml) into a flask 
(of at least 1 l size flask) containing LB broth (250 ml) with ampicillin (100 µg/ml). 
The flask was then incubated for 18 h at 37 °C with shaking (200 rpm) using a 
temperature-controlled flask shaker. 
 
2.4.1.3. Long term storage of transformed cells 
A single colony was isolated from each LB plate and incubated in LB broth (1-
2 ml) containing ampicillin. The culture was grown for 8 h. Glycerol solution (30 % 
v/v) was prepared and sterile filtered. The culture (0.5 ml) was mixed with sterile 
glycerol (0.5 ml) solution and transferred to a cryo-preservation vial, obtained from 
Corning Ltd., then stored at -80 °C. 
 
2.4.1.4. Plasmid isolation and purification 
After incubating the 250 ml bacterial culture flask for 18 h at 37 °C with 
shaking (200 rpm) using a temperature-controlled flask shaker, cells were harvested 
by centrifugation, using Beckman floor centrifuge model J2-MC (Beckman Coulter) 
at 6,000 rpm using Beckman JA-10 rotor for 15 mins at 4 °C. Cell pellets, obtained 
after completely removing the supernatant liquid, were resuspended in 10 ml ice-
cooled P1 buffer (50 mM Tris-Cl, 10 mM EDTA and 100 µg/ml RNase A, pH 8.0), 
complete mixing was allowed by vortexing until no cell clumps remained. Then, 10 
ml of P2 lysis buffer (200 mM aqueous NaOH, 1 % w/v sodium dodecyl sulfate) was 
added to the cell suspension. The tube was then inverted gently 4 times and incubated 
at 20 °C for 5 mins. Ice-cooled P3 neutralisation buffer (10 ml, 3.0 M potassium 
acetate, pH 5.5) was added into the cell lysates and the mixture was inverted gently 4 
times. The lysate was poured into the barrel of the Qiafilter cartridge and incubated 
for 10 mins, with the outlet nozzle closed. 
The HiSpeed Maxi Tip (a syringe column with a filtration unit) was 
equilibrated with 10 ml buffer QBT (750 mM NaCl, 50 mM 3-[N-morpholino] 
propanesulfonic acid (MOPS), 15 % isopropanol v/v, 0.15 % Triton X-100 v/v) and 
the column was allowed to empty by gravity flow. The outlet nozzle cap of the 
Qiafilter cartridge was removed and the plunger was gently inserted into the cartridge. 
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The filtrate was collected into the equilibrated Maxi Tip and allowed to be filtered 
through the resin. After that, 60 ml of buffer QC (1.0 M NaCl, 50 mM MOPS, 15 % 
isopropanol v/v, pH 7.0) was added to wash the HiSpeed Maxi Tip. Entrapped DNA 
in the resin was eluted by adding 15 ml of buffer QF (1.25 M NaCl, 50 mM Tris-Cl, 
15 % isopropanol v/v, pH 8.5) into the tip. The eluted solution was kept in a 50 ml 
Falcon tube. Isopropanol (10.5 ml) was then added and mixed well to precipitate the 
DNA, then the mixture was incubated for 5 mins at 20 °C.  
A DNA collection unit (QIA precipitator tip) was attached to the nozzle of a 
30 ml syringe from which a plunger was removed. Then, the eluate/isopropanol 
mixture that has the precipitated DNA was added to the precipitator unit, and the 
plunger was inserted into the syringe using constant pressure. DNA was entrapped in 
the precipitator unit. Then, the tip and the plunger were removed from the syringe. 
After that, the tip was reconnected again to the syringe nozzle and 2 ml of 70 % EtOH 
v/v was added into the syringe. DNA was washed by pressing EtOH through the QIA 
precipitator using inserted plunger at a constant pressure. The tip and the plunger were 
removed from the syringe and DNA was dried by pushing air through the precipitator 
2-3 times and the outlet nozzle of the precipitator was dried with absorbent paper. 
To elute the DNA in the tip, 1 ml of buffer TE (10mM Tris-HCl, 1mM EDTA, 
pH 8) was added into a new 5 ml syringe to which the precipitator tip was connected. 
The plunger was attached and pushed gently. The eluted solution was collected in an 
ultracentrifuge tube (1.5 ml). The previous step was repeated by the transfer of the 
eluate in the 1.5 ml ultracentrifuge tube to the 5 ml syringe to which the precipitator 
tip was connected and eluted again in the same 1.5 ml tube. DNA solution was stored 
at -20 °C. 
 
2.4.1.5. Analysis of the purification procedure 
The DNA obtained can be quantified by the maximum UV absorption at 260 
nm. This wavelength is an average of the absorption of the individual nucleotides 
which vary between 256 – 281 nm. DNA was determined by measuring the maximum 
absorption at 260 nm for nucleic acids and 280 nm for proteins. Ratios of A260/A280 
between 1.75–1.90 are considered acceptable for DNA purity (136,137). 
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Plasmid DNA yields and quality were analyzed spectrophotometrically using 
Gene Quant II RNA/DNA calculator (Biochrom Ltd). Plasmid DNA sample 5 µl was 
diluted to 100 µl with TE buffer, in a microcuvette. The absorbance was measured at 
260 nm (A260) and 280 nm (A280). TE buffer (100 µl) was used as a standard 
reference. The calculation for DNA concentration by dilution factor 20, and a 
conversion factor for double stranded dsDNA, 50 µg/ml/A260. 
 
2.4.2. DNA Condensation Studies 
DNA condensation was carried out to investigate the neutralization of the 
negative charges of the phosphate groups on the DNA backbone. These studies 
include:  
 
1. Ethidium bromide fluorescence quenching assay 
2. Light scattering assay 
3. Gel electrophoresis study 
 
2.4.2.1. Ethidium bromide fluorescence quenching assay 
Each concentration of the DNA (pEGFP) stock solutions (approximately 1 
µg/µl) was determined spectroscopically and 6 µg (approximately 6 µl) of DNA was 
diluted to 3 ml with HEPES buffer in a glass cuvette stirred with a micro-flea. 
Immediately prior to analysis, EthBr solution (3 µl, 0.5 mg/ml) was added to the 
stirring solution and allowed to equilibrate for 10 mins. 
Aliquots (5 µl) of spermine (10 x 0.04 mg/ml, and then 5 x 0.2 mg/ml) were 
then added to the stirring solution and the fluorescence measured after 1 min 
equilibration using Perkin-Elmer LS 50B luminescent spectrometer (λex = 260 nm and 
λem = 600 nm with slit width 5 nm) while stirring using an electronic stirrer (Rank 
Brothers Ltd.). The total polyamine solution added to the DNA solution did not 
exceed 5 % of the total volume of the solution, so no correction was made for sample 
dilution. The fluorescence was expressed as the percentage of the maximum 
fluorescence when EthBr was bound to the DNA in the absence of competition for 
binding and was corrected for background fluorescence of free EthBr in solution as 
optimized by Geall and Blagbrough (138). This correction and the subsequent 
normalization were performed using an Excel spreadsheet.  
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For synthesized lipopolyamines, commercially available transfecting agents, 
Lipofectin, Lipofectamine (available as liposomal formulations) and the non-
liposomal formulation Transfectam
®
, the lipopolyamines were prepared as stock 
solutions using absolute EtOH as solvent and diluted with HEPES buffer to the 
specified concentrations directly before use. Aliquots were added to the stirring 
solution of 3 ml HEPES buffer in a glass cuvette containing DNA (6 µg) and EthBr 
(1.5 µg). The fluorescence was measured after 1 min equilibration using Perkin-Elmer 
LS 50B luminescent spectrometer (λex = 260 nm and λem = 600 nm with slit width 5 
nm) while stirring using an electronic stirrer (Rank Brothers Ltd.). The total 
lipopolyamine solution added to the DNA solution did not exceed 5 % of the total 
volume of the solution, so no correction was made for sample dilution. The 
fluorescence was expressed as the percentage of the maximum fluorescence when 
EthBr was bound to the DNA in the absence of competition for binding and was 
corrected for background fluorescence of free EthBr in solution. This correction and 
the subsequent normalization were performed using an Excel spreadsheet.  
 
The DNA polyamine complex composition is expressed as N/P 





                       eq.[1] 
 
 Ammonium equivalents of the polyamine were determined from pKa value of 
each amino group at pH 7.4 (HEPES buffer) according to the Henderson-Hasselbach 
equation: 
 




                                                          eq. [2] 
 
The N/P charge ratio was calculated according to the ammonium/phosphate, 
(+/-) charge ratio of the investigated lipopolyamines to DNA. For DNA it was 









-diacyl spermines it was calculated as 1 mole 
contains two amino groups that are (fully) protonated (positively charged) at pH 7.4. 
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-dialkyl spermine it was calculated as 1 mole (molecular weight) 
contains four amino groups (2 primary and 2 tertiary) that are fully protonated at pH 
7.4. 
In the case of the commercially available lipopolyamine (DOGS, 
Transfectam
®
) it was calculated as 1263 g/mole (trifluoroacetate salt) that contains 
three are fully protonated nitrogens (more accurately 2.92) at pH 7.4, although 
Transfectam
®
 has four nitrogens (two secondary amines and two primary amines, 
ignoring the two neutral amides) that can be protonated in strong acid. 
In the liposomal formulation Lipofectin, the cationic lipid DOTMA carries 1 
positive charge (ammonium eq/mole) (2)while the cationic lipid DOSPA in the 
Lipofectamine formulation and carries 4 positive charges (ammonium eq/mole) (15). 
In the non-liposomal formulations, Transfectam
®
 carries 3 positive charges (139). 
 
Binding constant calculation 
 From EthBr fluorescence quenching results for DNA interaction with the 
condensing agent, the binding constant of the DNA condensing agent (vector) to DNA 
can be calculated and compared with the loss of EthBr fluorescence as a function of 
DNA condensing agent concentration. The drug concentration producing 50 % 
inhibition of fluorescence is approximately inversely proportional to the binding 
constant (140). Denny and co-workers (141) established the binding equations of 
DNA to both EthBr and vectors as follows:   
 
[ ] [ ] [ ]vectorDNAvectorDNA −↔+                                              eq. [3] 
 
[ ] [ ] [ ]EthBrDNAEthBrDNA −↔+                                               eq. [4] 
 
Kb (vector) = 
[ ]




                                                   eq. [5] 
 
Kb (EthBr) = 
[ ]




                                                    eq. [6] 
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Kb (vector) = 
[ ] [ ] ( )




                  eq. [7] 
 
At 50 % residual fluorescence, the ratio of [DNA-vector] to [DNA-EthBr] is 
equal to 1. Therefore, the “apparent” equilibrium constant (Kb) of polyamine binding 
was calculated, taking into account that Morgan et al. (140) reported that the binding 




, as follows: 
 




                                                        eq. [8] 
 
The concentration of the condensing agent producing 50 % intercalated EthBr 
fluorescence inhibition was calculated experimentally. 
 
2.4.2.2. Light scattering assay 
A light scattering experiment was designed to investigate particle formation as 
a result of DNA condensation by polyamines and lipopolyamines. The apparent UV 
absorbance at 320 nm, where there is no DNA absorbance interference above 300 nm, 
was measured showing light scattering (i.e., decreased light transmission) (23). All 
DNA (linear calf thymus) solutions were diluted using TE buffer and their 
concentrations were measured by GeneQuant II spectrophotometer. HEPES buffer 
was made of 2 mM HEPES, 20 mM NaCl, 10 µM EDTA, and MilliQ water, the pH 
was adjusted to 7.4 with aqueous NaOH solution. HEPES buffer was filtered through 
a 0.22 µm membrane prior to use. 
Spermine (17 mg) was dissolved in MilliQ water (1 ml as a stock solution). 
DNA 60 µg (of 1 mg/ml solution) diluted to 3 ml with HEPES buffer in a cuvette with 
a micro-flea, and the concentration determined spectroscopically (Milton Roy 
Spectronic 601 spectrometer, 1 cm path length, 3 ml cuvette). UV measurement of 
DNA in buffer was performed and adjusted to zero. Then, aliquots (5 µl) of spermine 
(10 x 0.4 mg/ml, and then 5 x 2.0 mg/ml) were then added to the stirring solution and 
the absorbance (light scattering) at 320 nm measured after 1 min stirring to allow the 
mixture to reach equilibrium. The Apparent UV absorbance values were then plotted 
against N/P ratios. 
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2.4.2.3. Gel electrophoresis study 
Agarose (1 g, electrophoresis grade, Gibco) was added to 100 ml of 1x TAE 
(Tris-Acetate-EDTA, 40 mM Tris-Acetate and 1 mM EDTA) buffer. The mixture was 
then heated in a microwave oven at the max power to boiling for 2 mins with swirling 
the flask 3-4 times while boiling to dissolve the agarose. When the agarose was 
completely dissolved, the solution was then allowed to cool to a consistency that can 
be poured. Then EthBr was added to a concentration of 1.0 µg/ml. When the gel was 
cooling down, the gel tray was securely sealed at the ends with tape strips to form a 
fluid-tight seal. The comb was placed over the gel tray. After that, when the agarose 
had been cooled to about 60°C, it was poured into the gel tray to a depth of 4-8 mm. 
Then the gel was allowed to set at 20 ºC for 30 mins followed by refrigeration for 
further 15 mins for complete solidification of the gel. The comb was removed from 
the solidified gel as well as the tape from the edges of the gel tray. The gel was then 
transferred to the electrophoresis chamber, Kodak Biomax QS 710 (Kodak), and 
submerged into the electrophoresis buffer (TAE buffer). 
For pEGFP lipoplex formation, two solutions were prepared for each well, 
solution A (DNA) and solution B (lipopolyamine). Solution A was prepared by 
diluting DNA solution (0.5-1 µg/well) to 5 µl using 1x TAE buffer, in a sterile 1.5 ml 
micro-centrifuge tube, gently mixed using a vortex, for 2 s and incubated for 30 mins 
at 20 ºC. Solution B was prepared by diluting the lipopolyamine solution to 10 µl 
using 1x TAE buffer, in a sterile 1.5 ml micro-centrifuge tube, gently mixed using a 
vortex, for 2 s and incubated for 30 mins at 20 ºC. The complex was then prepared by 
mixing solution A and B (brief vortex, 1 s) then incubated for 20 mins at 20 ºC. 
Each lipopolyamine used in solution B was at a different volume according to 
the required N/P ratio for 0.5-1 µg DNA/well, as described above in the N/P 
determination section for EthBr assay. 
Samples (15 µl) of plasmid DNA (0.5 µg), either free or complexed with the 
lipopolyamine (according to the charge ratio) were mixed with the loading dye 
(blue/orange loading dye 6X, Promega) and loaded into the wells. The loading dye 
was used at a 1X final concentration and contains 0.03 % xylene cyanol FF (4 kbp 
migration), 0.03 % bromophenol blue (300 bp migration), 0.4 % orange G (50 bp 
migration), 10mM Tris-HCl (pH 7.5) and 50mM EDTA (pH 8). Electrophoresis at 75 
V/cm (Bio-Rad Power Pack 300, Bio-Rad Laboratories Ltd) was carried out for 1 h. 
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The gel was removed and the (unbound) free DNA in the agarose gel was visualized 
under UV using GeneGenius (Syngene). 
 
2.4.3. DNase I Sensitivity Assay 
Briefly, in a typical assay, pEGFP plasmid (1µg) was complexed with the varying 
amounts of the lipospermines using the indicated charge ratios in a total volume of 30 
µl in HEPES buffer, pH 7.4, and incubated at 20 ºC for 30 mins on a rotary shaker. 
Subsequently, the complexes were treated with 10 µl DNase I (Qiagen, at a final 
concentration of 1 µg/ml) in presence of 20 mM MgCl2 and incubated for 20 mins at 
37°C. The reactions were then halted by adding EDTA (to a final concentration of 50 
mM) and incubated at 60°C for 10 mins in a water bath. The aqueous layer was 
washed with 50 µl of phenol:chloroform:isoamylalcohol (25:24:1 mixture, v/v) and 
centrifuged at 10,000 rpm for 5 mins. The aqueous supernatants were separated, 
loaded (15 µl) with loading dye on a 1% agarose gel (pre-stained with ethidium 
bromide1.0 µg/ml) and electrophoresed at 100 V for 1 h as described above in the gel 
electrophoresis study. 
 
2.4.4. RiboGreen Intercalation Assay 
RiboGreen solution (Invitrogen, 50 µl dil. 1 to 20) was added to each well of a 
96-well plates (opaque bottom), containing 50 ng of siGENOME Non-Targeting 
siRNA #1 (Dharmacon) either free or complexed with different amounts Trans-IT or 
lipospermines according to the N/P ratio containing in TE buffer, and the fluorescence 
measured after 5 mins equilibration using FLUOstar Optima Microplate Reader 
(BMG-LABTECH), λex = 480 nm, λem = 520 nm. The fluorescence was expressed as 
the percentage of the maximum fluorescence when RiboGreen was bound to the RNA 
in the absence of competition for binding and was corrected for background 
fluorescence of free RiboGreen in solution. This correction and the subsequent 
normalization were performed using an Excel spreadsheet. The amount of siRNA 
available to interact with the probe was expressed as a percentage of the control that 
contained naked siRNA only, according to the following formula: % free siRNA = 




 - 47 - 
2.4.5. Tissue Culture and Transfection Experiments 
 
2.4.5.1. Primary skin cell line FEK4 
A primary skin cell line was used in the transfection experiments. FEK4 cells 
are human primary fibroblasts derived from newborn foreskin explants (142-144), 
which were used as a model for human primary cells (passage dependent cell line). 
FEK4 cells were kindly provided by Prof. R. M. Tyrrell, Department of Pharmacy and 
Pharmacology, University of Bath, UK. Cells were cultured in Earle’s Minimal 
Essential Medium (EMEM) with a final Foetal Calf Serum (FCS) concentration of 15 
% v/v according to the following formula (for 500 ml): 
 
10X EMEM  50 ml 
7.5 % NaHCO3  13.5 ml 
200 mM L-glutamine  5 ml 
Penicillin (10,000 IU/ml)/Streptomycin (10,000 IU/ml) 2.5 ml 
Foetal calf serum (FCS) 75 ml 
Autoclaved MilliQ Water  354 ml 
 
FCS was heat inactivated before use by defrosting at 37 
o
C and heating at 56 
o
C for 45 mins in a temperature-controlled water bath (Grant). Sterile PBS solution 
was used in all transfection experiments to wash cells and contains 0.01 M phosphate 
buffer, 0.0027 M KCl and 0.137 M NaCl in MilliQ water at pH 7.4. Trypsin was 
diluted to a working concentration at 0.25 % w/v with PBS. 
Cells were visually assessed daily for evidence of microbial contamination 
under an inverted light microscope (Wilovert Hund). All aseptic techniques for cell 
culture were carried out in a laminar flow cabinet (Intermed MDH Ltd.) designed for 
vertical re-circulation of air. A temperature-controlled water bath (Grant) was used to 
warm the media for cell culture experiments. A monolayer of primary skin cell lines 
was grown in 25 ml EMEM supplemented with 15 % FCS v/v in 150 cm
2
 (T150) flasks 
from NUNC. Cell lines were incubated at 37 
o
C, 5 % CO2, 95 % air and humidified 
atmosphere using an LEEC PF2 incubator (Sanyo). Primary skin cells were passaged 
twice (minimum once) a week and used between passages 9-16. 
Primary cells were passaged (subcultured) by trypsinisation technique. The 
growth medium was aspirated from the flasks. Then, cells were washed twice with 
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PBS solution (10 ml/T150 flask). PBS solution was then removed by aspiration. Cells 
were treated with trypsin 0.25 % w/v (3 ml/T150 flask) and incubated for 5-10 mins at 
37 
o
C and 5 % CO2 v/v for trypsinisation reaction. After that, the flasks were gently 
tapped to assess the detachment of the cells, which were checked under a light 
microscope to ensure at least 85 % cell detachment. To stop trypsinisation, 10 ml of 
15 % FCS v/v EMEM was added to the flask. The cell suspension was then 
transferred to a 15 ml Falcon tube, obtained from Falcon, for separation of cells by 
centrifugation at1,200 rpm for 5 mins using a cells centrifuge, Falcon 6/300 MSE 
(Sanyo). Cells were re-suspended in 6 ml of 15 % FCS v/v EMEM and seeded at a 
concentration of 1 x 10
6
 cells/flask (T150) containing 25 ml 15 % FCS v/v EMEM for 
next passage. 
To determine the concentration of cells in a sample, a viable count was carried 
out using a haematocytometer slide. A stained cell suspension was prepared by mixing 
trypsinized cells (50 µl) with the same volume of nigrosin or trypan blue (50 µl) 0.4 % 
(w/v) solution in PBS. The cell sample was loaded into the raised sides of the glass 
chambers (top and bottom) covered with a coverslip 0.1 mm above the chamber floor 
until the whole chamber was fully loaded. The slide was then placed under an inverted 
light microscope. Viable cells were detected using a bright halo light around their cell 
membrane. On the other hand, dead cells were permeabilized by the dye and appeared 
as black spheres under the microscope. The viable cell number in the four squares 
surrounding the central square and this was repeated for the other side of the 
haemocytometer chamber. The viable cell concentration in the original cell suspension 
was calculated using the following equation: 
 





      eq. [9] 
 
 For cell storage, cells were detached from a confluent monolayer by 
trypsinisation as described before followed by centrifugation at 1,200 rpm for 5 mins. 
The supernatant was then discarded and the cell pellets were re-suspended in the 
growth media at a concentration of 2 x 10
5
 cells/ml. A cell freezing solution (10 % 
v/v) of growth media with a filter-sterilized solution of dimethylsulfoxide (DMSO) as 
a cryopreservative was prepared. Cell suspension (0.4 ml) was dispensed with 0.6 ml 
of cell freezing solution into cryotubes and stored at -70 
o
C overnight. After that, 
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tubes were fitted into a Union Carbide LR-40 liquid nitrogen freezer where they were 
stored at approximately -150 
o
C (long-term, years). 
 For cell recovery, the contents of the cryotube were thawed rapidly by brief 
incubation at 37 
o
C in a water bath, followed by dilution with 10 ml of fresh growth 
medium. Cells were centrifuged for 5 mins at 1200 rpm and the supernatant was 
discarded. Cell pellets were then re-suspended in 10 ml of fresh medium, and then 1 x 
10
6
 cells were transferred to a flask (T150) containing 25 ml of growth medium and 
incubated under standard culture conditions. Cells were cultured for at least two 
passages in order to establish them before any experiments were carried out. 
Transfection experiments were carried out using pEGFP, encoding for 
enhanced green fluorescent protein as a reporter gene, either complexed with DNA 
condensing agents, or free (naked DNA) as a negative control. Cells were seeded in 
12-well plates, obtained from NUNC. DNA was used at a concentration of 1 µg/well. 
DNA condensing agents used for FEK4 primary cells transfection were the liposomal 
formulations Lipofectin (DOTMA/DOPE 1:1 w/w) and Lipofectamine 
(DOSPA/DOPE 3:1 w/w), and the non-liposomal formulations Transfectam
®
 (DOGS) 
and all designed and synthesized lipospermines. 
For the DNA-vector complex formation experiment, two solutions were 
prepared for each well (12-well plate), solution A (DNA) and solution B (condensing 
agent). Solution A was prepared by diluting DNA solution (1 µg/well) to 50 µl using 
Opti-MEM, a serum free media (Gibco), in a sterile 1.5 ml micro-centrifuge tube, 
gently mixed using a vortex, for 2 s and incubated for 30 mins at 20 ºC. Solution B 
was prepared by diluting transfection agents solution to 50 µl using Opti-MEM, serum 
free media, in a sterile 1.5 ml micro-centrifuge tube, gently mixed using a vortex, for 
2 s and incubated for 30 mins at 20 ºC. The complex was then prepared by mixing 
solution A and B with vortex for 1 s then incubated for 20 mins at 20 ºC. 
Each transfection agent used in solution B was at a different volume according 
to the required N/P ratio for 1 µg DNA/well, as described before in the N/P 
determination section for EthBr assay. 
For FEK4 transfection, 5x 10
4
 cells/well were seeded in 12-well plates in 2 ml 
of 15 % FCS v/v EMEM. Cells were incubated at 37 
o
C and 5 % CO2 v/v in a CO2 
incubator for 24 h to reach 50-60 % confluency. Prior to transfection, the media were 
replaced with 400 µl of the 15 % FCS v/v EMEM to which 100 µl of the transfection 
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complex, as a result of mixing solution A and B, was added to the plates for the total 
volume of 500 µl/well except for control cells where Opti-MEM 500 µl was added (no 
DNA complex solution). The transfected plates were incubated for 4 h at 37 
o
C in an 
atmosphere of 5 % CO2 v/v. After that, the 15 % FCS v/v EMEM with DNA complex 
in the incubated plates was aspirated and replaced with 2 ml of 15 % FCS v/v EMEM 
media and incubated for a further 44 h at 37 
o
C in an atmosphere of 5 % CO2 v/v. 
 The study using naked DNA was performed to assess if there was any 
transfection efficiency from naked DNA compared to the lipoplexes. The same 
transfection protocol used before was applied, except for solution B that contains only 
serum free media without any DNA condensing agent to be added. For all transfection 
studies, each data point represents the mean ± standard deviation (± SD) of triplicate 
samples and each experiment was repeated three times. 
 
2.4.5.2. HtTA cell transfection 
Human cervix carcinoma, HeLa derivative and transformed cell line (HtTA) 
(145,146) was used as a model for carcinoma cells (an immortal cell line). The HtTA 
cells being stably transfected with a tetracycline-controlled transactivator (tTA) 
consisting of the tet repressor fused with the activating domain of virion protein 16 of 
the herpes simplex virus (HSV). HtTA cells were kindly provided by Prof. R. M. 
Tyrrell, Department of Pharmacy and Pharmacology, University of Bath, UK. Cells 
were cultured in Earle’s Minimal Essential Medium (EMEM) with a final FCS 
concentration of 10 % v/v according to the following formula (for 500 ml): 
 
10X EMEM 50 ml 
7.5 % NaHCO3 13.5 ml 
200 mM L-glutamine 5 ml 
Penicillin (10,000 IU/ml)/Streptomycin (10,000 IU/ml) 2.5 ml 
Foetal calf serum (FCS) 50 ml 
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FCS was heat inactivated before use by defrosting at 37 
o
C and heating at 56 
o
C for 45 mins in a temperature-controlled water bath (Grant). Trypsinisation 
procedures were carried out using the same protocol for FEK4 sub-culturing. The 
culture was incubated at 37 
o
C in an atmosphere of 5 % CO2 v/v. HtTA cells were 
passaged every 3 days. 
For the transfection (gene delivery) and the resultant gene activity 
(transfection efficiency) the same protocol for HtTA transfection was used as 
described above for FEK4. Briefly, HtTA cells were seeded at 50,000 cell/well in 12 
well plates in 1 ml EMEM media with 10 % FCS v/v for 24 h to reach a plate 
confluency of 50-60 % on the day of transfection. The complex was prepared by 
mixing pEGFP (1 µg) with the cationic liposomes or lipopolyamine in serum free 
media Opti-MEM according to the charge ratio at 20 ºC for 30 m, and then incubated 
with the cells in EMEM media with 10 % FCS v/v for 4 h at 37
 o
C in 5 % CO2 v/v, 
then the cells were cultured for a further 44 h in growth medium at 37 
o
C in 5 % CO2 
v/v before the assay. 
 
2.4.5.3. Transfection experiments in the absence of serum for FEK4 and HtTA 
cells 
For the transfection (gene delivery) and the resultant gene activity 
(transfection efficiency), the same seeding protocol for FEK4 and HtTA transfection 
was used as described above. Then, in the transfection step, the cells were incubated 
in serum-free media Opti-MEM (instead of full-growth media) for 4 h at 37
 o
C in 5 % 
CO2 v/v, then the cells were cultured for further 44 h in full-growth media (15 % FCS 
for FEK4 and 10 % FCS for HtTA) at 37 
o
C in 5 % CO2 v/v before the assay. 
 
2.4.6. Fluorescence Activated Cell Sorting Experiment 
To analyse the transfection efficiency of the delivered pEGFP, levels of green 
fluorescent protein (GFP positive cells) in the transfected cells were detected using a 
fluorescence activated cell sorting (FACS) machine (147) Becton Dickinson FACS 
Vantage dual Laser Instrument, (argon ion laser 488 nm) (Becton Dickinson 
Biosciences). FACS is used to determine the fluorescent molecules (or biomolecules) 
inside studied cells. Individual cells pass through a laser beam allowing the light 
scatter and fluorescence characteristics of each cell to be measured. Filter lens (F) for 
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emission detection was chosen based on the fluorophore used. In our experiment, 
EGFP is detected by F1 (λex = 488 nm, λem = 530 nm). 
 
2.4.7. siRNA Transfection Experiments in the Presence of Serum for FEK4 and 
HtTA Cells 
We used Label IT
® 
RNAi Delivery Control (Mirus) which consists of a 
fluorescein-labelled double-stranded RNA duplex that has the same length (ds 21-
mer), charge, and configuration as standard siRNA used in RNAi studies.  
For the siRNA-vector complex formation experiment, two solutions were 
prepared for each well (12-well plate), solution A (RNA) and solution B (condensing 
agent). Solution A was prepared by diluting 1.25 µl solution siRNA (12.5 pmol/well) 
to 12.5 µl using 10X RNAi Dilution Buffer (Mirus, diluted by RNase and DNase free 
water), in a sterile 1.5 ml micro-centrifuge tube, gently mixed using a vortex, for 2 s 
and incubated for 30 mins at 20 ºC. Solution B was prepared by diluting transfection 
agents solution to 50 µl using Opti-MEM, serum free media, in a sterile 1.5 ml micro-
centrifuge tube, gently mixed using a vortex, for 2 s and incubated for 30 mins at 20 
ºC. The complex was then prepared by mixing solution A and B with vortex for 1 s 
then incubated for 20 mins at 20 ºC. 
 Each transfection agent used in solution B was at a different volume according 
to the required concentration using broad-spectrum TransIT-TKO
®  
Transfection 
Reagent as a positive control and naked Label IT
® 
RNAi as a negative control. 
 For transfection, 50,000 cells/well were seeded in 12-well plates in 2 ml of 15 
% FCS v/v EMEM and 10 % FCS v/v EMEM for FEK4 and HtTA Cells respectively 
were incubated at 37 
o
C and 5 % CO2 v/v in a CO2 incubator for 24 h to reach 50-60 
% confluency. Prior to transfection, the media replaced with 437.5 µl of the 15 % FCS 
v/v EMEM in case of FEK4 cells and the10 % FCS v/v EMEM in case of HtTA cells 
to which 62.5 µl of the transfection complex, as a result of mixing solution A and B, 
was added to the plates for final volume of 500 µl/well except for control cells where 
500 µl of Opti-MEM with serum was added (no RNA complex solution). The 
transfected plates were incubated for 4 h at 37 
o
C in an atmosphere of 5 % CO2 v/v. 
After that, the FCS EMEM with RNA complex in the incubated plates was aspirated 
and replaced with 2 ml of FCS EMEM media and incubated for a further 44 h at 37 
o
C 
in an atmosphere of 5 % CO2 v/v. 
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 The study using naked RNA was performed to assess if there was any 
transfection efficiency from naked RNA compared to the lipoplexes. The same 
transfection protocol used before was applied, except for solution B that contains only 
serum free media without any RNA condensing agent to be added. For all transfection 
studies, each data point represents the mean ± standard deviation (± SD) of triplicate 
samples and each experiment was repeated three times. 
 
2.4.8. Preparation of Cell Samples for FACS Analysis for both DNA and siRNA 
After transfection (4 h), and then incubation (44 h), for either DNA or siRNA, 
the cells were detached through aspiration of the media from 12-well plates. Then, 
cells were washed twice with PBS solution (1 ml/well). PBS buffer was removed by 
aspiration. Cells were treated with trypsin 0.25 % w/v (0.5 ml/well) and incubated for 
5 mins at 37 
o
C and 5 % CO2 v/v for trypsinisation reaction. After that, the plates were 
gently tapped to assess the detachment of the cells, which were checked under 
microscope to ensure at least 85 % of cells were detached. To stop trypsinisation The 
cell suspension was then transferred to FACS polystyrene test tubes (12 x 75 mm), 
obtained from Falcon, filled with 1 ml of 15 % FCS EMEM for separation of cells by 
centrifugation at 1,200 rpm for 5 mins 20 ºC using a cells centrifuge, Falcon 6/300 
MSE (Sanyo). Cells were re-suspended in PBS (1 ml/tube) for further centrifugation 
at 1,200 rpm for 5 mins at 20 ºC. Cell suspension for FACS analysis was obtained by 
dissolving the pellet in 500 µl PBS/tube. Untreated (untransfected) cell sample was 
used as a control in the measurement. 
CELLQuest v.1.0 software (Becton Dickinson Biosciences) was used to 
analyse FACS data. Typically, 10,000 events were collected. Recordings were made 
at green fluorescence (FL1) and data were expressed as histograms. Only a subset of 
the data obtained from healthy cells data (major population) was analysed through a 
gate setting. This gating was determined from the dot plots between forward-scattered 
light (FSC) and side-scattered light (SSC). FSC is a parameter proportional to cell size 
and SSC indicates the cell granularity or internal complexity. In the histogram of 
events at different fluorescence intensity control group, the fluorescence intensity 
range (M1) was set as a constant range throughout the experiments. For EGFP 
detection, the % fluorescence cells sorting events in the established range (M1) was 
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reported with the correction of the background fluorescence of the control sample. 
The same for fluorescein-tagged RNA which has λex = 495 nm and λem = 518 nm. 
 
2.4.9. Cytotoxicity (MTT) Assay of the Formed DNA-Lipoplexes on Transfected 
Cell Lines 
The MTT assay is a colorimetric assay to evaluate the metabolic activity of 
viable cells to convert a soluble tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)] into an insoluble formazan crystal (148). This 
assay is used to investigate the cytotoxic effects of lipopolyamines and lipoplexes 
(pEGFP complexes). primary cell line was used in the cytotoxicity experiments, FEK4 
cells are human primary fibroblasts derived from newborn foreskin explants, which 
were used as a model for human primary cells (mortal cell line), and these cells were 
cultured in EMEM with a final serum concentration of 15 % v/v. HtTA was used as a 
model for carcinoma cells (an immortal cell line), and these HtTA cells were cultured 
in EMEM with a final FCS concentration of 10 % v/v. Lipopolyamines used in the 
MTT assay were the liposomal formulations Lipofectin (DOTMA/DOPE 1:1 w/w) 
and Lipofectamine (DOSPA/DOPE 3:1 w/w) and the non-liposomal formulations 
Transfectam
®
 (DOGS), and all our synthetic lipospermines. 
For DNA-vector complex formation, two solutions were prepared for each 
well (96-well plate), solution A (DNA) and solution B (condensing agent). Solution A 
was prepared by diluting DNA solution (0.2 µg/well) to 10 µl using Opti-MEM, a 
serum free media, in a sterile 1.5 ml micro-centrifuge tube, gently mixed using a 
vortex (2 s) and incubated for 30 mins 20 ºC. Solution B was prepared by diluting 
transfection agent solution to 10 µl/well using Opti-MEM, serum free media, in a 
sterile 1.5 ml micro-centrifuge tube, gently mixed using a vortex (2 s) and incubated 
for 30 mins at 20 ºC. The complex was then prepared by mixing solution A and B 
with vortex for 1 s then incubated for 20 mins at 20 ºC. Each transfection agent used 
in solution B was at a different volume according to the required N/P ratio for 0.2 µg 
DNA/well, as described before in the N/P determination section for EthBr assay. 
For primary fibroblasts and carcinoma cells toxicity study, 8,000 cells/well 
were seeded in 96-well plates, obtained from NUNC, in 200 µl of 15 % FCS v/v 
EMEM and 10 % FCS v/v EMEM in the case of primary fibroblasts and HtTA, 
respectively. Cells were incubated at 37 
o
C and 5 % CO2 v/v in a CO2 incubator for 24 
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h to reach 50-60 % confluency. The medium was removed and replaced with 80 µl of 
15 % FCS v/v EMEM and 10 % FCS v/v EMEM in the case of primary fibroblasts 
and HtTA, respectively to which 20 µl of either the transfection complex (lipoplex), 
the free lipopolyamine, or the free DNA (naked DNA) was added to the plates except 
for control cells where FCS EMEM (100 µl) was added (no DNA complex solution). 
The plates were incubated for 4 h at 37 
o
C in an atmosphere of 5 % CO2 v/v. After 
that, the FCS EMEM complex containing media in the incubated plates was aspirated 
and replaced with 200 µl of 15 % FCS v/v EMEM and 10 % FCS v/v EMEM in the 
case of primary fibroblasts and HtTA, respectively. Then, incubated for a further 44 h 
at 37 
o
C in an atmosphere of 5 % CO2 v/v. 
 After incubation for 44 h, the media was replaced with 90 µl of fresh media 
and 10 µl of sterile filtered MTT solution (Sigma-Aldrich) (5 mg/ml) to reach a final 
concentration of 0.5 mg/ml. Then the plates were incubated for a further 4 h at 37 
o
C 
in an atmosphere of 5 % CO2 v/v. After incubation, the media and the un-reacted dye 
were aspirated and the formed blue formazan crystals were dissolved in 200 µl/well of 
DMSO. The produced colour was measured using a plate-reader (VERSAmax

) at 
wavelength 570 nm. The % viability related to control wells containing cells without 















viabilitycell                                                           eq. [10] 
 For all cytotoxicity (MTT) studies, each data point represents the mean ± 
standard deviation (± SD) of triplicate samples and each experiment was repeated 
three times. 
 
2.4.10. Cytotoxicity (MTT) Assay of the Formed siRNA-Lipoplexes 
The same assay as detailed above, but for RNA-vector complex formation. 
Two solutions were prepared for each well (96-well plate), solution A (siRNA) and 
solution B (condensing agent). Solution A was prepared by diluting 0.25 µl solution 
siRNA (2.5 pmol/well) to 2.5 µl using 10X RNAi Dilution Buffer (diluted by RNase 
and DNase free water), in a sterile 1.5 ml micro-centrifuge tube, gently mixed using a 
vortex, for 2 s and incubated for 30 mins at 20 ºC. Solution B was prepared by 
diluting transfection agents solution to 10 µl using Opti-MEM, serum free media, in a 
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sterile 1.5 ml micro-centrifuge tube, gently mixed using a vortex, for 2 s and 
incubated for 30 mins at 20 ºC. The complex was then prepared by mixing solution A 
and B with vortex for 1 s then incubated for 20 mins at 20 ºC. Each transfection agent 
used in solution B was at a different concentration, as described above in the 
transfection experiments. 
For the primary fibroblasts and carcinoma cells toxicity study, 8,000 cells/well 
were seeded in 96-well plates, obtained from NUNC, in 200 µl of 15 % FCS v/v 
EMEM and 10 % FCS v/v EMEM in the case of primary fibroblasts and HtTA, 
respectively. Cells were incubated at 37 
o
C and 5 % CO2 v/v in a CO2 incubator for 24 
h to reach 50-60 % confluency. The medium was removed and replaced with 87.5 µl 
of 15 % FCS v/v EMEM and 10 % FCS v/v EMEM in the case of primary fibroblasts 
and HtTA, respectively to which 12.5 µl of either the transfection complex (lipoplex), 
the free lipopolyamine, or the free RNA (naked RNA) was added to the plates for 
final volume of 100 µl except for control cells where 100 µl of serum Opti-MEM was 
added (no RNA complex solution). The plates were incubated for 4 h at 37 
o
C in an 
atmosphere of 5 % CO2 v/v. After that, media in the incubated plates were aspirated 
and replaced with 200 µl of 15 % FCS v/v EMEM and 10 % FCS v/v EMEM in the 
case of primary fibroblasts and HtTA, respectively. The plates were then incubated for 
a further 44 h at 37 
o
C in an atmosphere of 5 % CO2 v/v. The same procedures and 
calculations were followed as for the DNA cytotoxicity assay described above. 
 
2.4.11. Characterization of the Formed Nanoparticles 
 
2.4.11.1. Particle size 
 Particle size of the lipoplexes was measured by laser light scattering using a 
NANOSIGHT LM10 (NANOSIGHT, Salisbury, UK). The samples containing 1 µg of 
DNA or 332 ng (25 pmoles) siRNA were prepared at the effective concentration of 
lipospermine and diluted to a final volume of 200 µl with PBS. The mean particle 
sizes were determined in at least two independent experiments, each with five 
independent measurements, using NTA Analytical Software 
 The average particle size for the lipoplexes formed (at their effective 
concentration of transfection), after mixing with a vortex mixer, was determined using 
a laserlight scattering using a NANOSIGHT LM10 (NANOSIGHT, Salisbury, UK) 
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(nano-particle analysis range:  10-1,000 nm, Laser output:  20 mW at 650 nm, Real-
time dynamic nano-particle visualization, particle-by-particle analysis, particle 
counting and sizing, and particle size distributions displayed as histograms). All 
measurements were carried out on lipoplexes with 1 µg/200 µl plasmid DNA or 25 
pmol/200 µl siRNA in HEPES buffer at pH 7.4 and 20 °C. 
For pEGFP lipoplex formation, two solutions were prepared for each sample, 
solution A (DNA) and solution B (lipopolyamine). Solution A was prepared by 
diluting DNA solution (1 µg/100 µl) in 1.5 ml micro-centrifuge tube, gently mixed 
using a vortex for 2 s, and then incubated for 30 mins at 20 ºC. Solution B was 
prepared by diluting the lipopolyamine solution to 100 µl using HEPES buffer, in 1.5 
ml micro-centrifuge tube, gently mixed using a vortex for 2 s, and then incubated for 
30 mins at 20 ºC. The complex was then prepared by mixing solutions A and B (brief 
vortex, 1 s), incubated for 20 mins at 20 ºC and then injected in the machine using a 1 
ml sterile syringe. 
Each lipopolyamine used in solution B was at a different concentration for the 
required N/P ratio for 1 µg DNA/200 µl as described above in the N/P determination 
section for the EthBr fluorescence quenching assay. 
For siRNA lipoplex formation, two solutions were prepared for each sample, 
solution A (RNA) and solution B (lipopolyamine). Solution A was prepared by 
diluting RNA solution (332 ng/25 µl) in 1.5 ml micro-centrifuge tube, gently mixed 
using a vortex (2 s), and then incubated for 30 mins at 20 ºC. Solution B was prepared 
by diluting the lipopolyamine solution (at its effective concentration) to 175 µl using 
HEPES buffer, in 1.5 ml micro-centrifuge tube, gently mixed using a vortex for 2 s, 
and then incubated for 30 mins at 20 ºC. The complex was then prepared by mixing 
solutions A and B (brief vortex, 1 s), and then incubated for 20 mins at 20 ºC and then 
injected in the machine using 1 ml sterile syringe. 
 
2.4.11.2. Zeta potential 
ζ-Potential measurements were determined using a Delsa™Nano Zeta 
Potential and Submicron Particle Size Analyzer (Beckman Coulter) which determines 
particle size by measuring the rate of fluctuations in laser light intensity scattered by 
particles as they diffuse through a fluid, for size analysis measurements and/or 
electrophoretic light scattering (ELS), which determines electrophoretic movement of 
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charged particles under an applied electric field from the Doppler shift of scattered 
light, for zeta potential determination. All measurements were carried out on 
lipoplexes with 6 µg/ml plasmid DNA in HEPES buffer at pH 7.4 and 20 °C. 
For pEGFP lipoplex formation, two solutions were prepared for each well, 
solution A (DNA) and solution B (lipopolyamine). Solution A was prepared by 
diluting DNA solution (6 µg/ml) in 1.5 ml micro-centrifuge tube, gently mixed using 
a vortex for 2 s, and then incubated for 30 mins at 20 ºC. Solution B was prepared by 
diluting the lipopolyamine solution to 1.0 ml using HEPES buffer, in sterile 2 ml 
micro-centrifuge tube gently mixed using a vortex for 2 s, and incubated for 30 mins 
at 20 ºC. The complex was then prepared by mixing solutions A and B (brief vortex 1 
s) then incubated for 20 mins at 20 ºC. Each lipopolyamine used in solution B was at 
the required N/P ratio for 6 µg, as described above in the N/P determination for the 
particle size and the EthBr experimental sections.  
For siRNA lipoplex formation, two solutions were prepared for each sample, 
solution A (RNA) and solution B (lipopolyamine). Solution A was prepared by 
diluting RNA solution (75 pmol /75 µl) in 1.5 ml micro-centrifuge tube, gently mixed 
using a vortex for 2 s, and then incubated for 30 mins at 20 ºC. Solution B was 
prepared by diluting the lipopolyamine solution (at its effective concentration) to 300 
µl using HEPES buffer, in 1.5 ml micro-centrifuge tube, gently mixed using a vortex 
for 2 s, and then incubated for 30 mins at 20 ºC. The complex was then prepared by 
mixing solutions A and B by brief vortex (1 s), and then incubated for 20 mins at 20 
ºC, diluted to 2 ml, and then injected into the machine using a 3 ml sterile syringe. The 
ζ-potential measurements of the nanoparticles were computed from the 







U E =                                                                                             eq. [11] 
where UE is the electrophoretic mobility (velocity of the nanoparticles in a unit 
electric field), ζ is the zeta potential, ε is the dielectric constant, η is the solvent 
viscosity and f (κa) is Henry’s function, which in aqueous media and electrolyte is 
equal to 1.5, known as the Smoluchowski approximation. 
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2.4.12. Confocal Microscopy Studies 
 
2.4.12.1. Preparation of Mowiol coverslip mounting solution 
For the preparation of mounting media we used Mowiol (Mowiol 4.88, 
Calbiochem catalogue number 475904) a solution of polyvinyl alcohol which normally 
hardens overnight after slide preparation. For preparation, Mowiol (2.4 g) was added 
to glycerol (6 g) in a 50 ml plastic centrifuge tube equipped with a small stirrer-bar. 
While stirring, distilled water (6 ml) was added and left for 2 h at 20 ºC then 2M Tris 
(12 ml, pH 8.5) was added and the tube was incubated in warm water (50–60 ºC) for 
10 mins to dissolve the Mowiol, then centrifuged at 5,000 rpm for 15 mins to remove 
any undissolved solids, and stored as 1 ml aliquots in Eppendorf tubes at -20 ºC. On 
the day of the experiment, the tubes were thawed at 20 ºC prior to use. 
 
2.4.12.2. Preparation of slides for confocal microscopy visualization 
For both DNA and RNA we used the same transfection protocol for both 
FEK4 and HtTA using 6-well plates with a sterile round coverslip in the bottom of 
each well, and double the amount of DNA (2 µg/well) or fluorescein-tagged siRNA 
(25 pmol/well) and the transfecting agents at their optimum amount. At the end of 
transfection procedures (48 h), we prepared fresh 4% formaldehyde in PBS (w/v) 
from stocks of formalin 37% (w/v) (Sigma Aldrich). The transfected cells were 
washed twice with PBS, cells were fixed in 1 ml per well 4% formaldehyde/PBS at 20 
ºC for 20 mins, then the formaldehyde PBS solution was aspirated and the cells gently 
washed 3 times with PBS. After formaldehyde fixing, cells adhering to coverslip(s) 
were labelled with labelling solution according to the manufacturer’s protocol. 
Labelling solution contains both Alexa Fluor 594 wheat germ agglutinin for cell 
membrane labelling, (λex/λem 591/618 nm) and Hoechst 33342 for nuclei labelling 
(λex/λem 350/461 nm) mixed in one solution (from Invitrogen, Image-iT live plasma 
membrane and nuclear labelling kit). We prepared a solution with concentrations of 
Alexa Fluor 594 wheat germ agglutinin at 5.0 µg/ml and Hoechst 33342 stain at 2 
µM. Both combined in a single staining solution in PBS, then we applied 1 ml of 
labelling solution to cover cells adhering to coverslip(s) and incubated for 10 mins at 
20 ºC, then the labelling solution was removed and the cells were washed with PBS (2 
x 1 ml). 
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For slide preparation we used a Pap pen for immunostaining 2 mm tip width 
(Sigma-Aldrich), to draw a complete circle on the glass slide (the diameter of the circle 
was less than the diameter of the coverslip that will cover it). We placed a drop (20 µl) 
of mounting solution Mowiol (Calbiochem) in the centre of each marked circle. The 
coverslip was removed with forceps and the underside (non-cell side) was gently wiped 
with a Kimwipe
®
 tissue. Then the coverslip was carefully mounted, cell-side down, onto 
the mounting solution, we then used capillary action to drain the excess of mounting 
solution from under the coverslip with a Kimwipe
®
 tissue and left it in the dark (16 h) to 
solidify in order to be ready for confocal microscopy visualization. 
 
2.4.12.3. Confocal microscopy visualization 
 Following the DNA and siRNA transfection protocols, cells were seeded on a 
sterile coverslip at the bottom of each well. After 48 h, media were aspirated and cells 
were fixed with freshly prepared 4% formaldehyde solution in PBS (1 ml/well) for 15 
mins at 37 
o
C. After formaldehyde fixing, cells adhering to coverslips were labelled 
with labelling solution according to the manufacturer’s protocol. Labelling solution 
contained both Alexa Fluor 594 wheat germ agglutinin for cell membrane labelling, 
λex 591 nm and λem 618 nm, and Hoechst 33342 for nuclei labelling, λex 350 nm and 
λem 461 nm, mixed in one solution purchased from Invitrogen (Image-iT live plasma 
membrane and nuclear labelling kit), cell labelling with Alexa Fluor WGA (5 µg/ml) 
and Hoechst 33342 (2 µl, 2 µΜ). After that, labelled cells were mounted using 
mounting liquid (20 µl, Mow-Iol, Merck) and left for 16 h. Then, mounted cells in the 
coverslips were visualized using a confocal laser scanning microscope 
(LSM510META, Carl Zeiss) under the 60× oil immersion objective, with filters. The 
ZeissLSM510 Meta system consists of a Zeiss Axiovert 200M microscope Meta 
detector head (range 410-750 nm), Fujitsu/Siemens Computer, LSM Software Version 
4.0 and the high power objectives are Zeiss:  EC Plan- 63x/1.4 Oil DIC. For blue, 
green and red fluorescence, we used blue:  Violet Diode Laser (λex = 405 nm and λem 
420-480 nm) + BP 420-480 nm filter; green:  Argon Laser (λex = 488 nm and λem 505-
530 nm) + BP 505-530 nm filter; red:  HeNe543 Laser (λex = 543 nm and λem 560-615 
nm) + Meta 550-615 nm detection.  
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3.1. INTRODUCTION 
For gene therapy to realise its potential and become an efficient medicine for 
the treatment of diseases such as cancer, cystic fibrosis, inflammation, or for 
vaccination, key obstacles must be overcome. The essential requirements for gene 
delivery are the transport of DNA through the cell membrane and ultimately to the 
nucleus. The design of an efficient formula for the delivery of genetic material requires 
a detailed understanding of the barriers that hinder this process. Thus, efficient 
formulations of lipoplexes (150) or polyplexes (151-153) must be able to deliver safely 
the required DNA across the various cellular barriers to the nucleus. Barriers to DNA 
delivery also include complex formation between the DNA and the lipopolyamine 
leading to DNA nanoparticle formation by electrostatic charge neutralisation (to about 
90 % of the total negative charge) and overall packing as condensed DNA 
nanoparticles (154). So, a key first step in this method of gene formulation is masking 
the phosphate negative charges. This anion titration with a lipopolyamine causes 
alleviation of charge repulsion between remote phosphates along the DNA helix 
leading to collapse into a more compact structure that facilitates cell entry. 
For NVGT, except for naked (free, uncomplexed) DNA being trapped inside 
cells by direct association with the chromatin during mitosis, the (prodrug) DNA must 
be formulated. Small molecule synthetic cationic lipids are one of the major gene 
carriers for NVGT, often classified as liposomal and non-liposomal non-viral delivery 
vectors. They condense DNA into nanoparticles that are readily endocytosed by 
cultured cells, and facilitate endosomal escape leading to efficient nuclear delivery 
presumably entering through the nuclear pore complex (NPC). After nuclear entry, the 
payload DNA should ultimately be able to give the desired protein through 
transcription and translation. 
The possibility of reaching the goal of intracellular protein levels at therapeutic 
concentrations moves even more towards utilising non-viral gene therapy (NVGT). 
Since the design and formulation of Lipofectin by Felgner and co-workers, reported in 
1987 (2), the focus on non-viral vectors for DNA delivery has shown a remarkable 
increase worldwide (34,155). Cationic lipids are considered to be the major gene 
carriers among the non-viral delivery systems (156). They have the ability to condense 
DNA into particles that can be readily endocytosed by cultured cells, and facilitate 
endosomal escape leading to efficient delivery to the nucleus. Liposomal delivery 
vectors usually contain two types of lipids, a cationic lipid (positively charged 
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amphiphile) for DNA condensation and cellular membrane interaction, and a neutral 
helper lipid (phospholipid), most use dioleoylphosphatidyl ethanolamine (DOPE) 
(Fig. 3.1) to increase transfection efficiency as it has a membrane fusion promoting 
ability (2,3). Non-liposomal cationic-lipid delivery vectors combine both the 
characteristics of cationic and helper lipids e.g., Transfectam
®
 (dioctadecylamido-
glycyl spermine, DOGS) formulation (Fig. 3.1) (15,72) whose synthesis by Behr and 
co-workers (72) as a promising transfecting agent, encouraged several laboratories to 
focus on the synthesis of novel cationic lipids based on the naturally occurring 
polyamine spermine. 
One of the important factors to improve the release of free DNA or the lipoplex 
into the cytoplasm is the influence of the cationic lipid chain. Xu and Szoka (36) have 
reported that unsaturated hydrocarbon chains increase the transfection efficiency of the 
lipoplex by decreasing the rigidity of the bilayer and favouring a higher inter-
membrane transfer rate and lipid mixing, compared to their saturated counterparts. 
However, Engberts, Hoekstra and co-workers recently reported that, in certain cases, 
saturated fatty chains afforded better results than unsaturated chains (157). Also, 
Heyes et al. (93) showed that, among the cationic lipid analogues they synthesized 
with variation in the degree of saturation, the saturated C18 conjugates were 
internalized in to the cells more, although they are less efficient in gene silencing 
(siRNA delivery). 
In liposomal formulations, DOPE (Fig. 3.1) is often used as a helper lipid for 
liposomal formulation and for its fusogenic ability as it has the characteristics of non-
bilayer forming activity leading to destabilisation of the lipid bilayer (3). Oleoyl and 
oleyl chains have also been bound as esters and ethers in liposomal formulations:  1,3-
dioleoyloxy-2-(6-carboxyspermine) DOSPER (158), of 2,3-dioleyloxy-N-[2(spermine-




chloride (DOTMA)-DOPE (1/1 w/w, Lipofectin
®
) (Fig. 3.1). The use of cationic 
liposomes in poly-nucleic acid delivery was pioneered by Felgner and co-workers who 
developed the cationic liposome now commercially available as Lipofectin (2). 
Lipofectin is a 1:1 ratio of the cytofectin DOTMA and the naturally occurring, neutral 
lipid DOPE; Lipofectamine is a 3:1 (w/w) liposome formulation DOSPA and DOPE. 
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3.1.1. Methods for Cationic Liposome Formulation 
 The formulation of cationic liposomes, with or without a neutral co-lipid, has 
involved a number of different possible procedures. Broadly speaking these are:   
1. Sonication and/or vortex-mixing of an aqueous solution, 
2. Reverse-phase evaporation, 
3. Aqueous dilution of an ethanolic stock solution. 
 The method of formulation is undoubtedly important, but the extent to which it 
affects the efficiency of poly-nucleic acid transfer has yet to be properly investigated. 
DOTMA and its analogues are usually formulated into cationic liposomes with the 
neutral colipid DOPE. Liposomes are typically prepared by vortex-mixing of equimolar 
amounts of a cationic lipid and a neutral lipid at room temperature to produce large 
multilamellar vesicles (MLVs) which are then sonicated to produce small unilamellar 
vesicles (SUVs) suitable for gene transfection (159). Alternatively, rotary evaporation of 
the lipid mix (e.g., from chloroform or dichloromethane) to yield a film, which is 
evaporated for 1 h and then rehydrated in PBS at pH 7.4. Size-reduction can be carried 
out by repeatedly passing through a thermobarrel extruder with a sub-micron filter (160). 
However, cationic amphiphile DOGS (Transfectam) is non-liposomal and is formulated 
simply by ten-fold dilution of an aqueous ethanol stock solution into an aqueous buffer 
(72). 
In this study we are concentrating on lipopolyamines composed either of two 
symmetric or unsymmetrical (i.e., different) carbon chain, or lipophilic steroid 
attached (12,23,161-163), covalently bound to a polyamine e.g., spermine (1,12-
diamino-4,9-diazadodecane) (164). The first cellular barrier for the delivery of the 
DNA nanoparticles is the eukaryotic cell membrane which is composed mainly of 
phospholipids (50-90 % of total lipid content, most phospholipids are derivatives of 
diacyl-glycerol-3-phosphate), sterols (5-25 %), and glycol-lipids (usually less than 5 
%). The diacyl-glycerol chains (C14 to C24) are derived from linear fatty acids with 
varying degrees of unsaturation (165). In NVGT, cationic lipids which interact with 
the DNA payload also mediate cell-membrane transport, typically through adsorptive 
endocytosis or mediated by cations (166-168), both routes leading to internalization of 
the DNA complex nanoparticles. Such endocytosis is via the clathrin-coated pits 
(diameter 250-300 nm) (169), followed by fusion of the early endosome and sorting to 
the late endosomal compartment, hence avoiding degradation in the lysosome.  
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In this study, the effects on DNA formulation of a circular plasmid are 
investigated with variation in the position, length, saturation or the symmetry of the 
two fatty chains (diacyl or dialkyl) in our lipospermines or the attachment of a 
heterocyclic group on the two primary amines of lipospermines to increase its pKa 
these lipid chains are linked by amide bonds at the secondary amino groups of 









-diacyl spermine. This study includes the physicochemical 
characterisation of the lipoplexes nanoparticles formed, transfection results and 
cytotoxicity effects with the synthesized lipospermine formulations. The ability of this 
synthetic lipopolyamine to condense DNA was studied using ethidium bromide 
(EthBr) fluorescence quenching, light scattering assays and gel electrophoresis assay. 
The physicochemical characterization includes the particle size measurements and 
zeta potential studies. The ability of these formed complexes to protect DNA from 
degradation by DNase enzyme studied by the gel electrophoresis.  
Transfection efficiency was studied in an immortalized cancer cell line 
(HtTA), and in primary skin cells (FEK4) in presence and absence of serum to test the 
ability of these novel transfecting agents to work efficiently in the presence of serum 
which open the door for successful ones for further in vivo investigations, and 





 that incorporate such oleoyl or oleyl 






 is available as a mixture of the cationic lipid DOSPA and the 
neutral helper lipid DOPE as 3/1 w/w, respectively. While Lipofectin
®
 is available as 
a mixture of the cationic lipid DOTMA and the helper lipid DOPE as 1/1 w/w, 
respectively. The cytotoxicity of these compounds was studied in both primary skin 
and immortalised cancer cell lines using the MTT assay. Two commercially available 
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3.1.2. DNA Condensation 
The use of an efficient carrier for poly-nucleic acid delivery is a determinant 
factor for the successful application of gene delivery (172). This carrier is responsible 
for the complex process of gene delivery to the nucleus (154). Within the prerequisites 
for delivery of DNA across intact cytoplasmic membrane are condensation and 
masking the negative charges of the phosphate backbone. Condensation of DNA 
occurs when 90 % of the charge on DNA is neutralised (11,173). To investigate the 
neutralization of these negative charges along the DNA backbone that leads to 
collapse of the DNA into a more compact structure (nanoparticles), three experiments 
were carried out:   
1. Ethidium bromide fluorescence quenching assay, 
2. Light scattering assay, 
3. Gel electrophoresis study. 
 
The ability of spermine to condense calf thymus DNA, also Lipofectin, 
Lipofectamine, Transfectam and synthesized lipospermines to condense circular 
plasmids DNA pEGFP was investigated (pEGFP encoding for enhanced green 





dioleoyl spermine to condense DNA, leading to the formation of nanoparticles (that 
are suitable for gene delivery), was compared with the commercially available 
liposomal transfection formulations Lipofectin and Lipofectamine and non liposomal 
Transfectam. 
 
3.1.3. Ethidium Bromide Fluorescence Quenching Assay 
EthBr (2,7-diamino-9-phenylphenanthridinium-10-ethyl bromide, Fig. 3.2) a 
cationic dye that displays a marked increase in the fluorescence upon binding with 
DNA and RNA through the intercalation between the EthBr phenanthridinium moiety 
and adjacent base pairs of specific DNA sequences (174-176). The increase in the 
fluorescence of EthBr upon binding with DNA making EthBr a useful probe to 
measure drug-DNA interactions (164,174,175). The binding of cationic molecules 
with DNA is not entirely responsible for the release of EthBr, but alteration of the 
molecular flexibility of DNA through cationic compaction facilitated the release of 
bound EthBr (163,175,176). 










Fig. 3.2. Ethidium bromide (Eth Br) 
 
The significant enhancement of fluorescence when EthBr intercalates DNA is 
attributed to the hydrophobic environment surrounding the EthBr molecule leading to 
longer life time for the excited state (174,177). On the other hand, free EthBr (in 
solution) is strongly quenched by aqueous solvent, so it exhibits a weak fluorescence 
relative to that from intercalated dye (177). The fluorescence intensity of free EthBr 
(no DNA) in HEPES buffer solution (20 mM NaCl, 2 mM HEPES, 10 µM EDTA, pH 
7.4) was usually small (background). On the other hand, the fluorescence intensity of 
the EthBr solution was significantly increased after the addition of DNA solution, as a 
result of EthBr intercalation between DNA base-pairs. The fluorescence was 
expressed as the percentage of the maximum fluorescence when EthBr was bound to 
the DNA in the absence of competition for binding and was corrected for background 
fluorescence of free EthBr in solution. 
DNA condensation studies were started through investigating the effect of 
spermine to condense calf thymus DNA (Fig. 3.3). The charge ratio was calculated 
according to the ammonium/phosphate (+/-) charge ratio for spermine as 202.35 
g/mole spermine contains four nitrogens that can be protonated. Spermine has pKa 
values of 10.9, 10.1, 8.9 and 8.1, and according to Henderson-Hasselbach equation, 
spermine has 3.8 charges / molecule at pH 7.4 (23). Fig. 3.3 shows that the 
fluorescence of EthBr decrease as a function of increasing the N/P ratio of spermine. 
 These results confirmed that, both the number of positive charges and their 
distribution on the surface of the molecule have profound effects on DNA 
condensation as indicated in previous studies (161,178,179).  
 

















































Fig. 3.3. Plot of EthBr displacement assay and light scattering assay (relative 
maximum apparent absorbance at λ =320nm) of calf thymus DNA complexed with 
spermine 
 
The ability of the commercially available liposomal cationic lipids (Lipofectin, 




-dioleoyl spermine) to 





-dioleoyl spermine in comparison with the commercially available, liposomal 




 and non liposomal 
Transfectam. All cationic lipid formulations have the ability to condense completely 
DNA through the displacement of EthBr leading to fluorescence quenching. At lower 
charge ratios, and Transfectam and Lipofectamine has better ability to suppress 
fluorescence, which produces 50 % fluorescence decrease at N/P charge ratio 0.6 and 




-dioleoyl spermine and Lipofectin
®
, which produces 50 












































































































Fig. 3.4. Plot of EthBr fluorescence quenching assay of pEGFP DNA complexed with 
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Table 3.1. pEGFP DNA binding data 
Condensing agent Drug concentration at 50 % 































* “apparent” equilibrium binding constant of condensing agent to pEGFP DNA 
 
To quantify the ability of the investigated polyamines in condensing DNA, the 
binding constant of these polyamines with DNA was estimated (Table 3.1) and 
compared using EthBr assay that has been shown to be a valid method for comparison 
of DNA binding affinity (175). The drug concentration producing 50 % inhibition of 
fluorescence is approximately inversely proportional to the binding constant. 
From Table 3.1 data, the concentrations of condensing agents producing 50 % 
fluorescence inhibition were calculated (equation 1) as shown in the experimental 
chapter. The “apparent” equilibrium constant (Kapp) of polyamine binding was 





and the concentration of EthBr is 1.3 µM. From these results it was found that 




) between the compared 





could be attributed to the higher number of positive charges and the charge distribution 
on other polyamines because in Lipofectin the cationic lipid DOTMA carries 1 positive 
charge (ammonium eq/mole) (2) while the cationic lipid DOSPA in the Lipofectamine 





-dioleoyl spermine carries 2 positive charges, 
Transfectam
®
 carries 3 positive charges (139), and spermine carries 4 positive charges 
at physiological pH. 




                                                                           eq. [1] 
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DNA is condensed by neutralizing the DNA phosphate negative charges by the 
two primary amines that are positively charged at pH 7.4 and coated by the dioleoyl 









dioleoyl spermine-DNA lipoplex at lower charge ratio decreases the toxicity of the 
DNA delivering lipopolyamine. In addition, as the mammalian cell membrane is a 
semi-permeable membrane formed of phospholipids bilayer that allows the transport 
of macromolecules by endocytosis, neutralization of the negative charges on the DNA 
by polycations will improve the delivery of DNA through the cell membrane because 
of the presence of negative charges on both DNA and cell membrane. Also, the 
positively charged lipid complex will mediate transfection by fusion with cell 
membrane (36,150). 
 
3.1.4. Light Scattering Assay 
This experiment has been carried out to investigate the condensation of DNA 
by polyamines and the formation of particles (180). The apparent UV absorbance at 
320 nm (where there is no DNA absorbance above 300 nm) was measured (19,161) 
showing light scattering. The formation of DNA nanoparticles causes scattering of 
light that reduces light intensity at the UV detector. The results from Fig. 3.3 indicated 
the formation of particles upon interaction of spermine maximum at N/P ratio 2.5. 
In addition, Fig. 3.3 shows that the light scattering due to particle formation 
increases with the increase in the displaced EthBr and reaches the maximum at 
approximately the same charge ratio at which there is a maximum EthBr 
displacement, although the concentration of DNA used in light scattering experiments 
is ten times the concentration used in fluorescence quenching experiments which is 
related to the lack of sensitivity of the light scattering experiment in comparison with 
EthBr fluorescence assay. Also, from light scattering results, there is a decrease in the 
% relative maximal apparent absorbance (% rel. max. app. abs.) after reaching the 
maximum absorbance, which could be attributed to the formation of polyamine-DNA 
aggregates as reported by Gosule and Schellman (181) where any DNA intra-chain 
binding agents will also act as inter-chain segment binders. The formation of 
aggregates at high charge ratio, at the relatively high concentration of DNA in 
comparison with EthBr assay, will decrease the scattering light that will decrease the 
apparent absorption value. As this light scattering assay is much less sensitive than the 
EthBr fluorescence quenching assay, we decided not to use it anymore, and we 
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depended only on both the EthBr assay and agarose gel electrophoresis experiments 
for verification of pDNA condensation as found in many recent gene delivery 
publications. 
 
3.1.5. Agarose Gel Electrophoresis 
The complex formation of lipopolyamines polyanionic DNA (pEGFP) was 
examined by analysis of the electrophoretic mobility of the circular plasmid DNA-
lipopolyamine complex within an agarose gel (1 %) stained with EthBr. The unbound 
free DNA in the agarose gel was visualized under UV using GeneGenius (Syngene).  
 
 











-Dioleoyl spermine was able to condense pEGFP DNA efficiently (as a 
result of the interactions between the lipopolyamine ammonium ions and the DNA 
phosphate charges) at the optimised respective charge ratios (N/P) of transfection 





-dioleoyl spermine was able to completely inhibit the migration of 
the circular plasmid DNA from lipoplexes in the agarose gel at charge ratio of 




-dioleoyl spermine to completely 
immobilize pEGFP at higher charge ratios (charge ratio 3). While at lower charge 
ratios (≤ 2) a moderate inhibition of pEGFP in the agarose gel was observed (Fig. 
3.5). These results were in agreement with the EthBr fluorescence intensity (DNA 
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condensation) results (Fig. 3.4) that showed more than 80 % fluorescence quenching 




-dioleoyl spermine charge ratio of 3.  
 
3.1.6. Cell Culture and Transfection Experiments 
Two cell lines were used in the transfection experiment, FEK4 cells 
(143,144,182), are human primary fibroblasts derived from newborn foreskin explants 
(144) and HtTA cells are a human cervical carcinoma, HeLa derived and transformed 
cell line. Cells were cultured in Earle’s Minimal Essential Medium (EMEM) 
supplemented with foetal calf serum (FCS) 15 % in the case of FEK4 cells and 10 % 
in the case of HtTA cells, penicillin and streptomycin (50 IU/ml each), glutamine (2 
mM), and sodium bicarbonate (0.2 %). Primary cells were passaged once a week, and 
used between passages 7-15. 
For the transfection (gene delivery) and the resultant gene activity 
(transfection efficiency), cells were seeded in 12-well plates at a density of 5 x 10
4 
cells/well (in 1 ml EMEM with FCS) for 24 h to reach a 50-60 % confluency on the 
day of transfection. The complex was prepared by mixing pEGFP (1 µg/ml/well) with 
each lipopolyamine in Opti-MEM (serum free media, Gibco BRL) according to the 
charge ratio at 20 
o
C for 30 mins, and then incubated with the cells for 4 h at 37 
o
C in 
5 % CO2. Then the cells were washed and cultured for a further 44 h in growth 
medium at 37 
o
C in 5 % CO2. 
Levels of EGFP in the transfected cells were detected and corrected for 
background fluorescence of the control cells using a fluorescence activated cell 
sorting (FACS) machine (Becton Dickinson FACS Vantage dual Laser Instrument, 
argon ion laser 488 nm). The transfection efficiency was calculated based on the 
percentage of the viable cells that expressed EGFP (positive cells) in the total number 
of cells. 
The tested lipopolyamines were investigated for their gene delivery ability in 
cells using pEGFP as a reporter gene. 











































Fig. 3.6. Lipofection of primary skin cell line (FEK4) and cancer cell line (HtTA) 
transfected with pEGFP complexed with different concentrations of Lipofectin (left) 
and Lipofectamine (right) at different N/P ratios. The data show 3 different 









































Fig. 3.7. Lipofection of primary skin cell line (FEK4) transfected with pEGFP 
complexed with different concentrations of Transfectam (left) and of primary skin cell 
line (FEK4) and cancer cell line (HtTA) transfected with pEGFP complexed with 




-dioleoyl spermine (right). The data show 3 different 
experiments (3 replicates each) and the error bars are the standard deviation. 
 
Fig. 3.6 shows the transfection results of pEGFP into FEK4 and HtTA using 
Lipofectin and Lipofectamine at different charge ratios. These results show that 
Lipofectin is unable to achieve high transfection efficiency in FEK4 and HtTA cell 
lines up to charge ratio 5, it shows that Lipofectin achieves a maximum of 36% for 
FEK4 and 52% for HtTA transfection efficiency from charge ratio 2, while 
Lipofectamine results show 85% for FEK4 and 78% for HtTA transfection efficiency 
from charge ratio 5. In the case of Transfectam
®
, it shows a significant improvement 
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in the transfection levels of the primary cell line FEK4 at different charge ratios, from 
61 % at charge ratio 3 to up to 85 % transfection levels at charge ratio 8 with optimum 




-Dioleoyl spermine achieves 85 %for 
FEK4 and 78% for HtTA transfection efficiency at the optimum charge ratio of 
transfection 2.5 (Fig. 3.7). 
 



































Fig. 3.8. Viability of primary skin cell line (FEK4) and cancer cell line (HtTA) 
transfected with pEGFP complexed with different concentrations of Lipofectin (left) 
and Lipofectamine (right) at different N/P ratios The data show 3 different 



































Fig. 3.9. Viability of primary skin cell line (FEK4) transfected with pEGFP 
complexed with different concentrations of Transfectam (left) and of primary skin cell 
line (FEK4) and cancer cell line (HtTA) transfected with pEGFP complexed with 
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-dioleoyl spermine (right). The data show 3 different 
experiments (3 replicates each) and the error bars are the standard deviation. 
 
Two cell lines were used in the transfection experiment; primary cell line 
FEK4 cells and cancer cell line HtTA were used for the cytotoxicity studies too. 
Lipofectin achieves a viability range from 90% to 50 % for FEK4 and 82% to 
38% for HtTA viability from charge ratio ascending from 1 to 5 with viability of 87% 
for FEK4 and 71% for HtTA at its maximum transfection efficiency at N/P ratio 2, 
while Lipofectamine results show viability range from 87% to 55% for FEK4 and 
78% to 45% for HtTA from charge ratio ascending from 1 to 5 which is the max 
transfection efficient ratio (Fig. 3.8). In the case of Transfectam
®
, it shows reduction 
in the viability of the primary cell line FEK4 from 87 % at charge ratio 3 to 60 % at 





-Dioleoyl spermine (Fig. 3.9) achieves cell viability 92% to 72 % for 
FEK4 and 85% to 54% for HtTA with cell viability 83%for FEK4 and 65% for HtTA 
at the optimum charge ratio of transfection 2.5. 
The increased toxicity levels of the lipoplex could be attributed to the high 
efficiency of the lipopolyamine in transfecting the primary and cancer cell lines 
investigated. 
 
3.1.8. Characterization of the Lipoplex Formulations 
 
Lipoplex Particle Size and Zeta-Potential Measurement 
Condensation of DNA into nanoparticles is a way to decrease the size of the 
delivered gene in order to facilitate cellular membrane entry by endocytosis and 
subsequent trafficking to the nucleus. Zeta potential characterizes the stability of the 
formulation. Romoren et al. (183) investigated the long-term stability of chitosan-
based polyplex solutions (25 mM sodium acetate buffer, pH 5.5) at different 
temperatures (4 °C, 25 °C, 45 °C) over a period of up to 1 year. They showed the 
relation between the change in the physicochemical characteristics of the polyplexes 
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3.1.8.1. Lipoplex Particle Size Measurement 
The average particle size for the lipoplexes formed (at their optimum charge 
ratio of transfection) between plasmid DNA and lipopolyamines, after mixing with 
vortex mixer was determined using Nanosight LM10 (Nanosight). All measurements 
were carried out on lipoplexes having a 2 µg DNA/200µl in HEPES buffer at pH 7.4 
at 20 ºC. 
The characterization of particle size revealed that the average particle size of 
Transfectam
®





-dioleoyl spermine (150 nm). Lipoplexes with liposomal reagents, Lipofectin 
and Lipofectamine showed larger average particle sizes of 200 and 245 nm, 
respectively, as indicated in Table 3.2. All the particle size measurements were carried 
out on the lipoplexes at their optimum charge ratio of transfection. 
The results of pEGFP (4.7 kbp) condensation and formation of 65 nm 
nanoparticles with Transfectam
®
 were in agreement with the results found by Dunlap 
et al. in their study of the commercial lipospermine condensation of plasmid DNA (5–
7 kbp) that induced condensates of 50–70 nm in diameter (184). 
 











Lipofectin 2.0 245 (15) 
Lipofectamine 4.5 200 (34) 





-Dioleoyl spermine 2.5 150 (12) 
Each lipoplex diameter value shows the mean ± S.D. 
 
3.1.8.2. Zeta-Potential Measurement 
Zeta- (ζ−) potential is an important parameter helping to predict the stability of 
the formulation as well as the ability of the positively charged particles to interact 
with cell membranes (185). Zeta potential depends on several factors including:  pH, 
ionic charge, ion size, and concentration of ions in solution (186). The interaction of 
DNA with cationic lipids leads to the formation of net charge on the surface of the 
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formed nanoparticles, either positive or negative according to the DNA- cationic lipid 
charge ratio, which attracts counter ions close to the surface of the formed 
nanoparticles (an electrical double layer). Ions close to the surface of the particle are 
bound relatively strongly to the surface until the hydrodynamic plane of shear. After 
this plane, ion distribution is determined by a balance of electrostatic forces and 
random thermal motion. The potential in this region, therefore, decays as the distance 
from the surface increases until, at sufficient distance, it reaches the bulk solution 
value (zero). The potential at this imaginary surface, the hydrodynamic plane of shear, 
which separates the thin layer of liquid bound to the solid surface and showing elastic 
behaviour from the rest of the liquid is the ζ-potential. The formed nanoparticles are 
considered to be stable when they have pronounced ζ-potential values, either positive 
or negative, but the tendency to aggregate is higher when the ζ-potential is close to 
zero. 
The average ζ-potential measurement for the lipoplexes formed (at their 
optimum charge ratio of transfection), after mixing with vortex mixer, was determined 
using a Delsa™Nano Zeta Potential and Submicron Particle Size Analyzer (Beckman 
Coulter). All measurements were carried out on 2 ml of lipoplexes solution with 3 
µg/ml plasmid DNA in HEPES buffer at pH 7.4 and 20 °C. The results revealed that 
the surface charge, as determined by ζ-potential measurements, was +2.17 for N4,N9-
dioleoyl spermine (at N/P charge ratio of 2.5), while the measured ζ-potential for 
naked DNA is -1.02 mV. After these preliminary studies we started to test our novel 





diacyl spermines), change the length (C18 and C14) and degree of saturation 






























-DIACYL SPERMINES:  SAR STUDIES ON NON-VIRAL 
       LIPOPOLYAMINE VECTORS FOR pDNA FORMULATION 
 









dimyristoleoyl, distearoyl and dioleoyl]-1,12-diamino-4,9-diazadodecane were 
synthesized from the naturally occurring polyamine spermine (Fig. 3.10). Their 
abilities to condense DNA and to form nanoparticles were characterized. Transfection 
efficiencies were studied in FEK4 primary skin cells and in an immortalized cancer 
























































Mol. Wt 731.26 






3.2.1. DNA Condensation 
 Fig. 3.11 shows the DNA condensation ability of the synthesized 









-dioleoyl spermine have the best DNA condensing 









-distearoyl spermine 60% 
fluorescence quenching at the same N/P ratio. 





































spermine was able to condense pEGFP DNA efficiently (as a result of neutralization of 
DNA phosphate negative charges by the lipopolyamine ammonium positive charges) at 
its optimised N/P charge ratio of transfection by inhibiting the electrophoretic mobility 
of plasmid DNA. 
 
Fig. 3.12. Typical 1% agarose gel assay of fluorescent EthBr intercalated in pEGFP, 





spermine at N/P ratios 2-12. 
 
3.2.2. Lipoplex Particle Size and ζ-Potential 
 The particle size measurements were carried out on the lipoplexes at their 
optimum concentration for transfection (Table 3.3). Particle size characterization by 
laser diffraction showed that the nanoscale particle size of the formed DNA 









dimyristoleoyl spermine) with an average particle size of 205 nm, compared with 





-dioleoyl spermine pEGFP lipoplex particle size of 150 nm (Table 3.3). Two 
representative ζ-potential measurements for the lipoplexes formed (at their optimum 
charge ratio of transfection with 3 µg/ml pEGFP) were measured with a Delsa™Nano 









dioleoyl spermine +3.69 mV. 
 































-Dimyristoyl spermine. 12 190 (39) 
 




















FEK4 Serum Free FEK4 Serum
HtTA Serum Free HtTA Serum
 









-dioleoyl spermine (3.32 µg) on the primary skin cell line 
FEK4 and the HeLa derived cancer cell line HtTA in the absence and presence of 
serum. 





























FEK4 Transfection HtTA Transfection 
FEK4 Viability HtTA Viability
 
























(11.31 µg) on the primary skin cell line FEK4and the HeLa derived cancer cell line 
HtTA. 
 
 The transduction of EGFP into a primary skin cell line FEK4 and a cancer cell 
line (HeLa-derived HtTA) was investigated in presence and absence of serum (Fig. 
3.13) and we found that there was no significant difference in the transfection levels in 









Encouraged by these positive results, all our subsequent transfection experiments are 
performed in the presence of serum. The optimum concentrations (in a final volume of 
0.5 ml) and their corresponding N/P charge ratios for transfection were experimentally 
determined by using ascending N/P ratios of lipospermines from 2, 4, 6 etc. until we 
reached around 80% transfection and there was not a further step-up in transfection 
efficiency at the next highest N/P ratio. So the optimum amounts (and corresponding 























-dimyristoyl spermine (11.31 µg N/P = 




-dioleoyl spermine typically shows 
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70% and 65% transfection ability and 70% and 60% cell viability for FEK4 and HtTA 





 dioleoyl spermine.  
In this section, we have investigated the change in the position then length and 
degree of saturation of the symmetrical diacyl fatty chain formulations of 
lipospermine on pDNA condensation and cellular delivery. The results from pEGFP 
condensation (Fig. 3.11), investigated using the EthBr fluorescence quenching assay, 









dimyristoleoyl spermine were able to condense DNA to less than 10% EthBr 









distearoyl spermine show 75% and 60% condensation respectively at the same N/P 
ratio. The lipid chains make a significant contribution to the DNA condensation, the 
differences are clear (Fig. 3.11) with respect to position and unsaturation, where 
pDNA condensation efficiency follows:  saturated-1,12< unsaturated-1,12< 
unsaturated-4,9 regioisomers. 
Particle size of the final gene formulation is also an important factor in 
improving gene delivery (187,188). Particle size results (Table 3.3) for pDNA showed 
average particle size 205 nm. On the relationship between particle size and 
transfection efficiency, there are no definite limits to the nanoparticle size that are 
suitable for transfection (189). Nanoparticles have relatively higher intracellular 
uptake than microparticles (155). Also, on the nanoscale, smaller-size polyplexes are 
more able to enter cells and thereby increase the efficiency of transfection (190). 





-dioleoyl spermine  (transfection efficiency FEK4 70%, HtTA 65% and cell 
viability FEK4 70%, HtTA 60%) was a better vector based on these two factors of 

























). Based on these DNA 
transfection and cell viability results, we investigated the change in the position and 
length of the symmetrical diacyl fatty chain formulation of lipospermine on siRNA 
condensation and cellular delivery. 
The DNA compacting properties of polyamines (especially spermine) are well-
known, hence the use of spermine as the cationic part in several synthetic DNA 
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carriers. Clement and his research group recently reported the use 
lipophosphoramidate as the lipidic part of lipospermines for gene delivery (191). Due 
to their high net charge at physiological pH, polyamines effectively charge neutralize 
the phosphodiester backbone of DNA (192). Many pKa measurements have been 
made on spermidine, spermine, and their derivatives (193,194) which all indicate their 
high number of positive charges at physiological pH. Spermidine typically shows pKa 
values of:  11.1, 10.0 and 8.6 or 10.9, 9.8 and 8.4 (195) and spermine:  pK1 10.9, pK2 





-regioisomeric analogues we have separated the two primary 
amines from the (significant base-weakening) transient charges on the secondary 
amines, and the primary amines may therefore be assumed to have pKa values typical 




-diacyl analogues will carry two positive 





means that these analogues will still carry two positive charges at pH = 7.4, but their 
pKa values are likely to follow those of putrescine (1,4-diaminobutane) (10.8 and 9.4 
or 10.7 and 9.2) (197,198) and we assume that there will not be any significant effect 
from the γ-amide functional group. Thus, these novel conjugates are dibasic for N/P 
charge ratio calculations, and their efficient charge neutralisation by phosphate anion 
titration will be a function of steric more than electronic effects when compared with 

























) for DNA 
transfection efficiency. 




-dioleoyl spermine was shown to be better than 









-diacyl spermines with changes to the length of the fatty chain from C10 to C18 
and also using saturated or mono unsaturated when available. 
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-DIACYL SPERMINES:   
       NON-VIRAL LIPOPOLYAMINE VECTORS FOR EFFICIENT pDNA  
       FORMULATION 
 





-diacyl spermines on plasmid DNA (pDNA) condensation and then compare their 









-[didecanoyl, dilauroyl, dimyristoyl, dimyristoleoyl, dipalmitoyl, distearoyl, 





4,9-diazadodecane conjugates (Fig. 3.15) are designed to range from C10 to C18, but 
they also include C20 (diretinoyl) which due to its structure is comparable to C13-C14 
in overall length. The abilities of these novel compounds to condense DNA and to form 
nanoparticles were studied using EthBr fluorescence quenching and nanoparticle 
characterization techniques. Transfection efficiency was studied in our usual FEK4 










analogues derived by reduction of the best two diacyl compounds, as they can carry up 





























































Mol. Wt. 619.04 
 
 


































































Mol. Wt. 767.20 
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3.3.1. DNA Condensation 
In Fig. 3.16, the DNA condensation abilities of the synthesized lipopolyamines 









-dimyristoleoyl spermine have the best DNA 


















-dioleoyl spermine show 75% fluorescence 




-dilauroyl spermine is only able to achieve about 

















N4,N9-didecanoyl spermine N4,N9-dilauroyl spermine
N4,N9-dimyristoyl spermine N4,N9-dimyristoleoyl spermine 
N4,N9-dipalmitoyl spermine N4,N9-dioleoyl spermine 
N4,N9-distearoyl spermine












spermine was able to prevent the migration of pEGFP DNA efficiently, as a result of 
neutralization of DNA phosphate negative charges by the lipopolyamine ammonium 
positive charges at their optimised respective charge ratios (N/P) of transfection. Thus, 
by completely inhibiting the electrophoretic mobility of plasmid DNA, we conclude 
that they are charge neutralised, experimental evidence which supports the pEGFP 
DNA condensation data that we obtained from the EthBr fluorescence quenching 
assay (Fig. 3.16). Of course, it is not essential that the DNA is fully condensed, 
provided that nanoparticles are formed, if entry is via the clathrin coated pit, in 
comparison with relying upon entry during mitosis as in the use of naked DNA. 
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Fig. 3.17. Typical 1% agarose gel assay of fluorescent EthBr intercalated in pEGFP, 





spermine at N/P ratios 2, 6 and 10. 
 
3.3.2. Lipoplex Particle Size and Zeta-Potential Measurements 
 











































-Dioleoyl spermine 2.5 150 (12) 2.17 
 
 The particle size and ζ-potential characterization measurements were carried 
out on the lipoplexes at their optimum N/P charge ratio of transfection (Table 3.4). 
Particle size characterization by laser diffraction showed that the nanoscale particle 




-dimyristoleoyl spermine) to 









-distearoyl spermine) with an 
average particle size of 161 nm (Table 3.4). The particle size of the final pDNA 
formulation is also an important factor in improving gene delivery (187,188). 
 The surface charge, as determined by ζ-potential measurements on the 
lipoplexes at their experimentally determined optimum N/P charge ratios of 









-dilauroyl spermine); the 
measured ζ-potential for naked DNA is -1.02 mV. 
 
3.3.3. DNase I Protection 
The DNase I protection assay was carried using plasmid DNA complexed with 
different N/P charge ratios of the lipopolyamines. Reasonably intense undigested 
DNA bands were detected in the gel as a control, and there was no band in the lane for 
uncondensed DNA which was fully digested by DNase I as negative control (Fig. 
3.18). we performed the DNase protection assay using different N/P charge ratios of 




-dioleoyl spermine the intense band of undigested 
DNA appeared at N/P charge ratio 3 (Fig. 3.18) which means that the lipoplex formed 
from condensed pEGFP DNA with this lipopolyamine is effectively protected from 
DNase I enzyme, and this may contribute to the lipoplex serum stability. 
 
 
Fig. 3.18. Typical 1% agarose gel of fluorescent EthBr intercalated in pEGFP, assay 
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3.3.4. Transfection Experiments and In Vitro Cytotoxicity 
The transduction of EGFP into a primary skin cell line FEK4 and a cancer cell 
line (HeLa-derived HtTA) was investigated. The optimum concentrations (in a final 
volume of 0.5 ml) and their corresponding N/P charge ratios for transfection were 
experimentally determined by using ascending N/P ratios of lipospermines from 2, 4, 
6 etc. until we reached around 80% transfection and there was not a further step-up in 











































Fig. 3.19. Lipofection of the primary skin cell line FEK4 and the cancer cell line 


































-dipalmitoyl spermine at different N/P charge ratios. 





Fig. 3.21. FACS analysis showing the live FEK4 (above left) and HtTA (above right) 
populations gated, and FEK4 (lower left) and HtTA (lower right) after 48 h 




-dioleoyl spermine:  untransduced 
cells,  EGFP-positive cells. 
  
 
Fig. 3.22. FACS analysis of FEK4 (left) and HtTA (right) after 48 h transfection of 
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 From our typical results, shown in Figs. 3.19 and 20 (for 2 x C12, 2 x C14, and 
2 x C16 saturated chains, respectively), we conclude that for the lipopolyamines that 




-dioleoyl spermine, transfection efficiency increases with 
N/P charge ratio. That these lipopolyamines are pDNA delivery vectors which can 









- dimyristoleoyl spermine in both cell 
lines (Figs. 3.21 and 3.22). Only a subset of the data obtained from healthy cells (the 
major population) was analysed through a gate setting. This gating was determined 
from the dot plots. 
Further transfection efficiency studies (carried out in triplicate on 3 separate 
experiments, n = 9) showed that there was no significant difference between the 
transfection efficiency in the presence (FEK4 82.9% ± 4.3, HtTA 75.4% ± 5.5) or 
absence (FEK4 85.3% ± 1.4, HtTA 78.0% ± 1.7) of serum (Fig. 3.13). 
 Encouraged by these positive results, all our subsequent transfection 
experiments are performed in the presence of serum. However, the toxicity also 
increases (decrease in cell viability) as the N/P charge ratio is increased (Fig. 3.23). 
The required lipopolyamine amounts and the corresponding N/P charge ratios to 
deliver pEGFP (1 µg in 50 µl, in a total final volume of 0.5 ml) for optimum 













-dimyristoyl spermine (9.4 µg, 










































































-dimyristoleoyl spermine (right) at different N/P ratios on the 
primary skin cell line FEK4 and the cancer cell line HtTA. 
 
 The transfection results (histograms in Fig. 3.24) indicate that there is no 
significant difference in the transfection ability of the different lipospermines (at their 





distearoyl spermine which is much lower. However, the cell viability (MTT assay) 




-dioleoyl spermine typically shows 
83% and 65% cell viability for FEK4 and HtTA cells, respectively. The shorter chain 
lipospermines, especially di-C14, both saturated and cis-mono-unsaturated, whilst 
efficient at cell transfection, are toxic to both cell lines (viability less than 40%, and 
often under 20%). It is often proposed that toxicity increases with increasing n-alkyl 
chain length, e.g., going from C2 to C8 (199-201) and similarly to C10 (202), as such 
cationic surfactants are known to increase membrane permeability. Although this is not 
an immutable rule, as was found for C2 to C12 in the 8-alkylberberine chloride series 
where upon elongating the aliphatic chain, toxicity decreased gradually (203). We are 





is used at a significantly low N/P charge ratio, and the shorter chain analogues are used 
at higher N/P ratios. 














































































































































































-diretinoyl spermine) (23.2 µg) on FEK4 (above) and on HtTA cell lines (below) 
The data represent 3 different experiments (3 replicates each) and the error bars represent 
the S.D. 









dioleoyl spermine, the former with poor transfection and the latter with high 
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transfection, but both showing good cell viability at practical concentrations for 




-dioleoyl spermine, made us investigate further these 
vectors but with four positive charges at physiological pH from amide reduction to the 



















spermine. The results (Fig. 3.25) show that there is not a large difference in the 
transfection efficiency, neither gain nor loss, on doubling the number of positive 




-dioleoyl spermine, while there is a great 









-distearoyl spermine shows transfection efficiencies of 28% and 26% 













-dioleyl spermine 80% and 76%, but the 
cell viabilities drop from around 65-90% to 10-42%. Therefore, the two alkyl 































FEK4 Transfection HtTA Transfection 
FEK4 Viability HtTA Viability
 



















(6.7 µg) on the primary skin cell line FEK4 and the HeLa derived cancer cell line 
HtTA. 
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3.3.5. Confocal Microscopy Visualization 
Using confocal laser scanning microscopy with one labelling solution 
(Invitrogen) containing both Alexa Fluor 594 wheat germ agglutinin (5 µg/ml) for cell 
membrane labelling, and Hoechst 33342 (2 µΜ) for nuclei labelling, we have shown 
(Fig. 3.26) that FEK4 cells were successfully transfected with pDNA as the cells 
biosynthesized EGFP by transcription and translation. 
 
 
Fig. 3.26. Transfection of the primary skin cell line FEK4 with pEGFP showing 




-dioleoyl spermine. The 
cell lipid bilayers fluoresce red from the Alexa Fluor 594 and the nuclei fluoresce blue 
from the Hoechst 33342 (LSM510META, under the 60× oil immersion objective). 
 
 In this section, we have investigated effects resulting from changes in the 




- diacyl fatty chain formulations of lipospermines on 
DNA condensation and cellular delivery. The results from pEGFP condensation, 
investigated by EthBr fluorescence quenching assay, revealed that five of our 





-dilauroyl spermine had not quenched the EthBr 
fluorescence to 20% by N/P charge ratio 3.5 (Fig. 3.16). Particle size of the final 
nanoscale formulation is also an important factor in improving gene delivery 
(187,188). Particle size results (Table 3.4) showed an average particle size of 161 nm. 
On the relationship between particle size and transfection efficiency, all our lipoplexes 
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are in the range 130-220 nm, and they transfected target cell lines efficiently. If 
internalisation is via a clathrin coated pit, there will be an upper-size limit of 250-300 
nm (169), although larger sizes of nanoparticles still do achieve transfection, 
presumably by a different mechanism (189). Nanoparticles have relatively higher 
intracellular uptake than microparticles (155). Also, on the nanoscale, smaller-size 
polyplexes are more able to enter cells and thereby increase the efficiency of 
transfection (190). 
 The lipid moiety in our cationic lipids interacts with the phospholipid bilayer 
of the cell membrane, and that facilitates cell entry, either in crossing the membrane 
bilayer and/or in helping to weaken the endosomal bilayer and thereby aid escape into 
the cytosol. DNA, either as a nanoparticle or now free (uncomplexed) from the 
condensing lipopolyamine, must now traffic to the nucleus and cross the nuclear 
membrane which is thought to occur through the NPC or by direct association with 
the chromatin during mitosis. After nuclear entry, the payload DNA should 
successfully be able to give the desired protein through transcription and translation. 
The first key step in this gene formulation is DNA condensation into nanoparticles by 
masking the negative charges of the phosphate backbone. As introduced above, an 
advantage of cationic lipids is that this titration of the phosphate anions with a 
lipopolyamine causes alleviation of charge repulsion between remote phosphates 
along the DNA helix leading to collapse into a more compact structure that facilitates 
cell entry. Furthermore, the packing of the lipid chains make a significant contribution 
to this DNA compaction (Fig. 3.16). 
 It have previously reported the importance of the substituents in the lipid 
moiety conjugated to the cationic polyamine to achieve improvements in DNA 
condensation efficiency for non liposomal formulations where the lipid moiety must 
be considered in shape (volume) and substituent pattern, as well as the polyamine 
moiety and its pKa values (12,161,162,170,171). The design and synthesis of novel 
cationic lipids based on the tetra-amine spermine, as non-liposomal formulations, 
where the lipid moiety is a long carbon chain, were largely investigated by Behr et al. 
(72) and Remy et al. (15) with their design and preparation of the highly efficient 
lipopolyamine DOGS (dioctadecylamido-glycyl spermine, Transfectam
®
). It is 
generally agreed that the length and type of the aliphatic chains incorporated into 
cationic lipids significantly affect their transfection efficiency, but this needs 
experimental verification. Thus, a series of vectors differing in their hydrophobic 
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domains have been prepared. Behr and co-workers made a series of lipopolyamines 
and found that their gene delivery efficiency was independent of chain saturation 
(oleoyl vs. stearoyl lipopolyamines) (15). Further, when comparing saturated chains, 
McGregor et al. found C18 chains to be optimal in a series of gemini surfactants 
according to the order C18 > C16 > C14 (204), which was also reported by Scherman 
and co-workers with a series of linear polyamine-based vectors (205). Results 
obtained with DMRIE (206) (1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl-
ammonium bromide, an analogue of DOTMA), alkyl acyl carnitine esters (207) and 
bis-ether lipids related to DOTAP (208) have shown that a comparison of vectors 
based solely on the lengths of the two saturated aliphatic chains led to the order C14 > 
C16 > C18 (in terms of transgene expression). Early liposomal studies therefore led to 
the proposal that a shorter chain length may facilitate intermembrane mixing, an 
important factor in endosomal escape (206). A common moiety is the use of cis-
mono-unsaturated alkyl chains e.g., the oleoyl group (C18). This leads to higher 
transfection levels than the corresponding saturated e.g., stearoyl (C18) derivatives, a 
result possibly related to the issues of hydrophobic moiety hydration or packing 
(206,207). 
 By incorporating two aliphatic chains and then stepwise changing their length, 
we have shown that the all our synthesized lipospermines afford transfection results in 





-dioleoyl spermine has the lowest (N/P = 2.5) while the others ranged over N/P 
ratios 10-20. This may give a lead to their higher toxicity, often more than 60% 




-dioleoyl spermine which, with its two 





distearoyl spermine.  




-dioleoyl spermine is much 




-diacyl spermine (C10-C18) which gave us a 




-diacyl spermine (C20-C24) even with different degrees of 




-dioleoyl spermine in order to find the 
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Mol. Wt 899.58. 
















[diarachidoyl, diarachidonoyl, dieicosenoyl, dierucoyl and dinervonoyl]-1,12-
diamino-4,9-diazadodecane (Fig. 3.27) were studied. The abilities of these novel 
compounds to condense DNA and to form nanoparticles were studied using EthBr 
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fluorescence quenching and nanoparticle characterization techniques. Transfection 
efficiency was studied in FEK4 primary skin cells and in an immortalized cancer cell 






3.4.1. DNA Condensation 
 In Fig. 28, we show the DNA condensation ability of the synthesized 





has the best DNA condensing ability, 90% EthBr fluorescence quenched at N/P 









-dierucoyl spermine is only able to achieve around 60% fluorescence 
quenching at the same N/P ratio. The gel electrophoresis results (Fig. 3.29) show, by 




-dinervonoyl spermine was 
able to condense pEGFP efficiently (as a result of neutralization of DNA phosphate 






















Fig. 3.28. Plot of EthBr fluorescence quenching assay of pEGFP complexed with 
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Fig. 3.29. Typical 1% agarose gel of fluorescent EthBr intercalated in pEGFP, assay 





spermine at N/P charge ratios 1, 2, 3. 
 
3.4.2. Lipoplex Particle Size and Zeta-Potential Measurements 
 The particle size and ζ-potential characterization measurements were carried out 
on the lipoplexes at their optimum N/P charge ratio for transfection (see:  Table 3.5).  
 
































-Dinervonoyl spermine 4 190 (30)  
 
 The physicochemically important parameter, ζ-potential helps to predict the 
stability of the formulation and the ability of the positively charged nanoparticles to 
interact with cell membranes. The ζ-potential measurements on the lipoplexes, at their 
optimum concentrations of transfection, show that all values are positive (Table 3.5), 
therefore there is a net positive charge on the surface. For DNA lipoplexes, ζ-potentials 









spermine) (209-211), the measured ζ-potential for naked DNA is -1.0 mV.  
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3.4.3. pEGFP Transfection Experiments and In Vitro Cytotoxicity 
 The transduction of EGFP into a primary skin cell line (FEK4) and a cancer 
cell line (HeLa-derived HtTA) was investigated. All our polynucleotide delivery 
experiments are performed in the presence of serum. The optimum concentrations (in 
a final volume of 0.5 ml) and their corresponding N/P charge ratios for transfection 
were experimentally determined by using ascending N/P ratios of lipospermines from 
2, 4, 6 etc. until we reached around 80% transfection and there was not a further step-





















Arachidonoyl FEK4 Arachidonoyl HtTA
Nervonoyl FEK4 Nervonoyl HtTA
 
Fig. 3.30. Lipofection of the primary skin cell line FEK4 and the cancer cell line 









-dinervonoyl spermine at different N/P charge ratios. 
 
 The results in Fig. 3.30 show that the transfection efficiency is related to the 
N/P ratio. On the other hand, the toxicity also increases as the N/P ratio is increased 
(Fig. 3.31). So the optimum concentrations (and corresponding N/P charge ratios) for 




















































































FEK4 Transfection HtTA Transfection
 FEK4 Viability HtTA Viability
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-dinervonoyl spermine) (5.4 µg) on FEK4 and on the HeLa derived 
HtTA cell lines. 
 
 The results (Fig. 3.32) indicate that the transfection ability of the different 
lipospermines (at their optimum pDNA delivery N/P ratios) on both cell lines lie in 




-diarachidoyl spermine (5-10%). The cell viability 
(MTT assay) results indicate that while there is not a large difference in the viability 
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 We have investigated the biological effects of increasing the length of the 
symmetrical diacyl fatty chain formulation of lipospermine on pDNA condensation 
and cellular delivery. The results from pEGFP condensation (Fig. 3.28), investigated 





-dioleoyl spermine was able to condense DNA to less than 20% 









-dierucoyl spermine were not able to quench the EthBr 
fluorescence by 80% even at N/P charge ratio 6 (Fig. 3.28). The particle size of the 
final pDNA formulation is also an important factor in improving gene delivery 





-dierucoyl spermine showed a pDNA lipoplex particle size of 210 nm (mean 
value ± S.D. 31, n = 9). As discussed above, these long chain lipid moieties interact 
with the phospholipid bilayers (206) of cell membranes, facilitating cell entry, either 
in crossing the membrane bilayer and/or in helping to weaken the endosomal bilayer 
and thereby aid escape into the cytosol. The lipid chains make a significant 
contribution to the DNA compaction (Fig. 3.28) (162,164) and this is observable in 
the agarose gel permeation assay (Fig. 3.29). Heparan sulfate and other cell-surface 
polyanionic (sulfated) glycosaminoglycans are also involved in the cell binding of 
cationic lipoplexes and polyplexes leading to non-specific endocytosis. They interact 
with the net positive charge on the cationic lipoplexes and inhibit cation-mediated 
gene transfer, probably directing the lipoplexes into intracellular compartments that do 
not support transcription. Thus, the mechanisms of the uptake and the intracellular 
fate of lipoplexes are still obscure, but glycosaminoglycans may act as cellular 
receptors for cationic ligands, rather than only as passive cation binding sites (212-
216). 
 It has been proposed that a shorter chain length may facilitate intermembrane 
mixing, an important factor in endosomal escape (206). Variation in the acyl chain, 
longer than the oleoyl group (C18), has led to higher levels of transfection, a result 
possibly related to the issues of hydrophobic moiety hydration (206-208). Lindner and 
co-workers reported the use of very long chain lipids e.g., erucoyl and compared them 
with other shorter chains in their designed cationic lipids (77), while Cullis and co-
workers have studied the variation of the length of the acyl chains contained in the 
hydrophobic anchor from octanoyl to myristoyl to arachidoyl (217-219). 
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3.4.4. Confocal Microscopy Visualization 
 
Fig. 3.33. FEK4 cell line transfected with pEGFP showing cytosolic green 




-dieicosenoyl spermine. The nuclei 
fluoresce blue and the cell lipid bilayers red (LSM510META, under the 60× oil 
immersion objective). 
 
 Using confocal laser scanning microscopy with one labelling solution 
(Invitrogen) containing both Alexa Fluor 594 wheat germ agglutinin (5 µg/ml) for cell 
membrane (red) labelling, and Hoechst 33342 (2 µΜ) for nuclei (blue) labelling, we 
have shown (Fig. 3.33) that FEK4 primary cells were successfully transfected with 
pDNA as the cells biosynthesized EGFP by transcription and translation. 
The cell membranes are more complicated because they contain three classes 
of amphipathic lipids:  phosphplipids, glycolipids, and steroids. The fatty chains in 
phospholipids and glycolipids usually contain an even number of carbon atoms, 
typically between 14 and 24. The 16- and 18-carbon fatty acids are the most common. 
Fatty acids may be saturated or unsaturated, so due to the existence of different fatty 
chains in naturally occurring phospholipids, we adjusted the focus to target those 





the spermine backbone to mimic those naturally occurring phospholipids. 
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Mol. Wt. 865.44 
 












































Mol. Wt. 749.23 
 





The cell membranes are more complicated because they contain three classes 
of amphipathic lipids:  phosphplipids, glycolipids, and steroids. The fatty chains in 
phospholipids and glycolipids usually contain an even number of carbon atoms, 
typically between 14 and 24. The 16- and 18-carbon fatty acids are the most common. 
Fatty acids may be saturated or unsaturated, so due to the existence of different fatty 
chains in naturally occurring phospholipids, we adjusted the focus to target those 





the spermine backbone to mimic those naturally occurring phospholipids. 
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Due to the existence of unsymmetric fatty chains on C1 and C2 positions in 
many natural glycerophospholipids, the focus was changed to investigate those target 




 positions of spermine 
backbone to mimic those naturally occurring molecules from the lipid bilayer. So in 












































4,9-diazadodecane (Fig. 3.34) were therefore studied. The abilities of these novel 
compounds to condense DNA and to form nanoparticles were studied using EthBr 
fluorescence quenching and nanoparticle characterization techniques. Transfection 







3.5.1. DNA Condensation 
In Fig. 3.35, the DNA condensation abilities of the synthesized lipopolyamines 





spermine has the best DNA condensing ability, 90% EthBr fluorescence quenched at 




-dioleoyl spermine which show 90% at N/P 
ratio 5.5 while the other tested unsymmetric lipospermines only able to achieve 
around 70% fluorescence quenching at the N/P ratio 8. The gel electrophoresis results 





-stearoyl spermine was able to condense pEGFP efficiently (as a result of 
neutralization of DNA phosphate negative charges by the ammonium positive 
charges). 
 























Fig. 3.35. EthBr fluorescence quenching assay of pEGFP DNA complexed with four 







Fig. 3.36. Typical 1% agarose gel of fluorescent EthBr intercalated in pEGFP, assay 





stearoyl spermine at N/P ratios 2, 4, 6 and 8. 
 
3.5.2. Lipoplex Particle Size and Zeta-Potential Measurements 
The particle size and ζ-potential characterization measurements were carried 
out on the lipoplexes at their optimum concentration for transfection (see:  Table 3.6). 
Particle size characterization by laser diffraction showed that the nanoscale particle 









-myristoyl spermine) with an average 
particle size of 165 nm, (Table 3.6). 
 The pharmaceutically important ζ-potential helps to predict the stability of the 
formulation as well as the ability of the positively charged nanoparticles to interact 
with (phosphate containing, negatively charged) cell membranes(185). Nanoparticles 
are considered to be stable when they have pronounced ζ-potential values, either 
positive or negative; the tendency for particles to aggregate is higher when the ζ-
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potential is close to zero (171). The surface charge, as determined by ζ-potential 
measurements on the lipoplexes at their optimum N/P charge ratio of transfection, 









-oleoyl spermine); the 
measured ζ-potential for naked DNA is -1.02 mV. 
 




























-stearoyl spermine 8 170 (24) 2.47 
 



















 FEK4 Serum Free FEK4 Serum
HtTA Serum Free HtTA Serum
 










-stearoyl spermine) (8.87 µg) N/P ratio 8 on the primary skin cell line FEK4 
and the HeLa derived cancer cell line HtTA in the absence and presence of serum. 
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 The transduction of pEGFP into the primary skin cell line FEK4 and the 
cancer cell line (HeLa-derived HtTA) was investigated in both the presence and 
absence of serum (Fig. 3.37). Most pleasingly, we found that there was no significant 









-stearoyl spermine. Encouraged by these positive 
results, all our subsequent transfection experiments are performed in the presence of 
serum and this is a significant step for all modern formulations moving towards 
clinical trials. 
 The optimum concentrations (in a final volume of 0.5 ml) and their 
corresponding N/P charge ratios for transfection were experimentally determined by 
using ascending N/P ratios of lipospermines from 2, 4, 6 etc. until we reached around 
80% transfection and there was not a further step-up in transfection efficiency at the 
next highest N/P ratio. Results in Figs. 3.38 and 3.39 show that the transfection 
efficiency is related to the N/P ratio, increasing with higher N/P ratios. On the other 
hand, the toxicity also increases as with increasing N/P ratio, but it is not linear (Fig. 









-myristoyl spermine have a very slight increase in their toxicity, at 









-oleoyl spermine show high toxicity at N/P charge ratio over 10. The 
transfection efficiency can be immediately seen from our FACS analyses in both cell 
lines (Fig. 3.41) with gating to measure mainly live cells. So the optimum 
concentrations (and corresponding N/P charge ratios) for transfection (in 0.5 ml) were 









































-retinoyl spermine (11.33 µg, 
N/P = 10). In summary, the pEGFP delivery results (Fig. 3.42, histograms) indicate 


















spermine (at their optimum pDNA delivery N/P ratios) on both cell lines while the 
other five unsymmetric lipospermines are less efficient. 
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 The cell viability (MTT assay) results (Fig. 3.42, lines) indicate that while 




-dioleoyl spermine and 
most of the tested unsymmetric lipospermines, typically (60-85%) except for those 



































Cholesteryl-Oleoyl FEK4 Cholesteryl-Oleoyl HtTA
Lithocholoyl-Oleoyl  FEK4 Lithocholoyl-Oleoyl HtTA
 
Fig. 3.38. Lipofection of the primary skin cell line FEK4 and the cancer cell line 




























Palmitoyl-Retinoyl FEK4 Palmitoyl-Retinoyl HtTA
Oleoyl-Retinoyl FEK4 Oleoyl-Retinoyl HtTA
Fig. 3.39. Lipofection of the primary skin cell line FEK4 and the cancer cell line 









-retinoyl spermine at different N/P charge ratios. 




















Fig. 3.40. Cytotoxicity effect of pEGFP (1 µg) complexed with different 




Fig. 3.41. FACS analysis of FEK4 (left) and HtTA (right) after 48 h transfection of 




-stearoyl spermine:  untransduced cells,   
EGFP-positive cells. 
 












































































































FEK4 Transfection HtTA Transfection 
FEK4 Viability HtTA Viability
 











































-retinoyl spermine) (11.33 µg) on the 
primary skin cell line FEK4 and the HeLa derived cancer cell line HtTA. 
 
3.5.4. Confocal Microscopy Visualization 
 Using confocal laser scanning microscopy with one labelling solution 
(Invitrogen) containing both Alexa Fluor 594 wheat germ agglutinin (5 µg/ml) for cell 
membrane labelling, and Hoechst 33342 (2 µΜ) for nuclei labelling, we have shown 
(Fig. 3.43) that FEK4 cells were successfully transfected with pDNA as the cells 
biosynthesized EGFP by transcription and translation. In this section, we have 
investigated effects resulting from using of the unsymmetrical diacyl fatty chain with 
different length or degree of saturation, cholesterol, lithocholic acid and retinoic acid 
formulations of lipospermines on DNA condensation and cellular delivery. 
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Fig. 3.43. The FEK4 primary cell line transfected with pEGFP showing cytosolic 




-oleoyl spermine. The 
nuclei fluoresce blue from the Hoechst 33342 and the cell lipid bilayers fluoresce red 
from the Alexa Fluor 594 (LSM510META, under the 60× oil immersion objective). 
 
 The results from pEGFP condensation, investigated by EthBr fluorescence 




-oleoyl spermine is the best condensing 
result (90% at N/P 3.5) while three of our synthetic lipopolyamines were able to 
condense DNA to less than 30% EthBr fluorescence at N/P ratio 8 (Fig. 3.35) (11). 
Particle size of the final nanoscale formulation is also an important factor in 
improving gene delivery (187,188). Particle size results (Table 3.6) showed an 
average particle size of 165 nm. On the relationship between particle size and 
transfection efficiency, all our lipoplexes are in the range 90-210 nm, and they 
transfected target cell lines efficiently. With regard to the mechanism for this cell 
entry, it is known that nanoparticles have relatively higher intracellular uptake than 
microparticles (155) although larger sizes of nanoparticles still do achieve 
transfection, presumably by a different mechanism (189). Further, when comparing 
the composition of the phospholipid bilayer of the cell membrane we find a high 
percentage of unsymmetrical fatty chains, so we try to mimic the nature by 
characterize ansymmetrical diacyl spermine as transfecting agents. So we are trying to 
take the advantage of having short and long fatty chains in the same molecules, 
saturated and unsaturated fatty chain or fatty Acid with cholesterol. Early liposomal 
studies therefore led to the proposal that a shorter chain length may facilitate 
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intermembrane mixing, an important factor in endosomal escape (206). A common 
moiety is the use of cis-mono-unsaturated alkyl chains e.g., the oleoyl group (C18). 
This leads to higher transfection levels than the corresponding saturated e.g., stearoyl 
(C18) derivatives, a result possibly related to the issues of hydrophobic moiety 
hydration or packing (206,207). by incorporating two different lipid moieties, we have 
shown that all our synthesized lipospermines afford transfection results varying in 
range, and at different N/P ratios and also most of the tested unsymmetric diacyl 




-oleoyl spermine, so by combination 





spermine is an excellent vector for NVGT. 
As lipopolyamines possess substantial buffering capacity below physiological 
pH, they are efficient transfection agents without the addition of (further) membrane-
disruption agents. This observation led us to test heterocyclic substituted 
lipospermines for their gene delivery potential because it will increase the pKa of the 
vector by increasing the number of nitrogen atoms in the lipospermines that can be 
protonated in the endosome as the pH drops to 5.5, i.e., their pKas are around 5-7. 
Indeed, it makes the polymeric network an effective proton sponge at virtually any 
physiological pH (38). Our idea is that its efficiency relies on extensive lysosome 
buffering that protects DNA from nuclease (DNase) degradation, and consequently 
lysosomal swelling and rupture provide an escape mechanism for the particles, based 
on the hypothesis that a causal relationship exists between the protonation reservoir of 
a molecule below neutral pH and its transfection efficiency. This relationship may be 
the basis for the design of new synthetic vectors. Endosome buffering may protect 
DNA from lysosomal nucleases, but it may also perturb either the trafficking of 
endosomes or their osmolarity. For instance, massive vesicular ATPase-driven proton 
accumulation followed by passive chloride influx into endosomes buffered with 
lipospermine should cause osmotic swelling and subsequent endosome disruption. 
Furthermore, because the monomeric unit has such low molecular mass, the whole 
molecule will behave as an extensive proton sponge (38). 
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3.6.1. pEGFP Transfection Experiments and In Vitro Cytotoxicity 
 In this study, we have investigated the formulation effects resulting from 




-diacyl spermines (myristoyl, palmitoyl, stearoyl, and 
oleoyl) each end-capped with the (weakly basic) nitrogen-containing heterocycles:  
imidazole, pyridine and quinoline. The surface charge, as determined by ζ-potential 





-dioleoyl spermine was found to be + 17.55 mV. 
 
  
Fig. 3.45. FACS analysis of FEK4 (left) and HtTA (right) after 48 h transfection of 





















Myr-Imida FEK4 Myr-Imida HtTA
Myr-Pyri FEK4 Myr-Pyri HtTA
Myr-Quino FEK4 Myr-Quino HtTA
Fig. 3.46. Lipofection of the primary skin cell line FEK4 and the cancer cell line 





-dimyristoyl spermine at different N/P charge ratios. 






















Fig. 3.47. Lipofection of the primary skin cell line FEK4 transfected with pEGFP (1 




-diacyl spermine at 































FEK4 Transfection HtTA Transfection 
FEK4 Viability HtTA Viability
 
Fig. 3.48. Lipofection and cytotoxicity effects of pEGFP (1 µg) complexed with 
Myristoyl (9.4 µg), Myr-Imida (7.11 µg), Myr-Pyri (7.31 µg) and Myr-Quino (5.48 
µg) on the primary skin cell line FEK4 and the HeLa derived cancer cell line HtTA. 




























FEK4 Transfection HtTA Transfection 
FEK4 Viability HtTA Viability
Fig. 3.49. Lipofection and cytotoxicity effects of pEGFP (1 µg) complexed with 
Palmitoyl (20.50 µg), Palm-Imida (5.08 µg), Palm-Pyri (5.21 µg) and Palm-Quino 





























FEK4 Transfection HtTA Transfection 
FEK4 Viability HtTA Viability
Fig. 3.50. Lipofection and cytotoxicity effects of pEGFP (1 µg) complexed with 
Stearoyl (16.70 µg), Stear-Imida (13.55 µg), Stear-Pyri (8.33 µg) and Stear-Quino 
(6.16 µg) on the primary skin cell line FEK4 and the HeLa derived cancer cell line 
HtTA. 




























FEK4 Transfection HtTA Transfection 
FEK4 Viability HtTA Viability
 
Fig. 3.51. Lipofection and cytotoxicity effects of pEGFP (1 µg) complexed with 
Oleoyl (2.77 µg), Oleoyl-Imida (8.09 µg), Oleoyl-Pyri (13.82 µg) and Oleoyl-Quino 
(9.20 µg) on the primary skin cell line FEK4 and the HeLa derived cancer cell line 
HtTA. 
 
 The transduction of EGFP into a primary skin cell line (FEK4) and a cancer 
cell line (HeLa-derived HtTA) was investigated. All our polynucleotide delivery 
experiments are performed in the presence of serum and can achieve high transfection 





-distearoyl spermine in both cell lines (Fig. 3.45) The optimum concentrations 
(in a final volume of 0.5 ml) and their corresponding N/P charge ratios for transfection 
were experimentally determined by using ascending N/P ratios of lipospermines from 
2, 4, 6 etc. until we reached around 80% transfection and there was not a further step-
up in transfection efficiency at the next highest N/P ratio. Results in Figs. 3.46 and 
3.47 show that the transfection efficiency is related to the N/P ratio. So the optimum 
concentrations (and corresponding N/P charge ratios) for transfection (Figs. 3.48-




-dimyristoyl spermine (7.11 µg, 



















-dipalmitoyl spermine (5.21 µg, N/P = 4), di-2-quinolinyl-



















-distearoyl spermine (6.16 














-dioleoyl spermine (9.20 µg, N/P = 6). 





dimyristoyl spermine heterocyclic derivatives (at their optimum pDNA delivery N/P 
ratios) there is no improvement, neither in the transfection ability nor the cell viability, 




-dimyristoyl spermine on both cell lines, but there was a 
significant decrease in the amount of transfecting agent required to achieve this 





spermine series (Fig. 3.49), there is a slight improvement in the transfection ability, 
still the same high level of toxicity, but also with a significant decrease in the amount 





-distearoyl spermine series (Fig. 3.50), the imidazole derivative only 




-distearoyl spermine, but it is not toxic. 
While both the distearoyl pyridine and quinoline analogues show much higher 









-distearoyl spermine on both cell lines, but 
on the other hand both the distearoyl pyridine and quinoline analogues are extremely 









-dioleoyl spermine in both transfection efficiency and cytotoxicity (cell 
viability). Even the pyridine and quinoline analogues show the same high levels of 
transfection efficiency, but this is only achieved with a significant level of toxicity. 









-dioleoyl spermine) is a useful 





spermine. No other research groups have reported efficient pDNA delivery with such 
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3.6.2. Confocal Microscopy Visualization 
 
 
Fig. 3.52. Transfection of the primary skin cell line FEK4 with pEGFP showing 





dioleoyl spermine. The cell lipid bilayers fluoresce red from the Alexa Fluor 594 and 
the nuclei fluoresce blue from the Hoechst 33342 (LSM510META, under the 60× oil 
immersion objective). 
 
 Using confocal laser scanning microscopy with one labelling solution 
(Invitrogen) containing both Alexa Fluor 594 wheat germ agglutinin (5 µg/ml) for cell 
membrane labelling (red), and Hoechst 33342 (2 µΜ) for nuclei labelling (blue), we 





-dioleoyl spermine as the vector, as the cells 
biosynthesized EGFP by transcription and translation. This was the best result from 




-dioleoyl spermine in both 
transfection efficiency and high cell viability. 
 We now turn our focus to the important topic of efficient non-viral 
formulations for siRNA delivery. Can we deliver siRNA to our two chosen cell lines 
using any of these pDNA delivery agents? Many research groups are actively 
searching for a non-viral vector that will give a high yield of siRNA delivery without 
paying the price in high cellular toxicity. 
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4.1. INTRODUCTION 
RNA interference (RNAi) is a naturally occurring phenomenon by which 
small interfering RNA (siRNA) can use enzymatic cleavage of a target mRNA to 
reduce or inhibit gene expression into proteins mediated by RNA induced silencing 
complex (RISC) (90,100,104). RNAi is initiated by short double-stranded RNA 
(dsRNA) molecules in the cytoplasm where they interact with the catalytic RISC 
component. The dsRNA can be both exogenous or endogenous whose pathways 
converge at the RISC complex (220). siRNAs form a class of 19-23 nucleotide-long 
RNA molecules that play a variety of roles in biology, most notably in the RNAi 
pathway where each siRNA interferes with (blocks) the expression of a specific gene 
(104). RNAi is commonly achieved with chemically synthesized siRNA 19-23-mers. 
 Efficient delivery of siRNA to targeted cells will also be important for the 
successful treatment of a variety of diseases. Modifications to synthetic siRNA can 
increase the half-life of circulating siRNA in animal models. Yet it is not enough to 
enhance siRNA stability if siRNA can not penetrate cells and tissues in vivo in a 
sufficient concentration to achieve efficient therapy. As siRNAs are ds molecules, 
delivery and cellular uptake are more difficult than for single-stranded (poly-
nucleotide) antisense agents, which bind to serum proteins and are taken up by cells 
and tissues in vivo. There are a few reports of functional RNAi being obtained by 
systematic delivery of antisense agents that have never reached a clinical trial. So a 
better understanding of the mechanism by which backbone modifications might help 
to enhance cellular and tissue uptake of naked RNAs, or how to develop alternative 
carriers for systemic delivery of siRNAs is still required. The essentially specific 
ability of synthetic siRNA to inhibit targeted genes, makes it an extremely powerful 
tool for functional genomics, it has attracted considerable interest recently (221). 
The biological usefulness of spermine (1,12-diamino-4,9-diazadodecane) and 
its conjugates (12,222-224) encouraged us to focus on the synthesis of novel cationic 
lipids based on the naturally occurring polyamine spermine (170,171,225,226). In an 
effort to improve the efficiency and control of siRNA delivery, these novel spermine 
based cationic lipid formulations have been investigated within our SAR approach to 
molecular pharmaceutics for molecular medicine. 
 As has been shown above for gene therapy, methods to deliver poly-nucleic 
acids fall into two classes. The first employs genetically altered viruses that, in most 
cases, have had their genome altered or “gutted” to prevent viral replication, reduce 
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cytotoxicity, and permit incorporation of the therapeutic transgene. These vectors can 
be extremely efficient at producing expression, with essentially only a single viral 
particle necessary to induce a measurable effect. However, problems of low virus titre, 
an inability to transfect non-dividing cells, induction of strong immune responses, and 
significant toxicity must still be overcome (227). The second class of delivery systems 
is collectively referred to as non-viral and involves the use complexes with synthetic 
carrier molecules e.g., cationic lipids or polymers. Such non-viral delivery systems 
can potentially have considerable advantages over their viral counterparts e.g., greater 
control of their molecular composition for simplified manufacturing and analysis 
(228,229), and relatively lower immunogenicity (230-233), but these non viral 
systems are still significantly less efficient than viral systems. Despite the early hopes 
and predictions, there is no correlation between pDNA and siRNA delivery, and 
therefore SAR studies need to be undertaken of the non-viral formulations of siRNA. 
In vitro uses simplify many of the problems associated with target cell 
delivery, target selectivity, homeostasis mechanisms and possible non-target cell 
toxicity encountered in vivo. Yet, the cellular membrane is still an important physical 
barrier to the efficient intracellular introduction of nucleic acids. Similarly as in gene 
delivery, passage through the cell membrane of nucleic acids is difficult to achieve as 
a result of their hydrophilic and polyanionic nature. Experience with DNA has 
provided a variety of chemical and physical techniques that should allow the 
transfection or infection of cells with extracellularly synthesized siRNA. The different 
techniques currently available for intracellular introduction of siRNA. The chemical 
techniques are generally based on the use of (poly)cations (107). Liposomes, and lipid 
complexes or conjugates with small molecules, polymers, proteins and antibodies, 
have all been used to facilitate delivery of siRNAs to target cells. With these delivery 
partners, more robust efficacy can be achieved with doses of siRNA that are 
substantially lower, less frequent or both (234). The cationic compounds condense the 
siRNA, resulting in the formation of particles. These particles generally bear a net 
positive charge, as an excess of the cation provides efficient condensation and 
prevents particle aggregation. The net positive charge of the particle additionally 
promotes electrostatic interaction with the overall negative charge of the cell 
membrane. Both by condensing the siRNA and promoting cell membrane interaction, 
relatively efficient cell transfection can be achieved. A range of cations exists that 
have been shown to promote the intracellular delivery of nucleic acids. Of these, the 
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cationic lipids, cationic lipopolyamines are the most prominent. The ultimate in vitro 
transfection-efficiency of a cationic compound appears to be dependent on the 
characteristics of the cells, as well as the properties of the cationic particle, e.g., cell 
medium compatibility, cell toxicity, strength of electrostatic interaction, cation 
structure, and particle size. Although interaction between the cell surface and the 
delivery system promotes siRNA uptake, appropriate intracellular trafficking should 
still follow the interaction (107). The cationic particles are likely taken up by cells 
through endocytosis. Therefore, the cationic particle and/or its siRNA should be able 
to escape the endosomal vesicle to evade lysosomal degradation to allow the RNAi 
effects to occur through cytoplasmic degradation of mRNA by externally applied 
siRNA, which is in the ultimate interest of pharmaceutical applications. 
 Lipids and polymers can have cytotoxic effects that might limit their use in 
siRNA delivery for particular disease indications and dosing paradigms. However, it 
seems to be possible to identify lipid-based formulations and dosing regimens for 
which cytotoxicity is minimal and the risk of histopathology is reduced. With 
advances in pharmaceutical development, these approaches may provide marked 
enhancements to siRNA delivery with acceptable biological and manufacturing 
considerations (234). Variations in chemical composition of cationic lipids can have a 
large impact on the functional properties of cationic lipid with decreased toxicity that 
are more compatible with administration (94,115).  
 As many cells and cell lines are either refractory to or adversely affected by 
transfection, and due to the transient nature of this methodology, more efficient (and 
less toxic) siRNA delivery vectors are required. The effect of the degree of saturation 
of certain mono-cationic lipid analogues was investigated to identify the fusogenic 
and transfection ability of these compounds by Heyes and co-workers (93). The 
saturated cationic lipid (1,2-distearyloxy-N,N-dimethyl-3-aminopropane (DSDMA)) 
was readily internalized in cells, despite it achieving almost no ability of gene 
silencing (siRNA delivery). Gene silencing increased with the degree of unsaturation 
as a result of the increase in the fusogenic ability of the cationic lipid, a lower 
transition temperature from Lα (lamellar organization) to HII (two-dimensional 
hexagonal state) (93). For this aspect of our research, we formulated a model siRNA 
21-mer with novel lipospermines in which the tetra-amine spermine (the cationic 
moiety) and fatty chains (the lipophilic moiety) that have been reported to improve 
transfection efficiency by fusion with cellular membranes, are covalently bound 
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together. We examine the non-viral siRNA delivery efficiency and compare it with the 
cell viability for self-assembled nanoparticles of siRNA (lipoplexes) formed by these 
new cationic lipids in order to develop vectors for siRNA delivery make comparisons 
with pDNA delivery using the same vectors although at different concentrations. 
Our model siRNA incorporates the Label IT
® 
RNAi Delivery Control which is 
designed as a tool to facilitate visualization and optimization of dsRNA 
oligonucleotide delivery during RNAi experiments, both in vitro and in vivo. The 
Label IT
®
 RNAi Delivery Control is a fluorescein-labelled RNA duplex that has the 
same length, charge, and configuration as standard siRNA. The sequence of the 
duplex (below) is not homologous to any known mammalian gene and is not known to 
affect any cellular events. It is also suitable for co-delivery with functional target-gene 
specific siRNA and should not affect the RNAi-mediated inhibition of the target gene. 
The non-enzymatic Label IT labelling reagent attaches to any reactive heteroatom on 
any nucleotide residue of DNA or RNA. This direct covalent attachment is made 
possible by a reactive alkylating agent with strong nucleic acid binding capability 
facilitated via electrostatic interactions. As the Label IT labelling technology will bind 
to any nucleotide, we cannot be sure where the fluorophore was attached exactly, but 
because the reaction is controlled we know that there are 1-2 labels per duplex. The 
delivered siRNA is a 21-nucleotide “target” sequence with UG-3’ overhangs: 
  GAGGCUCAACUGGCUGACCUG 
GUCUCCGAGUUGACCGACUGG 
That there is no obvious correlation between the successful transfecting agents 
for pDNA and those investigated for siRNA delivery, with non-viral vectors, means 
that this is an important area in current formulation research for poly-nucleic acid 





-dioleoyl spermine and other diacyl spermine analogues. Therefore, we are 
carrying further these investigations in order to characterize a successful siRNA 
delivery agent using the same basis, diacyl spermine derivatives. Although 
superficially similar, i.e., ds poly-anionic chains are to be delivered, the most 
immediate difference is the molecular size (length, and therefore weight) which will 
significantly vary the amount of cationic lipid to be used and therefore the toxicity 
(cell viability) of the formulation. Based on our successful use of lipospermines in 
gene delivery (above), the corresponding siRNA formulations are investigated using 
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our novel lipospermines with variation in the:  position, length, saturation, oxidation 
level or the symmetry of the two fatty chains (diacyl, dialkyl, and steroids) or the 
attachment of heterocyclic groups on the two primary amines of lipospermines to 
modulate their pKa. These lipid chains are linked by amide bonds at the secondary 




-diacyl spermines or the primary amino 




-diacyl spermines, and therefore comparisons (SAR 
studies) can be made between pDNA and siRNA delivery.  
It should not be assumed that this will lead to a 100% overlap of results 
between pDNA and siRNA delivery.  Indeed, it is (in part) the absence of such a study 
that has hampered progress in siRNA delivery. This study therefore also includes the 
physicochemical characterisation of the lipoplex nanoparticles formed, including the 
ability of the synthetic lipopolyamines to bind to siRNA studied using the RiboGreen 
fluorescence quenching assay. The physicochemical characterization includes the 
particle size measurements and zeta-potential studies. 
Transfection efficiency was studied in an immortalized cancer cell line 
(HtTA), and in primary skin cells (FEK4), always in the presence of serum to test the 
ability of these novel transfecting agents to work efficiently in the presence of serum 
RNase which opens the door for the successful vectors to be considered further with 
in vivo investigations. Indeed, if these non-viral formulations are not stable in the 
presence of serum, there is little or no point to studying them further. Furthermore, the 




The cytotoxicity of the lipoplexes was studied in both primary skin and 
immortalised cancer cell lines using the MTT assay, but with significantly different 
concentrations of the cationic lipid lipospermine formulations from those used 
previously to delivery pDNA, hence we cannot predict the toxicological outcomes. 
Cellular delivery of fluorescent-siRNA was also studied using confocal laser 
scanning microscopy with one labelling solution for both cell membrane and nuclei 
labelling in order to see if the payload was delivered successfully to the cytosol. 
 





-DIACYL SPERMINES:  SAR STUDIES OF NON-VIRAL 
       LIPOPOLYAMINE VECTORS FOR siRNA FORMULATION 
 
4.2.1. RNA Binding (RiboGreen Intercalation Assay) 
This assay is comparable with the EthBr fluorescence quenching assay widely 
used for initial pDNA formulation studies. RiboGreen solution (Invitrogen, 50 µl diluted 
1 to 20) was added to each well of an opaque bottomed 96-well plate containing free 
siRNA (50 ng) or complexed with lipospermines at different ratios in TE buffer (50 µl, 
10 mM Tris-HCl, 1 mM EDTA, pH 7.5, in diethyl pyrocarbonate)- (DEPC) treated water 
using FLUOstar Optima Microplate Reader (BMG-LABTECH), λex = 480 nm, λem = 
520 nm. The amount of siRNA available to interact with the probe was calculated by 
subtracting the values of the residual fluorescence (RiboGreen without siRNA) from 
those obtained for each measurement, and expressed as a percentage of the control that 
contained naked siRNA only, according to the following formula:  % free siRNA = 100 
x RiboGreen fluorescencecomplexes/RiboGreen fluorescencenaked siRNA.  
 The siRNA binding results from the RiboGreen intercalation assay, show that 
efficient fluorescence quenching occurs by N/P charge ratio 4 for all four 















-dimyristoleoyl spermine achieved 80% 























Fig. 4.1. Plot of RiboGreen intercalation assay of siRNA complexed with different 
lipospermines. 
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4.2.2. Lipoplex Particle Size and ζ-Potential 
 The particle size measurements were carried out on the lipoplexes at their 
optimum concentration for transfection after mixing with a vortex mixer and was 
determined using a NanoSight LM10 (NanoSight Ltd, Salisbury, UK). All 
measurements were carried out on lipoplexes with 25 pmol of siRNA (fluorescein-
labelled Label IT
®
 RNAi Delivery Control, Mirus) in HEPES buffer (0.2 ml) at pH 
7.4 and 20 
o
C. Results were analysed with the Nanoparticle Tracking Analysis (NTA) 
software. Particle size characterization by laser diffraction showed that the nanoscale 














dioleoyl spermine siRNA lipoplex particle size of 110 nm (Table 4.1).  
 


















-Dimyristoleoyl spermine 170 (34) 
 
 Our siRNA lipoplexes are 110 and 170 nm in diameter, and they transfected 
target cell lines efficiently. Two representative ζ-potential measurements for the 
lipoplexes formed (at their optimum charge ratio of transfection with 75 pmol siRNA) 









-dioleoyl spermine +3.69 mV. The formed 
nanoparticles are considered to be stable when they have pronounced ζ-potential 
values, either positive or negative, but the tendency to aggregate is higher when the ζ-
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4.2.3. siRNA Delivery and In Vitro Cytotoxicity in the Presence of Serum 
 Two cell lines were used in the transfection experiments, a human primary 
skin fibroblast cells FEK4 derived from a foreskin explant, and a human cervix 
carcinoma HeLa derivative and transformed cell line (HtTA) (145,146). The HtTA 
cells being stably transfected with a tetracycline-controlled transactivator (tTA) 
consisting of the tet repressor fused with the activating domain of virion protein 16 of 
the herpes simplex virus (HSV). Cells were cultured in Earle’s minimal essential 
medium (EMEM) supplemented with foetal calf serum (FCS) (15% in the case of 
FEK4 and 10% in the case of HtTA cells), penicillin and streptomycin (50 IU/ml 
each), glutamine (2 mM), and sodium bicarbonate (0.2%). 
 We used fluorescein-labelled Label IT
®
 RNAi Delivery Control (Mirus). 
FEK4 and HtTA cells were seeded at 50,000 cells/well in 12-well plates in EMEM (2 
ml) containing FCS (15% in the case of FEK4 and 10% in the case of HtTA cells) for 
24 h to reach a plate confluency of 50-60% on the day of transfection. Then the media 
were replaced by 437.5 µl fresh media. The lipoplex was prepared by mixing siRNA 
(12.5 pmol in 12.5 µl) with the different amounts of the lipopolyamines in Opti-MEM 
(typically 2-20 µg in 50 µl) at 20 °C for 30 mins and then incubated with the cells 
(final volume of 0.5 ml) for 4 h at 37 °C in 5% CO2 in full growth medium (in the 
presence of serum). Then the media were replaced by 2 ml of fresh media and 
cultured for 44 h in full growth media at 37 °C in 5% CO2 before the assay. 
 Levels of fluorescein-labelled siRNA in the transfected cells were detected and 
corrected for background fluorescence of the control cells using a fluorescence 
activated cell sorting (FACS) machine (Becton Dickinson FACS Vantage dual Laser 
Instrument, argon ion laser 488 nm). The transfection efficiency was calculated based 
on the percentage of fluorescein-positive cells in the total number of cells with λex = 
495 nm and λem = 518 nm. 
 The transduction of fluorescein tagged siRNA into a primary skin cell line 
FEK4 and a cancer cell line (HeLa-derived HtTA) was investigated. We aimed for 
transfection efficiency about 80% (or higher), but also with a view to minimal toxicity 
(high cell viability), minimum effective concentrations. These optimum transfection 
concentrations were experimentally determined by using ascending amounts of 
lipopolyamines (Figs. 4.2 and 4.3). 
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Fig. 4.2. Lipofection of the primary skin cell line FEK4 and the cancer cell line HtTA 





























Fig. 4.3. Lipofection of the primary skin cell line FEK4 and the cancer cell line HtTA 









-dimyristoleoyl spermine at different ratios. 
 
 FACS analysis (Fig. 4.4) of both cell lines, after 48 h transfection with 




-dioleoyl spermine, show high 
efficiency of transfection. The transfection of FEK4 primary cells (hard to transfect) 
and a cancer cell line (HtTA) were compared with a market leader TransIT-TKO 
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spermine 77% FEK4 and 85% HtTA) to the results of TransIT (91% FEK4 and 93% 






















Fig. 4.4. Gated FACS analysis of FEK4 (left) and HtTA (right) after 48 h transfection 




-dioleoyl spermine  




























FEK4 Transfection HtTA Transfection
FEK4 Viability HtTA Viability
Fig. 4.5. Lipofection and cytotoxicity effects of siRNA (12.5 pmol) complexed with 


















-dimyristoleoyl spermine) (12.0 
µg) on the primary skin cell line FEK4 and the HeLa derived cancer cell line HtTA. 
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 In this study, we have investigated the change in the position and length of the 
symmetrical diacyl fatty chain formulations of lipospermine on siRNA binding and 
cellular delivery. Particle size of the final gene formulation is also an important factor 
in improving gene delivery (187,188). Particle size results (Table 4.1) for siRNA are 
150 and 170 nm.  
From the combination of both the siRNA delivery and viability results we 




-dioleoyl spermine (transfection efficiency FEK4 77%, HtTA 





(transfection efficiency FEK4 80%, HtTA 87% and cell viability FEK4 76%, HtTA 
46%) are equally active and the best achievements based on these two factors then 








-dimyristoleoyl spermine (transfection 





dimyristoleoyl spermine came last because it is very toxic. 
 The lipid moiety in our cationic lipids interacts with the phospholipid bilayer 
of the cell membrane, and that facilitates cell entry, either in crossing the membrane 
bilayer and/or in helping to weaken the endosomal bilayer and thereby aid escape into 
the cytosol, so the position, length and degree of saturation play an important role in 
their design and formulation where the lipid moiety must be considered in shape 
(volume) and substituent pattern, as well as the polyamine moiety and its pKa values 









-dimyristoleoyl spermine are effective for siRNA delivery. It is as 
good as the commercially available TransIT-TKO
®
 for siRNA delivery. 









-diacyl regioisomers. So, for the 




-diacyl spermine with stepwise 
changes in the length of the fatty chain from C10 to C18. These changes will also be 
made with variation in the oxidation level, incorporating saturated or mono-
unsaturated acyl chains where available. As well as the mono-unsaturated analogues, a 
novel vitamin A derived (di-)retinoyl lipospermine was designed as a new vector for 
siRNA delivery. 
 





-DIACYL SPERMINES:  SAR STUDIES OF NON-VIRAL  
       LIPOPOLYAMINE VECTOR siFECTION EFFICIENCY VERSUS TOXICITY 
 





















Fig. 4.6. Plot of RiboGreen intercalation assay of siRNA complexed with different 
lipospermines. 
 





diacyl lipopolyamines is shown in the RiboGreen intercalation assay which is similar 
to the PicoGreen assay reported by Wagner and co-workers (235) and to the EthBr 
fluorescence quenching assay optimized by Geall and Blagbrough (176). These results 
from siRNA lipoplexes show that all the synthesized lipospermines achieve more than 





spermine which also achieved 85% fluorescence quenching at N/P = 4. 
 
4.3.2. Lipoplex Particle Size Measurements 
 The particle size characterization measurements were carried out on the 
lipoplexes at their optimum concentration for transfection (139). Particle size 
characterization by laser diffraction showed that the nanoscale particle size of the 














spermine) with C10 chain length. These lipoplex nanoparticles were ranged around 
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140 nm in diameter (Table 4.2). which is typical for such formulations e.g., 
Schiffelers et al., made polyplexes of PEI-PEG with siRNA of 90-120 nm, (236) and 
Ishida and co-workers prepared cationic lipoplexes typically of 280-308 nm (237). 
 




























-Dioleoyl spermine 110 (12) 
 




































Fig. 4.7. Lipofection of the primary skin cell line FEK4 and the cancer cell line HtTA 









-dimyristoleoyl spermine (right). 
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Fig. 4.8. Gated FACS analysis of FEK4 (left) and HtTA (right) after 48 h transfection 




-diretinoyl spermine:   





































































FEK4 Transfection HtTA Transfection
FEK4 Viability HtTA Viability
Fig. 4.9. Lipofection and cytotoxicity effects of siRNA (12.5 pmol) complexed with 




































-diretinoyl spermine) (12.0 µg) on the 
primary skin cell line FEK4 and on the HeLa derived cancer cell line HtTA. The data 
represent 3 different experiments (3 replicates each) and the error bars show the S.D. 
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 The transduction of fluorescein tagged siRNA into a primary skin cell line 
FEK4 and a cancer cell line (HeLa-derived) HtTA was investigated and compared 
with a market leader TransIT-TKO (Mirus). The practical concentrations (in a final 
volume of 0.5 ml) were experimentally determined by using ascending amounts of 
lipospermines until we reached around 80% transfection and there was not a further 
step-up in transfection efficiency at the next highest concentration. From our typical 









-dimyristoleoyl spermine, transfection efficiency increases with 
lipopolyamine ratio. The gated flow cytometric FACS analysis, Fig. 4.8, of FEK4 and 
HtTA cell lines after 48 h transfection of fluorescein-tagged siRNA complexed with 




-diretinoyl spermine, clearly shows a high 
percentage of live transduced fluorescein-positive cells. The siFection results (Fig. 





-dilauroyl spermine are comparable with the results obtained with a 
market leader TransIT, a commercially available reagent (91% FEK4 and 93% HtTA). 























-dilauroyl spermine (57%). The transfection results of siRNA delivery into 









-dilauroyl spermine (59%). 
 The cell viability (MTT assay) results (Fig. 4.9, lines) indicate that there is not 
a large difference in the viability of FEK4 (84%) and HtTA (75%) cells between the 









spermine while all the other shorter lipospermines are more toxic to both cell lines. 
The cytotoxicity of the siRNA lipoplexes is high, with C-14 (saturated or unsaturated) 
chains being the most toxic, but C-10, C12, and C16 conjugates are also toxic. The 




-diretinoyl spermine was investigated as it has two C-20 
chains, and might therefore show a further improvement over di-C-18 (distearoyl and 
dioleoyl) which are themselves less toxic than dipalmitoyl (C-16). However, 
diretinoyl spermine was significantly more toxic to both cell lines than either of the 
two C-18 compounds, and its shape and structure with its terminal trimethylated 
cyclohexene ring mean that it is closer in lipid volume to C-12 and C-14 than to C-18. 
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We considered that by more closely following the positive charge distribution 
of the naturally occurring tetraamine spermine i.e., mimicking spermine in one of its 
biologically important roles, that of stabilising condensed DNA wrapped around 
histones, so with more positive charges we might increase siRNA binding affinity. Or, 
by increasing the number of basic sites from 2 (diacyl-diamine) to four (tetraamine), 
we might produce a more efficient proton sponge effect when the early-endosomal pH 
starts to drop from cytosolic 7.4 to 5.5 on intracellular acidification, as spermine has 
3.8 positive charges at pH = 7.4 and can clearly support 4.0 positive charges in acidic 
milieu. We therefore reduced the two amide functional groups of our two most 
effective siRNA delivery agents that showed the highest cell viability, to form the 

























FEK4 Transfection HtTA Transfection 
FEK4 Viability HtTA Viability
 


















-dioleyl spermine) (4.0 
µg) on the primary skin cell line FEK4 and the HeLa derived cancer cell line HtTA. 
 


















-dioleyl spermine (Fig. 4.10) show that 
there is not a large difference in the transfection efficiency, neither gain nor loss, on 



















spermine 91% and 87%, but the cell viabilities drop from around 75% to 10-27%. 
Therefore, the two alkyl analogues are much more toxic (Fig. 4.10) to both cell lines. 
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4.3.4. Confocal Microscopy Visualization 
 
  
Fig. 4.11. The FEK4 primary cell line transfected with fluorescein-labelled siRNA 









-distearoyl spermine (right). The cell lipid 
bilayers fluoresce red from the Alexa Fluor 594 and the nuclei fluoresce blue from the 
Hoechst 33342 (LSM510META, under the 60× oil immersion objective). 
 
 Following the siRNA transfection protocols, cells were seeded on a sterile 
cover-slip at the bottom of each well. After 48 h, media were aspirated and cells were 
fixed with freshly prepared 4% formaldehyde solution in PBS (1 ml/well) for 15 mins 
at 37 
o
C. After formaldehyde fixing, cells adhering to cover-slips were labelled with 
labelling solution according to the manufacturer’s protocol. Labelling solution 
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contained both Alexa Fluor 594 wheat germ agglutinin for cell membrane labelling, 
λex = 591 nm and λem = 618 nm, and Hoechst 33342 for nuclei labelling, λex = 350 nm 
and λem = 461 nm, mixed in one solution purchased from Invitrogen (Image-iT live 
plasma membrane and nuclear labelling kit), cell labelling with Alexa Fluor WGA (5 
µg/ml) and Hoechst 33342 (2 µl, 2 µΜ). After that, labelled cells were mounted using 
mounting liquid (20 µl, Mowiol, Merck) and left for 16 h. Then, mounted cover-slips 
were viewed on a confocal laser scanning microscope (LSM510META,) under the 
60× oil immersion objective, with filters:  red λex = 543 nm and λem = 560-615 nm, 
blue λex = 405 nm and λem = 420-480 nm, and green λex = 488 nm and λem = 505-530 









-distearoyl spermine successfully delivered fluorescent-
siRNA to the cytosol of FEK4 cells. 
 These short chain synthetic lipospermines have the ability to deliver siRNA 
into FEK4 and HtTA cell lines. Whilst increasing the fatty acyl chain length over 
myristoyl (C-14) does not lead to any further increase in the transfection efficiency 





lipopolyamine has a similarly long (C-20) carbon chain which does deliver siRNA, 
but it is too toxic to be considered efficient. Increasing the number of positive charges 
in the conjugate from 2 to 4 resulted in significantly more toxic compounds. As 
shorter chain lipopolyamines are too cytotoxic, the most efficient lipopolyamines for 








-dioleoyl spermine. These 
are practical non-liposomal siFection vectors, comparable with TransIT. From these 













-diacyl spermines (C10-C18) 





-diretinoyl spermine with its two C-20 chains was significantly more 
toxic to both cell lines than the two C-18 compounds. This success with C18 gave us 





-diacyl spermine (C20-C24). We will also change the degree of saturation to 




-diacyl spermines that 
can achieve maximum in vitro siRNA delivery with minimum cytotoxicity. 
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-DIACYL SPERMINES:  NON-VIRAL 
       LIPOPOLYAMINE VECTORS FOR EFFICIENT siRNA DELIVERY 
 
4.4.1. Lipoplex Particle Size and Zeta-Potential Measurements 
 The particle size and ζ-potential characterization measurements were carried out 
on the lipoplexes at their optimum N/P charge ratio for transfection (see:  Table 4.3).  
 

























-Dinervonoyl spermine 110 (21)  
 
 The ζ-potential measurements on the lipoplexes, at their optimum 
concentrations of transfection, show that all values are positive (Table 4.3), therefore 
there is a net positive charge on the surface. For siRNA lipoplexes, ζ-potentials ranged 









spermine); the measured ζ-potential for naked siRNA -0.3, and for the siRNA lipoplex 
with TransIT-TKO +2.6 mV. 
 
4.4.2. siRNA Delivery and In Vitro Cytotoxicity 
 The transduction of fluorescein-tagged siRNA (RNAi Delivery Control, 
Mirus) into a primary skin cell line FEK4 and a cancer cell line (HeLa-derived HtTA) 
was investigated and compared with a market leader TransIT-TKO (Mirus) which 
works in the presence of serum. 
 The optimum concentrations for transfection (in a final volume of 0.5 ml) were 
experimentally determined by using ascending amounts of lipospermines, as described 
before, and high transfection efficiency is immediately seen from our FACS analyses 
in both cell lines (Fig. 4.12) with gating to measure mainly live cells. The siRNA 
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transfection efficiency results (carried out in triplicate on 3 separate experiments, n = 













-dierucoyl spermine for both cell 




-dierucoyl spermine FEK4 88.6% ± 7.2, HtTA 84.9% 
± 4.4) to the results of TransIT (91% FEK4 and 93% HtTA) even in the presence of 




-dinervonoyl spermine (63% FEK4 and 68% HtTA) has 





diarachidoyl spermine (42% FEK4 and 34% HtTA). 
 The cell viability (MTT assay) results (lines in Fig. 4.13) indicate that there is 
no significant difference in the viability of FEK4 (85%, p = 0.15) and HtTA (75%, p = 



















-dierucoyl spermine are both equally 
active as TransIT-TKO and the same viability range. 
 
  
Fig. 4.12. FACS analysis showing the live population gated (above), and of FEK4 





-dierucoyl spermine:   untransduced cells,  fluorescein-
positive cells. 
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Fig. 4.13. Lipofection and cytotoxicity effects of siRNA (12.5 pmol) complexed with 























dinervonoyl spermine) (6.0 µg) on FEK4 and HeLa derived HtTA cell lines. 
 






















Fig. 4.14. Plot of RiboGreen intercalation assay of siRNA complexed with different 
lipospermines. 
 
 The RiboGreen intercalation assay (Fig. 4.14) was performed on the three 
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The results show that efficient siRNA binding, as assessed by fluorescence quenching, 














spermine. These results give a clear idea about the ability of tested very long chain 
diacyl spermine to complete condense of siRNA. 
 We have investigated the biological effects of increasing the length of the 
symmetrical diacyl fatty chain formulation of lipospermine on siRNA condensation 





dierucoyl spermine showed an siRNA lipoplex particle size of 180 nm (mean value ± 
S.D. 28, n = 9). All our lipoplexes are in the range 110-180 nm, and they transfected 
target cell lines efficiently. 
 In crossing the cell membrane bilayer (i.e., cell entry) and/or in helping to 
weaken the endosomal bilayer and thereby aiding escape into the cytosol, the lipid 
moiety in our cationic lipids interacts with the phospholipid bilayer (206). The first 
key step in this siRNA formulation is nanoparticle formation by masking the negative 
charges of the phosphate backbone. This titration with a lipopolyamine causes 
alleviation of charge repulsion between remote phosphates along the RNA helix 
leading to collapse into a more compact structure that facilitates cell entry. 
 Using confocal laser scanning microscopy with one labelling solution 
(Invitrogen) containing both Alexa Fluor 594 wheat germ agglutinin (5 µg/ml) for cell 
membrane labelling, and Hoechst 33342 (2 µΜ) for nuclei labelling. Successful 
delivery of fluorescent-siRNA to the cytosol was also shown (Fig. 4.15). 
 Incorporating two aliphatic chains and then stepwise increasing their length, 









-dierucoyl spermine are two 
new, efficient delivery vectors that work in primary cell lines even in the presence of 










-dierucoyl spermine typically 89% FEK4 and 85% HtTA along with cell 
viability at least as high as TransIT (>80%). These novel very long chain 
lipopolyamines are remarkably non-toxic and capable of delivering siRNA primary 
cell lines in the presence of serum and with efficiency equalling a market leader, 
TransIT-TKO. They are two important new non-viral siRNA delivery vectors. 
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4.4.4. Confocal Microscopy Visualization 
  
  
Fig. 4.15. The FEK4 primary cell line transfected with fluorescein-labelled siRNA 









-dierucoyl spermine (below). The nuclei 
fluoresce blue from the Hoechst 33342 and the cell lipid bilayers fluoresce red from 
the Alexa Fluor 594 (LSM510META, under the 60× oil immersion objective). 
 
 Cell membranes are complicated as they contain a variety of different classes 
of lipids. The cell membrane consists of three classes of amphipathic lipids:  
phospholipids, glycolipids, and steroids, most of the plasma membrane is lipid. The 
fatty chains in phospholipids and glycolipids usually contain an even number of 
carbon atoms, typically between 14 and 24, the 16- and 18-carbon fatty acids are the 
most common. Fatty acids may be saturated or unsaturated, so due to existence of 
different fatty chains in naturally occurring phospholipids, we adjusted the focus to 





-positions of the spermine backbone, mimicking naturally occurring 










-DIACYL SPERMINES:  NON-VIRAL 
       LIPOPOLYAMINE VECTORS FOR EFFICIENT siRNA DELIVERY 
 
4.5.1. Lipoplex Particle Size and Zeta-Potential Measurements 
 The particle size and ζ-potential characterization measurements were carried 
out on the lipoplexes at their optimum concentration for transfection (see:  Table 4.4). 
Particle size characterization by laser diffraction showed that the nanoscale particle 














stearoyl spermine) with an average particle size of 155 nm (Table 4.4). 
 The surface charge, as determined by ζ-potential measurements on the 
lipoplexes at their optimum N/P charge ratio of transfection, show e.g., that two 









-oleoyl spermine); the measured ζ-potential for naked siRNA -0.3, 
and for the siRNA lipoplex with TransIT-TKO +2.6 mV. 
 























-stearoyl spermine 170 (46) 
 
4.5.2. RNA Binding (RiboGreen Intercalation Assay) 
 The RiboGreen intercalation assay (Fig. 4.16) was performed on most ot the 
unsymmetrical synthesized lipospermine delivery vectors. The results show that 
efficient siRNA binding, as assessed by 90% fluorescence quenching at N/P charge 




-myristoyl spermine which 
show 80% fluorescence quenching at N/P charge ratio 4.5. 
 




























Fig. 4.16. Plot of RiboGreen intercalation assay of siRNA complexed with different 
unsymmetrical lipospermines. 
 
4.5.3. siRNA Delivery and In Vitro Cytotoxicity 
 The transduction of fluorescein tagged siRNA into a primary skin cell line 
FEK4 and a cancer cell line (HeLa-derived) HtTA was investigated and compared 
with a market leader TransIT-TKO (Mirus). The practical concentrations (in a final 
volume of 0.5 ml) were experimentally determined by using ascending amounts of 
lipospermines until we reached around 80% transfection and there was not a further 
step-up in transfection efficiency at the next highest concentration.  
  
Fig. 4.17. Gated FACS analysis of FEK4 (left) and HtTA (right) after 48 h 





spermine   untransduced cells,  fluorescein-positive cells. 
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 The gated flow cytometric FACS analysis, Fig. 4.17, of FEK4 and HtTA cell 





-stearoyl spermine, clearly shows a high 
percentage of transduced fluorescein-positive cells. From our typical results, Figs. 








































Fig. 4.18. Lipofection of the primary skin cell line FEK4 and the cancer cell line 
























Myristoleoyl-Myristoyl  FEK4 Myristoleoyl-Myristoyl HtTA
Oleoyl-Stearoyl  FEK4 Oleoyl-Stearoyl HtTA
Fig. 4.19. Lipofection of the primary skin cell line FEK4 and the cancer cell line 









-stearoyl spermine at different ratios. 
 















Cholesteryl-Oleoyl  FEK4 Cholesteryl-Oleoyl HtTA
Lithocholoyl-Oleoyl FEK4 Lithocholoyl-Oleoyl HtTA
Fig. 4.20. Lipofection of the primary skin cell line FEK4 and the cancer cell line 



















































































































FEK4 Transfection HtTA Transfection
FEK4 Viability HtTA Viability
Fig. 4.21. Lipofection and cytotoxicity effects of siRNA (12.5 pmol) complexed with 










































-retinoyl spermine) (6.0 
µg) on the primary skin cell line FEK4 and the HeLa derived cancer cell line HtTA. 
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 The siFection results (Fig. 4.21, histograms) indicate that the transfection 
ability of the tested unsymmetrical lipospermines are comparable with the results 
obtained with a market leader TransIT, a commercially available reagent (91% FEK4 





































-oleoyl spermine (72%). The siRNA delivery results into cancer HtTA 









-retinoyl spermine (72%). 
The cell viability (MTT assay) results (Fig. 4.21, lines) indicate that there is 
not a large difference in the viability between the commercially available TransIT-




































-oleoyl spermine lipospermines are more toxic to 
both cell lines. 
 We have investigated the biological effects of using novel lipospermines with 
two unsymmetric lipid moieties which differ in length, degree of saturation or nature 
of the fatty chain on the formulation, condensation and cellular delivery of siRNA. The 
results from RNA condensation (Fig. 4.16), investigated using the fluorescence 
quenching assay, revealed that most of our synthetic lipospermines were able to 





-stearoyl spermine was able to quench the fluorescence by 80% at the same 
N/P charge ratio 6 (Fig. 4.16). The particle size of the final RNA formulation is also an 
important factor in improving delivery (187,188). Results for siRNA showed particle 









-myristoyl spermine showed an siRNA lipoplex particle size of 170 nm 
(mean value ± S.D, n = 9). These lipoplexes are in the range 130-170 nm, and they 
transfected target cell lines efficiently. 
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 Incorporating two unsymmetrical chains or other lipid moieties, our siRNA 

























-retinoyl spermine typically 91% FEK4 and 72% HtTA are efficient 
delivery vectors that work in primary cell lines and in the presence of serum. They 
demonstrate efficiencies comparable to the results obtained with TransIT typically 
91% FEK4 and 93% HtTA, along with cell viability at least as high as TransIT 
(>80%). These novel unsymmetric lipopolyamines are remarkably non-toxic and 
capable of delivering siRNA to hard-to-transfect primary cell lines in the presence of 
serum and with efficiency equalling a market leader, TransIT-TKO. 
 It is now generally agreed that the length and type of the aliphatic chains (the 
hydrophobic domain) incorporated into cationic lipids significantly affect their pDNA 
transfection efficiency, but this factor is not really understood yet for siRNA delivery. 
This series of vectors have differing hydrophobic domains. A shorter chain length 
may facilitate intermembrane mixing, an important factor in endosomal escape which 
will deliver the siRNA directly into the cytosol, experimental evidence for this is that 




-myristoyl spermine was one of the best in this 
series. 
As lipopolyamines possess substantial buffering capacity near physiological 
pH, they are efficient transfection agents without the addition of cell targeting or 
membrane-disruption agents. This observation led us to test nitrogen-containing 
heterocyclic-substituted lipospermines for their siRNA delivery potential because the 
increase in the pKa of the protonatable amino nitrogen atom may make a significant 
difference, as above with the polyamines acting as an effective proton sponge (38). 
Our idea is that its efficiency relies on extensive lysosome buffering which protects 
siRNA from RNase nuclease degradation. The protonation reservoir of a molecule 
around neutral pH has not previously been studied in siRNA delivery. This 
relationship may be the basis for the design of new synthetic vectors. 
 





-DIACYL SPERMINES:  NON-VIRAL 
       LIPOPOLYAMINE VECTORS FOR EFFICIENT siRNA DELIVERY 
 
 There are three series of N-heterocycles (imidazole, pyridine and quinoline) 
investigated in this section, as:  4-imidazolylmethyl, 2-pyridinylmethyl, and 2-




-diacyl spermines, acylated with 
myristoyl (C14), palmitoyl (C16), stearoyl (saturated C18) and oleoyl (mono-cis-
unsaturated C18). They will each carry only two positive charges at physiological pH 
(7.4) as the aliphatic amines are much more basic than the heterocyclic amines, whose 



































stearoyl    R= (CH2)16CH3
oleoyl       R= (CH2)7CH=CH(CH2)7CH3
 
Fig. 4.22. Heterocyclic derivatives of lipospermines. 
 
4.6.1. Zeta-Potential Measurements 
 The ζ-potential characterization measurements were carried out on the 
lipoplexes at their optimum concentration for transfection (see:  Table 4.5). The 
surface charge, as determined by ζ-potential measurements on the lipoplexes at their 
optimum concentration of transfection, show three typical values are positive and 









-dipalmitoyl spermine); the measured ζ-potential for 
naked siRNA -0.3, and for the siRNA lipoplex with TransIT-TKO +2.6 mV. 
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Table 4.5. Zeta potential of siRNA lipoplexes 
Lipospermine 
siRNA-Lipoplex 















-dipalmitoyl spermine 11.76 
 
4.6.2. siRNA Delivery and In Vitro Cytotoxicity 
 The transduction of fluorescein-tagged siRNA (RNAi Delivery Control, Mirus) 
into a primary skin cell line FEK4 and a cancer cell line (HeLa-derived HtTA) was 
investigated, the optimum concentrations for transfection (in a final volume of 0.5 ml) 
were experimentally determined by using ascending amounts of lipospermines, and high 
transfection efficiency is immediately seen from our FACS analyses in both cell lines 
(Fig. 4.23) with gating to measure mainly live cells. 
 
  
Fig. 4.23. Gated FACS analysis of FEK4 (left) and HtTA (right) after 48 h 
transfection of fluorescein-tagged siRNA complexed with Stear-Pyri:  untransduced 
cells,   fluorescein-positive cells. 






























FEK4 Transfection HtTA Transfection 
FEK4 Viability HtTA Viability
 
Fig. 4.24. Lipofection and cytotoxicity effects of siRNA (12.5 pmol) complexed with 
(left) Myristoyl (12.0 µg), Myristoyl-Imida (8.0 µg), Myristoyl-Pyri (6.0 µg) and 
Myristoyl-Quino (8.0 µg) on the primary skin cell line FEK4 and the HeLa derived 




























FEK4 Transfection HtTA Transfection 
FEK4 Viability HtTA Viability
 
 
Fig. 4.25. Lipofection and cytotoxicity effects of siRNA (12.5 pmol) complexed with 
Palmitoyl (12.0 µg), Palmitoyl-Imida (6.0 µg), Palmitoyl-Pyri (6.0 µg) and Palmitoyl-
Quino (4.0 µg) on the primary skin cell line FEK4 and the HeLa derived cancer cell 
line HtTA. 
 



























FEK4 Transfection HtTA Transfection 
FEK4 Viability HtTA Viability
 
Fig. 4.26. Lipofection and cytotoxicity effects of siRNA (12.5 pmol) complexed with 
(left) Stearoyl (8.0 µg), Stearoyl-Imida (4.0 µg), Stearoyl-Pyri (4.0 µg) and Stearoyl-



























FEK4 Transfection HtTA Transfection 
FEK4 Viability HtTA Viability
 
Fig. 4.27. Lipofection and cytotoxicity effects of siRNA (12.5 pmol) complexed with 
Oleoyl (8.0 µg), Oleoyl-Imida (6.0 µg), Oleoyl-Pyri (4.0 µg) and Oleoyl-Quino (4.0 
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 The siRNA transfection efficiency results (carried out in triplicate on 3 
separate experiments, n = 9, histograms in Figs. 4.24-4.27) show the optimum 

























































dioleoyl spermine (4.0 µg). 









-dipalmitoyl spermine (all three heterocyclic) derivatives there is no 









-dipalmitoyl spermine (at their 
optimum delivery ratio) on both cell lines, but there was a significant decrease in the 
amount of transfecting agent required to achieve these comparably efficient 









spermine heterocyclic derivatives (Figs. 4.26 and 4.27) show that all the tested 





spermine derivative becomes more toxic from imidazole to quinoline through pyridine 









-dioleoyl spermine in cytotoxicity, then imidazole, and finally comes the 
quinoline derivative. So we can conclude from the above results of siRNA 





spermine is the best of all these heterocyclic derivatives which show high siRNA 
transfection efficiency typically 75% and 83% transfection ability and 77% and 74% 





-dioleoyl spermine, but there was a significant decrease in the amount of 
transfecting agent required to achieve this comparably efficient transfection, a 
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The heterocyclic substituted lipospermines show higher transfection efficiency 
over lipospermines as they show the same result at lower concentrations than the 
lipospermine analogues even as low as half of the concentration. Their high siRNA 
delivery potential is because of the increase on the pKa of the vector due to increasing 
the number of nitrogen atoms in the lipospermines that can be protonated in the 
endosome as the pH drops to 5.5, i.e., their pKas are around 5-7. Indeed, it makes the 
polymeric network an effective proton sponge at virtually any physiological pH (38). 
This extensive lysosome buffering effect protects both DNA and siRNA from 
nuclease degradation, and consequently lysosomal swelling and rupture provide an 
escape mechanism for the particles, based on the hypothesis that a causal relationship 
exists between the protonation reservoir of a molecule below neutral pH and its 
transfection efficiency. Endosome buffering may protect DNA and siRNA from 
lysosomal nucleases, but it may also perturb either the trafficking of endosomes or 
their osmolarity. For instance, massive vesicular ATPase-driven proton accumulation 
followed by passive chloride influx into endosomes buffered with lipospermine 
should cause osmotic swelling and subsequent endosome disruption. Furthermore, 
because the monomeric unit has such low molecular mass, the whole molecule will 
behave as an extensive proton sponge (38). 
Even all the tested heterocyclic lipopolyspermines show high transfection 





dioleoyl spermine is an efficient siRNA delivery agent that is non toxic with a 




-dioleoyl spermine. This is a new vector 
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CONCLUSIONS 
The ultimate goal of designing synthetic poly-nucleic acid-delivery vehicles is 
to build multimolecular nucleic acid/vector assemblies that are non-toxic and yet 
efficient enough to be used in therapy. In this way, practical non-viral gene delivery 
can be achieved in a clinical setting. Whilst there was an assumption in the early 
siRNA-delivery literature that it will follow pDNA delivery, or at least that gene 
delivery will be an indicator or guide to siRNA delivery efficiency, it is clear from 
these studies that this is incorrect. Furthermore, as there is a large charge difference 
between pDNA and siRNA, different concentrations of lipopolyamine vectors (N/P 
ratio) are going to be required, so overall cell viability cannot be assumed in moving 
from pDNA to siRNA delivery. 
From this thesis it can be concluded that our new vectors can potentially be 
used to formulate and efficiently deliver DNA and siRNA as the drug. In formulation 
terms, DNA is a medicinal substance that is difficult to formulate. This is because of 
the nature of both its size that is usually in Mega-Daltons, and the many thousands of 
negative charges (typically 10,000) on the phosphate backbone of the polynucleotide. 
The use of an efficient carrier (delivery vehicle) responsible for the complex process 
of successful DNA delivery to the nucleus is a determinant factor for the successful 
application of gene therapy. DNA is condensed naturally by basic proteins, histones 
with their many arginine and lysine amino acids each carrying a positive charge, and 
this is aided by positively charged polyamines spermine and spermidine. So, 
polycationic polyamines were utilized in the design of our gene carriers. 
Delivery vehicles for DNA formulation are either viral or non-viral vectors 
relying on (poly) cationic compounds. Non-viral formulation has to overcome cellular 
barriers (cell membrane entry, endosomal escape, nuclear entry, decomplexation, then 
transcription and translation) to achieve a successful delivery of the prodrug DNA. To 
overcome these barriers, investigations were carried out to improve the delivery of 
DNA through several approaches including:  the use of novel carriers, the delivery 
and internalisation to selected cell lines in the presence of serum, incorporating 
cationic moieties to improve endosomal escape e.g., utilising the proton sponge effect, 
or incorporating different fusogenic lipids. In these studies, the condensation of DNA 
and the formation of nanoparticles was monitored using EthBr fluorescence 
quenching and gel electrophoresis assays. In addition, EthBr was used to determine 
the binding affinity of the condensing agents for DNA. The binding of cationic 
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molecules with DNA is not entirely responsible for the release of EthBr, but alteration 
of the molecular flexibility of DNA through cationic compaction facilitated the release 
of bound EthBr. The number and/or the distribution of the positive charges on the 
molecule could have a significant effect on the affinity of the vector for DNA that 
leads to the efficient displacement of EthBr. Condensation of DNA into nanoparticles 
is a way to decrease the volume of the delivered gene in order to facilitate cellular 
membrane entry by endocytosis and subsequent trafficking to the nucleus. The 
characterization of particle size by laser light scattering revealed that the lipoplex 
particle sizes range from 90-250 nm. 
Transfection efficiency and cell viability (toxicity) experiments were carried 
out using pEGFP as a reporter gene, either complexed with DNA condensing agents, 
or free (naked) DNA as a negative control. DNA yields and purity were determined 
spectroscopically (OD260/OD280 = 1.80–1.90) and by agarose gel (1 %) analysis. FEK4 
cells are human primary fibroblasts derived from newborn foreskin explants were 
used as model for human primary cells. HeLa derived and transformed cell line 
(HtTA) was used as a model for an immortal cancer cell line. The cytotoxicity (cell 
viability) of these compounds was studied in both primary skin and immortalised 
cancer cell lines using an MTT assay. The formed lipoplexes (nanoparticles) were 
characterized by both average particle size (n = 9) and ζ-potential measurements. 
Zeta potential is an important parameter to predict the stability as well as the 
ability of the positively charged particles to interact with cell membranes. ζ-Potential 
results revealed that the surface charge was positive. In addition, gel electrophoresis 
results revealed that all spermine conjugates were able to condense pEGFP DNA and 
completely inhibit the migration of the circular plasmid DNA from lipoplexes in the 
agarose gel at their respective charge ratio of transfection. 
The transfection efficiencies of the synthesized lipopolyamines were studied in 
primary skin cells (FEK4) and in an immortalized (HeLa derived HtTA) cancer cell 
line using pEGFP as the reporter macromolecule with its fluorescent imidazolidinone 
moiety analysed by FACS. The results revealed high transfection efficiencies with 
many novel lipospermines (Table 5.1). These highly efficient transfecting agents were 
selected based on a combination of pDNA transfection efficiency for both cell lines 
(typically about 60%) and from the cytotoxicity of these compounds in both cell lines, 
using the MTT assay, selecting lipospermines that showed average viability for both 
cell lines of more than 40% (Table 5.2). 
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Table 5.1. Transfection efficiency (mean ± S.D.) of pEGFP complexes with the studied lipo-
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Table 5.2. Viability (mean ± S.D.) of the primary skin cell line FEK4 and the HeLa 















































































-Diarachidonoyl spermine 8 74.4±(7.9) 10.1±(1.6) 42 
 
The transfection of pEGFP (analysed by gated FACS) showed a higher 




-dioleoyl spermine (at N/P charge ratio of 2.5) than 
that obtained using commercially available liposomal Lipofectin
®
 formulation in 
FEK4 primary skin fibroblast and HtTA cell lines. On the other hand, there is no 
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dioleoyl spermine and the commercially available standard liposomal formulation 
Lipofectamine

 and non-liposomal cationic lipid Transfectam
®
. 




-dioleoyl spermine showed a significant 





spermine shows promising transfection results in tissue cultured cancer and skin 
fibroblast primary cell lines. Therefore, we investigated the effects on DNA 
formulation with variation in the position, length, degree of unsaturation and the 
symmetry of the two fatty chains of the synthetic lipospermines or even attaching 





-diacyl spermines (i.e., myristoyl, palmitoyl, stearoyl, and oleoyl). 
From the combination of the results obtained with our novel lipopolyamines, 
transfection efficiencies typically about 60% (Table 5.1), and cell viabilities more than 
40% (Table 5.2), we have experimental evidence for eleven new effective transfecting 
agents which are able to deliver the gene payload to cultured cells with good viability. 
































-dioleoyl spermine in their cell viability 
(cytotoxicity) effects on those cultured cells. 
So after these detailed studies on saturated and mono-unsaturated aliphatic 
chains, poly-unsaturated chains (from arachidonoic and retinoic acids), steroids and 
mixtures of these lipids conjugated to spermine, making a series of symmetrical and 









pEGFP DNA formulation and delivery to the primary skin cell line FEK4 and the 





-dioleoyl spermine which shows the same level of 




-dioleoyl spermine is 





spermine displays the lowest N/P ratio, highest transfection efficiency and the lowest 
cytotoxicity on both tested cell lines compared to all the tested lipospermines in this 
study. 
Further studies and characterizations were then carried out to examine if we 
can apply these results in an SAR study of siRNA delivery.  
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Table 5.3. Delivery efficiency (mean ± S.D.) of 12.5 pmol siRNA complexes with the 
studied lipopolyamines on the primary skin cell line FEK4 and the HeLa derived cancer 














dipalmitoyl spermine  
















































































-Dinervonoyl spermine 6 62.8±(2.1) 67.7±(3.0) 65 
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Table 5.4. Viability (mean ± S.D.) of the primary skin cell line FEK4 and the HeLa 
































































































-stearoyl spermine 20 70.5±(9.4) 18.4±(1.4) 45 
 
Using fluorescein-labelled siRNA (Label IT
®
 RNAi Delivery Control, a 21-
mer from Mirus) as a reporter, FEK4 primary skin cells and transformed HtTA cells 
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were examined in siFection efficiency and cytotoxicity (cell viability) experiments. 
The cytotoxicity of these compounds was studied using the MTT assay. The formed 
siRNA lipoplexes were monitored with the RiboGreen intercalation assay and 
characterized by both average particle size (n = 9) by laser light scattering, which 
revealed that the particle sizes range from 90-170 nm, and ζ-potential measurements 
(typically +3 to +19 mV). Gated FACS analysis of the delivery of Label IT
®
 RNAi 
Delivery Control, which has the same length, charge, and configuration as a standard 
siRNA, showed a higher siRNA transfection efficiency with many of our novel 
lipospermines compared to the commercially available market leader Trans-IT

. 
From the combination of the siRNA delivery (Table 5.3) and cell viability 
(Table 5.4) results obtained with our novel lipopolyamines, we have obtained 
experimental evidence for fifteen new effective transfecting agents which are able to 
deliver siRNA to cultured cells with good viability. Many (twelve) of these non-viral 












































































dioleoyl spermine have more than 75% cell viability (cytotoxicity) effect on the 













-dioleoyl spermine are at the top of the best 
transfecting agents from the all tested novel lipospermines, as they display the highest 
transfection efficiency and the lowest cytotoxicity on both the tested cell lines. 
While nine lipopolyamine conjugates occur in both series (Tables 5.1-5.4), 
there is no obvious correlation or SAR linking gene and siRNA delivery. What can be 
readily concluded from this study is that these selected small, non-polymeric and non-
liposomal lipopolyamine molecules show efficient transfection and siFection of 
primary cell lines with pDNA and siRNA with good cell viability even in the presence 
of serum nucleases. 
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